KR20150133097A - An electroluminescent compound and an electroluminescent device comprising the same - Google Patents

An electroluminescent compound and an electroluminescent device comprising the same Download PDF

Info

Publication number
KR20150133097A
KR20150133097A KR1020140059983A KR20140059983A KR20150133097A KR 20150133097 A KR20150133097 A KR 20150133097A KR 1020140059983 A KR1020140059983 A KR 1020140059983A KR 20140059983 A KR20140059983 A KR 20140059983A KR 20150133097 A KR20150133097 A KR 20150133097A
Authority
KR
South Korea
Prior art keywords
group
carbon atoms
substituted
mol
unsubstituted
Prior art date
Application number
KR1020140059983A
Other languages
Korean (ko)
Inventor
현서용
정성욱
김동원
Original Assignee
(주)피엔에이치테크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)피엔에이치테크 filed Critical (주)피엔에이치테크
Priority to KR1020140059983A priority Critical patent/KR20150133097A/en
Publication of KR20150133097A publication Critical patent/KR20150133097A/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B33/00Electroluminescent light sources
    • H05B33/12Light sources with substantially two-dimensional radiating surfaces
    • H05B33/14Light sources with substantially two-dimensional radiating surfaces characterised by the chemical or physical composition or the arrangement of the electroluminescent material, or by the simultaneous addition of the electroluminescent material in or onto the light source
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02BCLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
    • Y02B20/00Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

The present invention relates to an organic light emitting compound applied to an organic light emitting device. The organic light emitting compound: is represented by chemical formula 1; includes one or more substituted bodies represented by structural formula 1 or structural formula 2; and is capable of realizing an organic light emitting device having excellent luminous properties such as driving voltage, luminance, a long life and the like in the case of being applied as a phosphorescent host compound in a hole transporting functional layer or an emissive layer.

Description

유기발광 화합물 및 이를 포함하는 유기전계발광소자{An electroluminescent compound and an electroluminescent device comprising the same}TECHNICAL FIELD The present invention relates to an organic electroluminescent compound and an electroluminescent device comprising the same,

본 발명은 유기발광 화합물에 관한 것으로서, 보다 구체적으로는 유기전계발광소자의 발광층 호스트 화합물 또는 정공수송 재료로 채용되는 유기발광 화합물 및 이를 채용하여 장수명 및 발광 효율이 현저히 향상된 유기전계발광소자에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an organic light emitting compound, and more particularly, to an organic light emitting compound which is employed as a host compound or a hole transport material in an organic electroluminescent device, and an organic electroluminescent device .

유기전계발광소자는 투명 기판 위에도 소자를 형성할 수 있을 뿐 아니라, 플라즈마 디스플레이 패널(Plasma Display Panel)이나 무기 전계 발광(EL) 디스플레이에 비해 10 V 이하의 저전압 구동이 가능하고, 전력 소모가 비교적 적으며, 색감이 뛰어나다는 장점이 있고, 녹색, 청색, 적색의 3가지 색을 나타낼 수가 있어 최근에 차세대 디스플레이 소자로 많은 관심의 대상이 되고 있다.The organic electroluminescent device can not only form an element on a transparent substrate but also can operate at a low voltage of 10 V or less as compared with a plasma display panel (Plasma Display Panel) or an inorganic electroluminescence (EL) display, It has the advantage of excellent color and has three colors of green, blue, and red. It has recently become a subject of interest as a next generation display device.

다만, 이러한 유기전계발광소자가 상기와 같은 특징으로 발휘하기 위해서는 소자 내 유기층을 이루는 물질인 정공주입 물질, 정공수송 물질, 발광 물질, 전자수송 물질, 전자주입 물질 등이 안정하고 효율적인 재료에 의하여 뒷받침되는 것이 선행되어야 하나, 아직까지는 안정하고 효율적인 유기 전계발광 소자자용 유기물층 재료의 개발이 충분히 이루어지지 않은 상태이다. 따라서, 저전압 구동, 고효율 및 장수명을 갖는 새로운 재료의 개발이 계속 요구되고 있는 실정이다.However, in order for such an organic electroluminescent device to exhibit such characteristics, a hole injecting material, a hole transporting material, a light emitting material, an electron transporting material, and an electron injecting material, which are materials forming an organic layer in a device, However, until now, stable and efficient development of an organic layer material for an organic electroluminescence element has not been sufficiently developed yet. Therefore, there is a continuing demand for development of new materials having low-voltage driving, high efficiency and long life.

특히, 종래 정공수송 재료로 구리 프탈로시아닌(CuPc), MTDATA, 4,4'-비스[N-(1-나프틸)-N-페닐아미노]바이페닐(NPB), N,N'-다이페닐-N,N'-비스(3-메틸페닐)-(1,1'-바이페닐)-4,4'-다이아민(TPD) 등이 알려져 있으나, 이를 소자에 채용시 효율 및 수명이 저하되는 문제가 있고, 이를 개량하기 위하여 다양한 치환기를 갖는 아릴아민계 화합물에 대해서 개발되고 있으나, 여전히 효율과 장수명을 동시에 충족시키기에는 충분하지 않은 문제점을 갖고 있다.In particular, conventional hole transport materials include copper phthalocyanine (CuPc), MTDATA, 4,4'-bis [N- (1-naphthyl) -N- phenylamino] biphenyl (NPB), N, N, N'-bis (3-methylphenyl) - (1,1'-biphenyl) -4,4'-diamine (TPD) has been known. However, Based compound having various substituents in order to improve it, but it still has a problem that it is not enough to satisfy efficiency and long life at the same time.

또한, 유기 발광 소자에서 발광효율을 결정하는 가장 중요한 요인은 발광 재료이다. 발광 재료로는 현재 형광 재료가 널리 사용되고 있으나, 발광 메커니즘 상 인광 재료의 개발이 이론적으로 발광 효율을 보다 개선시킬 수 있는 방법 중의 하나이고, 이에 따라 현재까지 다양한 인광 재료에 대해서 개발이 이루어지고 있으며, 특히 인광 발광 호스트 재료로는 현재까지 CBP가 가장 널리 알려져 있고, BALq 유도체를 호스트로 이용한 유기 발광 소자가 공지되어 있다.Further, the most important factor for determining the luminous efficiency in an organic light emitting device is a light emitting material. However, the development of a phosphorescent material on a light-emitting mechanism is one of the ways that the luminous efficiency can be improved more theoretically. Accordingly, a variety of phosphorescent materials have been developed to date, In particular, CBP is the most widely known phosphorescent host material, and an organic light emitting device using a BALq derivative as a host is known.

그러나, 인광 발광 재료를 사용한 유기 발광 소자는 형광 발광 재료를 사용한 소자에 비해 전류 효율이 상당히 높으나, 인광 발광 재료의 호스트로 BAlq, CBP 등의 재료를 사용할 경우, 형광재료를 사용한 소자에 비해 구동 전압이 높아서 전력 효율면에서 큰 이점이 없고, 또한, 소자의 수명 측면에서도 만족할만한 수준이 되질 못하여 더욱 안정적이고, 고성능의 호스트 재료의 개발이 요구되고 있다.However, in the case of using a material such as BAlq or CBP as a host of a phosphorescent material, the organic electroluminescent device using the phosphorescent material has a higher current efficiency than the device using the fluorescent material, There is no great advantage in terms of power efficiency, and the life of the device can not be satisfactory. Thus, development of a more stable and high-performance host material is required.

대한민국 공개특허공보 제10-2012-0131870호Korean Patent Publication No. 10-2012-0131870

본 발명은 유기전계발광소자의 발광층 또는 정공주입층 내지 정공수송층에 채용되어 우수한 발광 특성을 구현할 수 있는 신규한 유기발광 화합물 및 이를 포함하는 유기전계발광소자를 제공하고자 한다.The present invention provides a novel organic electroluminescent compound which can be used for a light emitting layer, a hole injecting layer, and a hole transporting layer of an organic electroluminescent device to realize excellent luminescent characteristics, and an organic electroluminescent device including the same.

본 발명은 상기 과제를 해결하기 위하여, 하기 [화학식 1]로 표시되는 코어 골격에 하기 [구조식 1] 또는 [구조식 2]를 치환체로 갖는 것을 특징으로 하는 유기발광 화합물 및 이를 포함하는 유기전계발광소자를 제공한다.In order to solve the above problems, the present invention provides an organic electroluminescent compound having as a substituent the following structural formula 1 or structural formula 2 in a core skeleton represented by the following formula (1) and an organic electroluminescent device Lt; / RTI >

[화학식 1][Chemical Formula 1]

Figure pat00001
Figure pat00001

[구조식 1][Structural formula 1]

Figure pat00002
Figure pat00002

[구조식 2][Structural formula 2]

Figure pat00003
Figure pat00003

상기 [화학식 1] 및 [구조식 1] 내지 [구조식 2]에 따른 유기발광 화합물의 구체적인 구조 및 치환기에 대해서는 후술한다.The specific structures and substituents of the organic luminescent compounds according to the above formulas (1) and (1) to (2) will be described later.

본 발명에 따른 유기발광 화합물은 구조 평판도가 우수하고, 높은 삼중항(triplet) 상태를 가져서 종래 인광 호스트 화합물이나 정공수송 화합물에 비하여 보다 향상된 발광 효율과 장수명 특성의 구현이 가능하여 이를 채용한 유기전계발광소자는 다양한 디스플레이 소자에 유용하여 사용될 수 있다.The organic luminescent compound according to the present invention has an excellent structure flatness and a high triplet state, which enables to realize a luminescent efficiency and a longevity characteristic which are higher than those of conventional phosphorescent host compounds and hole transport compounds, The light emitting device can be used for various display devices.

도 1 내지 5는 본 발명의 일 실시예에 따른 유기전계발광소자의 구조를 예시한 단면도이다.1 to 5 are cross-sectional views illustrating the structure of an organic electroluminescent device according to an embodiment of the present invention.

이하, 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described more specifically.

본 발명은 하기 [화학식 1]로 표시되는 신규한 유기발광 화합물에 관한 것이다.The present invention relates to a novel organic luminescent compound represented by the following formula (1).

[화학식 1][Chemical Formula 1]

Figure pat00004
Figure pat00004

상기 [화학식 1]에서, X1 내지 X10은 각각 독립적으로 N 또는 CR1이고, X11은 단일결합이거나, CR2R3, CR4, NR5, PR6, SiR7R8, O 및 S 중에서 선택되는 것을 특징으로 한다.Wherein X 1 to X 10 are each independently N or CR 1 and X 11 is a single bond or CR 2 R 3 , CR 4 , NR 5 , PR 6 , SiR 7 R 8 , O and S, < / RTI >

상기 R1 내지 R8은 각각 독립적으로 수소, 중수소, 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐기, 치환 또는 비치환된 탄소수 3 내지30의 시클로알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 헤테로시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 30의 시클로알케닐기, 치환 또는 비치환된 탄소수 1 내지 30의 알콕시기, 치환 또는 비치환된 탄소수 6 내지 30의 아릴옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬티옥시기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴티옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬아민기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴아민기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 실릴기, 아미노기, 싸이올기, 시아노기, 히드록시기, 니트로기 및 할로겐기로 이루어진 군에서 선택된다.Each of R 1 to R 8 is independently selected from the group consisting of hydrogen, deuterium, a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 30 carbon atoms, a substituted or unsubstituted alkoxy group having 2 to 30 carbon atoms A substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted heterocycloalkyl group having 2 to 30 carbon atoms, a substituted or unsubstituted cycloalkenyl group having 5 to 30 carbon atoms, a substituted or unsubstituted C1- A substituted or unsubstituted C1 to C30 alkoxy group, a substituted or unsubstituted C6 to C30 aryloxy group, a substituted or unsubstituted C1 to C30 alkylthio group, a substituted or unsubstituted C1 to C30 arylthio group, An unsubstituted alkylamine group having 1 to 30 carbon atoms, a substituted or unsubstituted arylamine group having 5 to 30 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted aryl group having 5 to 50 carbon atoms, a substituted or unsubstituted C3 to C30 cycloalkyl having 3 to 30 carbon atoms, a substituted or unsubstituted C3 to C30 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl, A substituted or unsubstituted heteroaryl group having 2 to 50 carbon atoms, a substituted or unsubstituted silyl group, an amino group, a thiol group, a cyano group, a hydroxyl group, a nitro group and a halogen group.

또한, 상기 R1 내지 R8 중 인접한 치환기는 서로 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.The adjacent substituents of R 1 to R 8 may be connected with each other to form a monocyclic or polycyclic ring of an alicyclic or aromatic group and the carbon atom of the monocyclic or aromatic monocyclic or polycyclic ring formed may be N, Lt; / RTI > may be substituted with any one or more heteroatoms selected from < RTI ID = 0.0 >

또한, 상기 R1 내지 R8은 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
Each of R 1 to R 8 may further be substituted with at least one substituent, and the at least one substituent may be substituted with at least one substituent selected from the group consisting of deuterium, cyano group, halogen group, hydroxyl group, nitro group, An alkyl group having 1 to 24 carbon atoms, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, A heteroaryl group having 2 to 24 carbon atoms, an alkoxy group having 1 to 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, An alkylsilyl group having 1 to 24 carbon atoms, an arylsilyl group having 1 to 24 carbon atoms, and an aryloxy group having 1 to 24 carbon atoms.

본 발명에 따른 [화학식 1]의 유기발광 화합물은 하기 [화학식 2] 내지 [화학식 17] 중에서 선택되는 어느 하나일 수 있다.The organic electroluminescent compound of Formula 1 according to the present invention may be any one selected from the following Formulas 2 to 17:

Figure pat00005
Figure pat00005

상기 [화학식 2] 내지 [화학식 17]에서, X1 내지 X11의 정의는 상기 [화학식 1]에서의 정의와 동일하다.In the above formulas (2) to (17), the definitions of X 1 to X 11 are as defined in the above formula (1).

또한, 상기 X1 내지 X11의 각 치환기는 인접한 치환기와 서로 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.
Each of the substituents of X 1 to X 11 may be connected to adjacent substituents to form a monocyclic or polycyclic ring of an alicyclic or aromatic group, and the carbon atom of the formed alicyclic or aromatic monocyclic or polycyclic ring may be N , S and < RTI ID = 0.0 > O, < / RTI >

또한, 본 발명은 상기 [화학식 2] 내지 [화학식 17]에서 보는 바와 같은 코어 골격에 특징적인 치환체를 갖는 것을 특징으로 한다.In addition, the present invention is characterized by having a substituent characteristic of the core skeleton as shown in the above formulas (2) to (17).

먼저, [화학식 1] 내지 [화학식 17]에서, 상기 X2 내지 X6 중 적어도 하나 이상은 CR3이고, 상기 *-R3는 하기 [구조식 1]인 것을 특징으로 하고, 상기와 같은 코어 골격에 하기 [구조식 1]의 치환기를 적어도 하나 이상 포함하여 분자 구조 평판도가 매우 우수하고 삼중항 에너지가 높아 특히, 정공수송 재료로 활용될 수 있다.At least one of X 2 to X 6 in the formulas (1) to (17) is CR 3 , and * -R 3 is represented by the following structural formula (1) Has at least one substituent of the following structural formula 1 and has a very high molecular structure flatness and a high triplet energy, so that it can be used as a hole transport material.

[구조식 1][Structural formula 1]

Figure pat00006
Figure pat00006

[구조식 1]에서,In the structural formula 1,

L1은 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택된다.L 1 is a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted heteroarylene group having 2 to 50 carbon atoms in which at least one unsubstituted or substituted unsubstituted arylene group having 5 to 50 carbon atoms and a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms is fused.

n은 0 내지 4의 정수이고, n이 2 이상인 경우, 복수 개의 L1은 서로 동일하거나 상이할 수 있다.n is an integer of 0 to 4, and when n is 2 or more, a plurality of L 1 may be the same or different from each other.

Ar1 및 Ar2는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택된다.Ar 1 and Ar 2 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group, a substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl substituted or unsubstituted aryl group having 5 to 50 carbon atoms, And a substituted or unsubstituted C2 to C50 heteroaryl group in which one or more ring-opened cycloalkyl having 3 to 30 carbon atoms is fused.

또한, 상기 Ar1 및 Ar2는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.Ar 1 and Ar 2 may be bonded to each other or may be connected to adjacent substituents to form a monocyclic or polycyclic ring of an alicyclic or aromatic group. The carbon atom of the formed alicyclic or aromatic monocyclic or polycyclic ring may be N, S and < RTI ID = 0.0 > O, < / RTI >

p는 0 내지 3이 정수이고, 상기 p가 2 이상인 경우 복수의 *-( )는 서로 동일하거나 상이할 수 있다.p is an integer of 0 to 3, and when p is 2 or more, a plurality of * - () may be the same or different from each other.

또한, 상기 L1, Ar1 및 Ar2는 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
Further, L 1, Ar 1 and Ar 2 each may be further substituted with one or more substituents, the one or more substituents are deuterium, a cyano group, an alkyl group, a halogen group, a hydroxyl group, a nitro group, having 1 to 24 carbon atoms, A halogenated alkyl group having 1 to 24 carbon atoms, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, A heteroaryl group having 2 to 24 carbon atoms, a heteroarylalkyl group having 2 to 24 carbon atoms, an alkoxy group having 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms , An alkylsilyl group having 1 to 24 carbon atoms, an arylsilyl group having 1 to 24 carbon atoms, and an aryloxy group having 1 to 24 carbon atoms.

다음으로, [화학식 1] 내지 [화학식 17]에서, 상기 X2 내지 X10 중 하나 이상은 CR3이고, 상기 *-R3는 하기 [구조식 2]인 것을 특징으로 하고, 상기와 같은 코어 골격에 하기 [구조식 2]의 치환기를 적어도 하나 이상 포함하여 분자 구조 평판도가 매우 우수하고 삼중항 에너지가 높아 특히, 발광층의 인광 호스트 화합물로 활용될 수 있다.In the formulas (1) to (17), at least one of X 2 to X 10 is CR 3 , and * -R 3 is [Structural Formula 2] Has at least one substituent of the following formula [2] and has a very high molecular structure flatness and a high triplet energy, so that it can be used as a phosphorescent host compound in a light emitting layer.

[구조식 2][Structural formula 2]

Figure pat00007
Figure pat00007

상기 [구조식 2]에서,In the above formula 2,

L2는 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택된다.L 2 is a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted alkylene group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted heteroarylene group having 2 to 50 carbon atoms in which at least one unsubstituted or substituted unsubstituted arylene group having 5 to 50 carbon atoms and a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms is fused.

m은 0 내지 4의 정수이고, m이 2 이상인 경우, 복수 개의 L2는 서로 동일하거나 상이할 수 있다.m is an integer of 0 to 4, and when m is 2 or more, a plurality of L 2 may be the same or different from each other.

Ar3는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택된다.And Ar 3 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 heteroaryl group, a substituted or unsubstituted C6 to C30 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl, And a substituted or unsubstituted C2 to C50 heteroaryl group in which at least one of 3 to 30 cycloalkyls is fused.

또한, q는 0 내지 3이 정수이고, 상기 q가 2 이상인 경우 복수의 Ar3는 서로 동일하거나 상이할 수 있고, 상기 복수의 Ar3 및 이의 치환기는 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.And q is an integer of 0 to 3, and when q is 2 or more, a plurality of Ar 3 may be the same or different from each other, and the plurality of Ar 3 and the substituent thereof may be linked to adjacent substituents to form alicyclic or aromatic groups And a carbon atom of the formed alicyclic or aromatic monocyclic or polycyclic ring may be substituted with any one or more heteroatoms selected from N, S and O.

또한, 상기 L2 및 Ar3는 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
Each of L 2 and Ar 3 may be further substituted with one or more substituents. The substituent may be one or more substituents selected from the group consisting of deuterium, cyano, halogen, hydroxy, nitro, alkyl having 1 to 24 carbon atoms, An alkyl group having 1 to 24 carbon atoms, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, A heteroaryl group having 2 to 24 carbon atoms, an alkoxy group having 1 to 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, An alkylsilyl group having 1 to 24 carbon atoms, an arylsilyl group having 1 to 24 carbon atoms, and an aryloxy group having 1 to 24 carbon atoms.

본 발명에 있어서, 상기 치환기들의 예시들에 대해서 아래에서 구체적으로 설명하나, 이에 한정되는 것은 아니다.In the present invention, examples of the substituents will be specifically described below, but the present invention is not limited thereto.

본 발명에 있어서, 상기 알킬기는 직쇄 또는 분지쇄일 수 있고, 탄소수는 특별히 한정되지 않으나 1 내지 50인 것이 바람직하다. 구체적인 예로는 메틸기, 에틸기, 프로필기, n-프로필기, 이소프로필기, 부틸기, n-부틸기, 이소부틸기, tert-부틸기, sec-부틸기, 1-메틸-부틸기, 1-에틸-부틸기, 펜틸기, n-펜틸기, 이소펜틸기, 네오펜틸기, tert-펜틸기, 헥실기, n-헥실기, 1-메틸펜틸기, 2-메틸펜틸기, 4-메틸-2-펜틸기, 3,3-디메틸부틸기, 2-에틸부틸기, 헵틸기, n-헵틸기, 1-메틸헥실기, 시클로펜틸메틸기, 시클로헥틸메틸기, 옥틸기, n-옥틸기, tert-옥틸기, 1-메틸헵틸기, 2-에틸헥실기, 2-프로필펜틸기, n-노닐기, 2,2-디메틸헵틸기, 1-에틸-프로필기, 1,1-디메틸-프로필기, 이소헥실기, 2-메틸펜틸기, 4-메틸헥실기, 5-메틸헥실기 등이 있으나, 이들에 한정되지 않는다.In the present invention, the alkyl group may be linear or branched, and the number of carbon atoms is not particularly limited, but is preferably 1 to 50. Specific examples include methyl, ethyl, propyl, n-propyl, isopropyl, butyl, n-butyl, isobutyl, Ethyl, propyl, isopropyl, n-butyl, isobutyl, isobutyl, isobutyl, A tert-butyl group, a tert-butyl group, a 2-pentyl group, a 3,3-dimethylbutyl group, a 2-ethylbutyl group, a heptyl group, Ethylhexyl group, 2-propylpentyl group, n-nonyl group, 2,2-dimethylheptyl group, 1-ethyl-propyl group, 1,1-dimethyl-propyl group , Isohexyl group, 2-methylpentyl group, 4-methylhexyl group, 5-methylhexyl group and the like, but are not limited thereto.

본 발명에 있어서, 알콕시기는 직쇄 또는 분지쇄일 수 있다. 알콕시기의 탄소수는 특별히 한정되지 않으나, 입체적 방해를 주지 않는 범위인 1 내지 30개인 것이 바람직하다. 구체적으로, 메톡시기, 에톡시기, n-프로폭시기, 이소프로폭시기, i-프로필옥시기, n-부톡시기, 이소부톡시기, tert-부톡시기, sec-부톡시기, n-펜틸옥시기, 네오펜틸옥시기, 이소펜틸옥시기, n-헥실옥시기, 3,3-디메틸부틸옥시기, 2-에틸부틸옥시기, n-옥틸옥시기, n-노닐옥시기, n-데실옥시기, 벤질옥시기, p-메틸벤질옥시기 등이 될 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the alkoxy group may be linear or branched. The number of carbon atoms of the alkoxy group is not particularly limited, but is preferably in the range of 1 to 30, which does not cause steric hindrance. Specific examples thereof include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an i-propyloxy group, a n-butoxy group, an isobutoxy group, a tert- , Neopentyloxy group, isopentyloxy group, n-hexyloxy group, 3,3-dimethylbutyloxy group, 2-ethylbutyloxy group, n-octyloxy group, n- , A benzyloxy group, a p-methylbenzyloxy group, and the like, but are not limited thereto.

본 발명에 있어서, 상기 알케닐기는 직쇄 또는 분지쇄일 수 있고, 탄소수는 특별히 한정되지 않으나, 2 내지 40인 것이 바람직하다. 구체적인 예로는 비닐기, 1-프로페닐기, 이소프로페닐기, 1-부테닐기, 2-부테닐기, 3-부테닐기, 1-펜테닐기, 2-펜테닐기, 3-펜테닐기, 3-메틸-1-부테닐기, 1,3-부타디에닐기, 알릴기, 1-페닐비닐-1-일기, 2-페닐비닐-1-일기, 2,2-디페닐비닐-1-일기, 2-페닐-2-(나프틸-1-일)비닐-1-일기, 2,2-비스(디페닐-1-일)비닐-1-일기, 스틸베닐기, 스티레닐기 등이 있으나 이들에 한정되지 않는다.In the present invention, the alkenyl group may be straight-chain or branched, and the number of carbon atoms is not particularly limited, but is preferably 2 to 40. Specific examples include a vinyl group, a 1-propenyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, 2-phenylvinyl-1-yl group, 2,2-diphenylvinyl-1-yl group, 2-phenyl-2-yl group, But are not limited to, - (naphthyl-1-yl) vinyl-1-yl group, 2,2-bis (diphenyl-1-yl) vinyl-1-yl group, stilbenyl group, styrenyl group and the like.

본 발명에 있어서, 아릴기는 단환식 또는 다환식일 수 있고, 탄소수는 특별히 한정되지 않으나 6 내지 60인 것이 바람직하다. 단환식 아릴기의 예로는 페닐기, 비페닐기, 터페닐기, 스틸벤기 등이 있고, 다환식 아릴기의 예로는 나프틸기, 안트라세닐기, 페난트레닐기, 파이레닐기, 페릴레닐기, 테트라세닐기, 크라이세닐기, 플루오레닐기, 아세나프타센닐기, 트리페닐렌기, 플루오안트렌(fluoranthrene)기 등이 있으나, 본 발명의 범위가 이들 예로만 한정되는 것은 아니다.In the present invention, the aryl group may be monocyclic or polycyclic, and the number of carbon atoms is not particularly limited, but is preferably 6 to 60. [ Examples of the monocyclic aryl group include a phenyl group, a biphenyl group, a terphenyl group and a stilbene group. Examples of the polycyclic aryl group include a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, a perylenyl group, , A chlorenyl group, a fluorenyl group, an acenaphthacenyl group, a triphenylene group, and a fluororanthrene group, but the scope of the present invention is not limited to these examples.

본 발명에 있어서, 헤테로고리기는 이종원자로 O, N 또는 S를 포함하는 헤테로고리기로서, 탄소수는 특별히 한정되지 않으나 탄소수 2 내지 60인 것이 바람직하다. 헤테로고리기의 예로는 티오펜기, 퓨란기, 피롤기, 이미다졸기, 티아졸기, 옥사졸기, 옥사디아졸기, 트리아졸기, 피리딜기, 비피리딜기, 피리미딜기, 트리아진기, 트리아졸기, 아크리딜기, 피리다진기, 피라지닐기, 퀴놀리닐기, 퀴나졸린기, 퀴녹살리닐기, 프탈라지닐기, 피리도 피리미디닐기, 피리도 피라지닐기, 피라지노 피라지닐기, 이소퀴놀린기, 인돌기, 카바졸기, 벤조옥사졸기, 벤조이미다졸기, 벤조티아졸기, 벤조카바졸기, 벤조티오펜기, 디벤조티오펜기, 벤조퓨라닐기, 디벤조퓨라닐기, 페난트롤린기, 티아졸릴기, 이소옥사졸릴기, 옥사디아졸릴기, 티아디아졸릴기, 벤조티아졸릴기, 페노티아지닐기 등이 있으나, 이들에만 한정되는 것은 아니다.In the present invention, the heterocyclic group is a heterocyclic group containing O, N or S as a heteroatom, and the number of carbon atoms is not particularly limited, but is preferably 2 to 60 carbon atoms. Examples of the heterocyclic group include a thiophene group, a furane group, a furyl group, an imidazole group, a thiazole group, an oxazole group, an oxadiazole group, a triazole group, a pyridyl group, a bipyridyl group, a pyrimidyl group, A pyridazinyl group, a pyrazinopyrazinyl group, an isoquinoline group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolinyl group, an isoquinolyl group, , An indole group, a carbazole group, a benzoxazole group, a benzoimidazole group, a benzothiazole group, a benzocarbazole group, a benzothiophene group, a dibenzothiophene group, a benzofuranyl group, a dibenzofurancyl group, a phenanthroline group, An isothiazolyl group, an isoxazolyl group, an oxadiazolyl group, a thiadiazolyl group, a benzothiazolyl group, a phenothiazinyl group and the like, but is not limited thereto.

본 발명에 있어서, 아릴옥시기, 아릴티옥시기, 아릴술폭시기 및 아랄킬아민기 중의 아릴기는 전술한 아릴기의 예시와 같다. 구체적으로 아릴옥시기로는 페녹시기, p-토릴옥시기, m-토릴옥시기, 3,5-디메틸-페녹시기, 2,4,6-트리메틸페녹시기, ptert-부틸페녹시기, 3-비페닐옥시기, 4-비페닐옥시기, 1-나프틸옥시기, 2-나프틸옥시기, 4-메틸-1-나프틸옥시기, 5-메틸-2-나프틸옥시기, 1-안트릴옥시기, 2-안트릴옥시기, 9-안트릴옥시기, 1-페난트릴옥시기, 3-페난트릴옥시기, 9-페난트릴옥시기 등이 있고, 아릴티옥시기로는 페닐티옥시기기, 2-메틸페닐티옥시기, 4-tert-부틸페닐티옥시기 등이 있으며, 아릴술폭시기로는 벤젠술폭시기, p-톨루엔술폭시기 등이 있으나, 이에 한정되지 않는다.In the present invention, the aryl group in the aryloxy group, arylthioxy group, arylsulfoxy group and aralkylamine group is the same as the aforementioned aryl group. Specific examples of the aryloxy group include a phenoxy group, a p-tolyloxy group, an m-tolyloxy group, a 3,5-dimethyl-phenoxy group, a 2,4,6-trimethylphenoxy group, a ptert- Anthryloxy group, 2-naphthyloxy group, 2-naphthyloxy group, 4-methyl-1-naphthyloxy group, Anthryloxy group, 9-anthryloxy group, 1-phenanthryloxy group, 3-phenanthryloxy group, 9-phenanthryloxy group and the like. Examples of the arylthioxy group include phenylthioxy group, 2- A 4-tert-butylphenyloxy group, and the like. Examples of the arylsulfoxy group include benzene sulfoxy group and p-toluenesulfoxy group. However, the present invention is not limited thereto.

본 발명에 있어서, 시클로알킬기는 특별히 한정되지 않으나, 탄소수 3 내지 60인 것이 바람직하며, 구체적으로 시클로프로필기 시클로부틸기 시클로펜틸기 3-메틸시클로펜틸기 2,3-디메틸시클로펜틸기, 시클로헥실기, 3-메틸시클로헥실기, 4-메틸시클로헥실기, 2,3-디메틸시클로헥실기, 3,4,5-트리메틸시클로헥실기, 4-tert-부틸시클로헥실기, 시클로헵틸기, 시클로옥틸기 등이 있으나, 이에 한정되지 않는다.In the present invention, the cycloalkyl group is not particularly limited, but preferably has 3 to 60 carbon atoms, and specifically includes cyclopropyl group, cyclobutyl group, cyclopentyl group, 3-methylcyclopentyl group, 2,3-dimethylcyclopentyl group, Methylcyclohexyl group, 2,3-dimethylcyclohexyl group, 3,4,5-trimethylcyclohexyl group, 4-tert-butylcyclohexyl group, cycloheptyl group, cyclo An octyl group, and the like, but are not limited thereto.

본 발명에 있어서, 할로겐기의 예로는 불소, 염소, 브롬 또는 요오드가 있다.In the present invention, examples of the halogen group include fluorine, chlorine, bromine or iodine.

본 발명에 있어서, 아릴아민기의 예로는 치환 또는 비치환된 모노아릴아민기, 치환 또는 비치환된 디아릴아민기, 또는 치환 또는 비치환된 트리아릴아민기가 있다. 상기 아릴아민기 중의 아릴기는 단환식 아릴기일 수 있고, 다환식 아릴기일 수 있다. 상기 아릴기가 2 이상을 포함하는 아릴아민기는 단환식 아릴기, 다환식 아릴기, 또는 단환식아릴기와 다환식 아릴기를 동시에 포함할 수 있다.In the present invention, examples of the arylamine group include a substituted or unsubstituted monoarylamine group, a substituted or unsubstituted diarylamine group, or a substituted or unsubstituted triarylamine group. The aryl group in the arylamine group may be a monocyclic aryl group or a polycyclic aryl group. The arylamine group having at least two aryl groups may contain a monocyclic aryl group, a polycyclic aryl group, or a monocyclic aryl group and a polycyclic aryl group at the same time.

상기 아릴아민기의 구체적인 예로는 페닐아민기, 나프틸아민기, 비페닐아민기, 안트라세닐아민기, 3-메틸-페닐아민기, 4-메틸-나프틸아민기, 2-메틸-비페닐아민기, 9-메틸-안트라세닐아민기, 디페닐 아민기, 페닐 나프틸 아민기, 디톨릴 아민기, 페닐 톨릴 아민기, 카바졸기 및 트리페닐 아민기 등이 있으나, 이에 한정되는 것은 아니다.Specific examples of the arylamine group include a phenylamine group, a naphthylamine group, a biphenylamine group, an anthracenylamine group, a 3-methylphenylamine group, a 4-methylnaphthylamine group, But are not limited to, an amine group, a 9-methyl-anthracenylamine group, a diphenylamine group, a phenylnaphthylamine group, a ditolylamine group, a phenyltolylamine group, a carbazole group and a triphenylamine group.

본 발명에 있어서, 실릴기는 구체적으로 트리메틸실릴기, 트리에틸실릴기, t-부틸디메틸실릴기, 비닐디메틸실릴기, 프로필디메틸실릴기, 트리페닐실릴기, 디페닐실릴기, 페닐실릴기 등이 있으나 이에 한정되지 않는다.In the present invention, the silyl group is specifically exemplified by trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, vinyldimethylsilyl, propyldimethylsilyl, triphenylsilyl, diphenylsilyl, But are not limited thereto.

본 발명에 있어서, 헤테로아릴아민기 중의 헤테로 아릴기는 전술한 헤테로고리기의 예시 중에서 선택될 수 있다.In the present invention, the heteroaryl group in the heteroarylamine group can be selected from the examples of the above-mentioned heterocyclic group.

본 발명에 있어서, 알킬티옥시기, 알킬술폭시기 중의 알킬기는 전술한 알킬기의 예시와 같다. 구체적으로 알킬티옥시기로는 메틸티옥시기, 에틸티옥시기, tert-부틸티옥시기, 헥실티옥시기, 옥틸티옥시기 등이 있고, 알킬술폭시기로는 메실, 에틸술폭시기, 프로필술폭시기, 부틸술폭시기 등이 있으나, 이에 한정되지 않는다.In the present invention, the alkyloxy group in the alkylthio group and the alkyl group in the alkylsulfoxy group are the same as the aforementioned alkyl groups. Specific examples of the alkyloxy group include a methylthio group, an ethylthio group, a tert-butylthio group, a hexylthio group and an octylthio group. Examples of the alkylsulfoxy group include a mesyl group, an ethylsulfoxy group, a propylsulfoxy group, But are not limited thereto.

본 발명에 있어서, "치환 또는 비치환된"이란, 중수소, 할로겐기, 니트릴기, 니트로기, 히드록시기, 알킬기, 시클로알킬기, 알콕시기, 아릴옥시기, 알킬티옥시기, 아릴티옥시기, 알킬술폭시기, 아릴술폭시기, 알케닐기, 실릴기, 붕소기, 알킬아민기, 아랄킬아민기, 아릴아민기, 아릴기, 플루오레닐기, 카바졸기 및 N, O 및 S 원자 중 1개 이상을 포함하는 헤테로고리기 중 적어도 하나의 치환기로 치환 또는 비치환된 것을 의미한다.In the present invention, the "substituted or unsubstituted" means a group selected from the group consisting of deuterium, halogen, nitrile, nitro, hydroxy, alkyl, cycloalkyl, , An arylsulfoxy group, an alkenyl group, a silyl group, a boron group, an alkylamine group, an aralkylamine group, an arylamine group, an aryl group, a fluorenyl group, a carbazole group and at least one of N, O and S atoms Substituted or unsubstituted with at least one substituent in the heterocyclic group.

본 발명에 있어서, 치환된 아릴렌기라 함은, 페닐기, 비페닐기, 나프탈렌기, 플루오레닐기, 파이레닐기, 페난트레닐기, 페릴렌기, 테트라세닐기. 안트라센닐기 등이 다른 치환기로 치환된 것을 의미한다.In the present invention, the substituted arylene group means a phenyl group, a biphenyl group, a naphthalene group, a fluorenyl group, a pyrenyl group, a phenanthrenyl group, a perylene group, a tetracenyl group. Anthracenyl group and the like are substituted with other substituents.

본 발명에 있어서, 치환된 헤테로아릴렌기라 함은, 피리딜기, 티오페닐기, 트리아진기, 퀴놀린기, 페난트롤린기, 이미다졸기, 티아졸기, 옥사졸기, 카바졸기 및 이들의 축합헤테로고리기, 예컨대 벤즈퀴놀린기, 벤즈이미다졸기, 벤즈옥사졸기, 벤즈티아졸기, 벤즈카바졸기, 디벤조티오페닐기, 디벤조퓨란기 등이 다른 치환기로 치환된 것을 의미한다.
In the present invention, the substituted heteroarylene group includes a pyridyl group, a thiophenyl group, a triazine group, a quinoline group, a phenanthroline group, an imidazole group, a thiazole group, an oxazole group, a carbazole group and condensed heterocyclic groups, Such as a benzoquinoline group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzzcarbazole group, a dibenzothiophenyl group, a dibenzofurane group and the like are substituted with other substituents.

상기 [화학식 1]로 표시되는 본 발명에 따른 유기발광 화합물은 그 구조적 특이성으로 인하여 유기전계발광소자의 유기물층으로 사용될 수 있고, 보다 구체적으로 유기물층 내의 정공수송층 내지 정공주입층에 정공수송물질로 사용될 수 있다.The organic luminescent compound according to the present invention represented by Formula 1 can be used as an organic material layer of an organic electroluminescent device due to its structural specificity and more specifically can be used as a hole transport material in a hole transport layer or a hole injection layer in an organic material layer. have.

본 발명에 따른 [화학식 1]로 표시되는 정공수송물질로 채용될 수 있는 유기발광 화합물의 구체적인 예로는 하기 화합물들이 있으나, 이들에만 한정되는 것은 아니다.Specific examples of the organic luminescent compound that can be employed as the hole transporting material represented by Formula 1 according to the present invention include, but are not limited to, the following compounds.

Figure pat00008
Figure pat00008

Figure pat00009
Figure pat00009

Figure pat00010
Figure pat00010

Figure pat00011
Figure pat00011

Figure pat00012
Figure pat00012

Figure pat00013
Figure pat00013

Figure pat00014
Figure pat00014

Figure pat00015
Figure pat00015

Figure pat00016
Figure pat00016

Figure pat00017
Figure pat00017

Figure pat00018
Figure pat00018

Figure pat00019
Figure pat00019

Figure pat00020
Figure pat00020

Figure pat00021
Figure pat00021

Figure pat00022
Figure pat00022

Figure pat00023
Figure pat00023

Figure pat00024
Figure pat00024

Figure pat00025
Figure pat00025

Figure pat00026
Figure pat00026

Figure pat00027
Figure pat00027

Figure pat00028
Figure pat00028

Figure pat00029
Figure pat00029

Figure pat00030
Figure pat00030

Figure pat00031
Figure pat00031

Figure pat00032
Figure pat00032

Figure pat00033
Figure pat00033

Figure pat00034
Figure pat00034

Figure pat00035
Figure pat00035

Figure pat00036
Figure pat00036

Figure pat00037
Figure pat00037

Figure pat00038
Figure pat00038

Figure pat00039
Figure pat00039

Figure pat00040
Figure pat00040

Figure pat00041
Figure pat00041

Figure pat00042
Figure pat00042

Figure pat00043
Figure pat00043

Figure pat00044
Figure pat00044

Figure pat00045
Figure pat00045

Figure pat00046
Figure pat00046

Figure pat00047
Figure pat00047

Figure pat00048
Figure pat00048

Figure pat00049

Figure pat00049

상기 [화학식 1]로 표시되는 본 발명에 따른 유기발광 화합물은 그 구조적 특이성으로 인하여 유기전계발광소자의 유기물층으로 사용될 수 있고, 보다 구체적으로 발광층의 인광 호스트 화합물로 사용될 수 있다.The organic luminescent compound according to the present invention represented by Formula 1 can be used as an organic material layer of an organic electroluminescent device due to its structural specificity and more specifically as a phosphorescent host compound in a luminescent layer.

본 발명에 따른 [화학식 1]로 표시되는 발광층의 인광 호스트 화합물로 채용될 수 있는 유기발광 화합물의 구체적인 예로는 하기 화합물들이 있으나, 이들에만 한정되는 것은 아니다.Specific examples of the organic luminescent compound that can be employed as the phosphorescent host compound of the luminescent layer represented by Formula 1 according to the present invention include, but are not limited to, the following compounds.

Figure pat00050
Figure pat00050

Figure pat00051
Figure pat00051

Figure pat00052
Figure pat00052

Figure pat00053
Figure pat00053

Figure pat00054
Figure pat00054

Figure pat00055
Figure pat00055

Figure pat00056
Figure pat00056

Figure pat00057
Figure pat00057

Figure pat00058
Figure pat00058

Figure pat00059
Figure pat00059

Figure pat00060
Figure pat00060

Figure pat00061
Figure pat00061

Figure pat00062
Figure pat00062

Figure pat00063
Figure pat00063

Figure pat00064
Figure pat00064

Figure pat00065
Figure pat00065

Figure pat00066
Figure pat00066

Figure pat00067
Figure pat00067

Figure pat00068
Figure pat00068

Figure pat00069
Figure pat00069

Figure pat00070
Figure pat00070

Figure pat00071
Figure pat00071

Figure pat00072
Figure pat00072

Figure pat00073
Figure pat00073

Figure pat00074
Figure pat00074

Figure pat00075
Figure pat00075

Figure pat00076
Figure pat00076

Figure pat00077
Figure pat00077

Figure pat00078
Figure pat00078

Figure pat00079
Figure pat00079

Figure pat00080
Figure pat00080

Figure pat00081
Figure pat00081

Figure pat00082
Figure pat00082

Figure pat00083

Figure pat00083

상기와 같은 구조의 코어 구조에 다양한 치환기를 도입함으로써 도입된 치환기의 고유 특성을 갖는 유기발광 화합물을 합성할 수 있다. 예컨대, 유기전계발광소자의 제조시 사용되는 정공 주입층 물질, 정공 수송층 물질, 발광층 물질, 및 전자 수송층 물질에 사용되는 치환기를 상기 구조에 도입함으로써 각 유기물층에서 요구하는 조건들을 충족시키는 물질을 제조할 수 있다.An organic luminescent compound having the intrinsic characteristics of the substituent introduced by introducing various substituents into the core structure having the above structure can be synthesized. For example, by introducing a substituent used in a hole injecting layer material, a hole transporting layer material, a light emitting layer material, and an electron transporting layer material used in manufacturing an organic electroluminescent device into the structure, a material meeting the requirements of each organic material layer is manufactured .

특히, 본 발명에 따른 [화학식 1]로 표시되는 유기발광 화합물은 상기에서 살펴본 바와 같이, 특징적 코어 구조체에 치환기를 도입한 결과 평판 구조도가 우수하고, 높은 삼중항(triplet) 상태를 가짐을 확인하였는 바, 이를 유기전계발광소자의 유기물층에 채용시 효율, 구동전압, 수명 등에서 우수한 특성을 나타내는 유기전계발광소자의 구현이 가능하다.In particular, as described above, the organic luminescent compound represented by Formula 1 according to the present invention has a superior flat structure and a high triplet state as a result of introducing a substituent to the characteristic core structure. It is possible to realize an organic electroluminescent device exhibiting excellent characteristics in terms of efficiency, driving voltage and lifetime when the organic electroluminescent device is used in an organic material layer of the organic electroluminescent device.

본 발명의 화합물은 유기전계발광소자의 통상의 제조방법에 따라 소자에 적용할 수 있다.The compound of the present invention can be applied to a device according to a conventional method of manufacturing an organic electroluminescent device.

본 발명의 하나의 실시예에 따른 유기전계발광소자는 제1 전극과 제2 전극 및 이 사이에 배치된 유기물층을 포함하는 구조로 이루어질 수 있으며, 본 발명에 따른 유기발광 화합물을 소자의 유기물층에 사용한다는 것을 제외하고는 통상의 소자의 제조 방법 및 재료를 사용하여 제조될 수 있다.The organic electroluminescent device according to one embodiment of the present invention may have a structure including a first electrode, a second electrode and an organic material layer disposed therebetween, and the organic electroluminescent compound according to the present invention may be used for an organic material layer And can be manufactured using conventional device manufacturing methods and materials.

본 발명에 따른 유기전계발광소자의 유기물층은 단층 구조로 이루어질 수도 있으나, 2층 이상의 유기물층이 적층된 다층 구조로 이루어질 수 있다. 예컨대, 정공 주입층, 정공 수송층, 발광층, 전자 수송층, 전자 주입층 등을 포함하는 구조를 가질 수 있다. 그러나, 이에 한정되지 않고 더 적은 수의 유기물층을 포함할 수도 있다.The organic material layer of the organic electroluminescent device according to the present invention may have a single layer structure, but may have a multilayer structure in which two or more organic material layers are stacked. For example, a structure including a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer. However, it is not limited to this and may include a smaller number of organic layers.

따라서, 본 발명의 유기전계발광소자에서, 상기 유기물층은 정공 주입층, 정공 수송층, 전자 수송층, 전자 주입층, 정공 주입 및 정공 수송을 동시에 하는 층, 전자 주입 및 전자수송을 동시에 하는 층 및 발광층 중 1층 이상을 포함할 수 있고, 상기 층들 중 1층 이상이 상기 [화학식 1]로 표시되는 화합물을 포함할 수 있다.Therefore, in the organic electroluminescent device of the present invention, the organic material layer may be a hole injecting layer, a hole transporting layer, an electron transporting layer, an electron injecting layer, a layer simultaneously injecting and transporting holes, a layer simultaneously performing electron injection and electron transporting, One or more layers may be included, and at least one of the layers may include a compound represented by the above formula (1).

특히, 본 발명에 따른 유기발광 화합물은 정공수송 기능층 또는 발광층에 포함될 수 있으며, 발광층 내 호스트 물질로서 포함될 수 있다.In particular, the organic luminescent compound according to the present invention may be contained in the hole transporting functional layer or the luminescent layer, and may be included as a host material in the luminescent layer.

상기 [화학식 1]로 표시되는 화합물이 발광층 내 호스트 물질로서 포함되는 경우에, 상기 발광층은 1종 이상의 인광 도펀트를 포함할 수 있으며, 상기 발광층이 호스트 및 도펀트를 포함할 경우, 도펀트의 함량은 통상적으로 호스트 약 100 중량부를 기준으로 하여 약 0.01 내지 약 20 중량부의 범위에서 선택될 수 있다.In the case where the compound represented by Formula 1 is included as a host material in the light emitting layer, the light emitting layer may include at least one phosphorescent dopant. When the light emitting layer includes a host and a dopant, In the range of about 0.01 to about 20 parts by weight based on 100 parts by weight of the host.

본 발명의 일 실시예에 의하면, 상기 발광층에 본 발명에 따른 [화학식 1]로 표시되는 호스트 화합물과 하기의 [구조식 2] 내지 [구조식 8] 중에서 선택되는 도펀트 화합물을 1종 이상 더 포함할 수 있다.According to an embodiment of the present invention, the light emitting layer may further contain at least one dopant compound selected from the following [structural formulas 2] to [structural formula 8] in the host compound represented by the general formula [1] have.

[구조식 2][Structural formula 2]

Figure pat00084
Figure pat00084

Figure pat00085
Figure pat00085

Figure pat00086
Figure pat00086

Figure pat00087
Figure pat00087

Figure pat00088

Figure pat00088

[구조식 3][Structural Formula 3]

Figure pat00089

Figure pat00089

[구조식 4][Structural Formula 4]

Figure pat00090

Figure pat00090

[구조식 5][Structural Formula 5]

Figure pat00091

Figure pat00091

[구조식 6][Structural Formula 6]

Figure pat00092

Figure pat00092

[구조식 7][Structural Formula 7]

Figure pat00093

Figure pat00093

[구조식 8][Structural formula 8]

Figure pat00094

Figure pat00094

이와 같은 다층 구조의 유기물층에서 상기 [화학식 1]로 표시되는 화합물은 발광층, 정공 주입/정공 수송과 발광을 동시에 하는 층, 정공 수송과 발광을 동시에 하는 층, 또는 전자 수송과 발광을 동시에 하는 층 등에 포함될 수 있다.In the organic compound layer having such a multilayer structure, the compound represented by the formula (1) may be used in combination with a light emitting layer, a layer that simultaneously transports holes and holes, a layer that simultaneously transports holes and emits light, .

예컨대, 본 발명에 따른 유기 전자 소자의 구조는 도 1 내지 5에 예시되어 있다.For example, the structure of an organic electronic device according to the present invention is illustrated in Figs.

도 1에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 화학식 1로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.1 shows an organic electronic device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6 and a cathode 7 are sequentially laminated on a substrate 1 Structure is illustrated. In such a structure, the compound represented by Formula 1 may be included in the hole injecting layer 3, the hole transporting layer 4, the light emitting layer 5, or the electron transporting layer 6.

도 2에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 화학식 1로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4) 또는 전자 수송층(6)에 포함될 수 있다.2 shows the structure of an organic electronic device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5 and a cathode 7 are sequentially laminated on a substrate 1. In such a structure, the compound represented by Formula 1 may be included in the hole injecting layer 3, the hole transporting layer 4, or the electron transporting layer 6.

도 3에는 기판(1) 위에 양극(2), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 화학식 1로 표시되는 화합물은 상기 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.3 illustrates the structure of an organic electronic device in which an anode 2, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6, and a cathode 7 are sequentially stacked on a substrate 1. In such a structure, the compound represented by Formula 1 may be included in the hole transport layer 4, the light emitting layer 5, or the electron transport layer 6.

도 4에는 기판(1) 위에 양극(2), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 화학식 1로 표시되는 화합물은 상기 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.4 illustrates the structure of an organic electronic device in which an anode 2, a light emitting layer 5, an electron transport layer 6, and a cathode 7 are sequentially laminated on a substrate 1. In FIG. In such a structure, the compound represented by Formula 1 may be included in the light-emitting layer 5 or the electron-transporting layer 6.

도 5에는 기판(1) 위에 양극(2), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기 전자 소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 화학식 1로 표시되는 화합물은 상기 발광층(5)에 포함될 수 있다.5 illustrates the structure of an organic electronic device in which an anode 2, a light-emitting layer 5, and a cathode 7 are sequentially stacked on a substrate 1. As shown in Fig. In such a structure, the compound represented by Formula 1 may be included in the light emitting layer 5.

예컨대, 본 발명에 따른 유기 전자 소자의 구조는 도 1 내지 5에 예시되어 있다.For example, the structure of an organic electronic device according to the present invention is illustrated in Figs.

도 1에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.1 shows an organic electroluminescent device 1 in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5, an electron transporting layer 6 and a cathode 7 are sequentially laminated on a substrate 1 Are illustrated. In this structure, the compound represented by the formula (1) may be included in the hole injection layer (3), the hole transport layer (4), the light emitting layer (5) or the electron transport layer (6).

도 2에는 기판(1) 위에 양극(2), 정공 주입층(3), 정공 수송층(4), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1]로 표시되는 화합물은 상기 정공 주입층(3), 정공 수송층(4) 또는 전자 수송층(6)에 포함될 수 있다.2 shows a structure of an organic electroluminescent device in which an anode 2, a hole injecting layer 3, a hole transporting layer 4, a light emitting layer 5 and a cathode 7 are sequentially laminated on a substrate 1 . In such a structure, the compound represented by the formula (1) may be included in the hole injection layer (3), the hole transport layer (4), or the electron transport layer (6).

도 3에는 기판(1) 위에 양극(2), 정공 수송층(4), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1]로 표시되는 화합물은 상기 정공 수송층(4), 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.3 illustrates the structure of an organic electroluminescent device in which an anode 2, a hole transport layer 4, a light emitting layer 5, an electron transport layer 6, and a cathode 7 are sequentially laminated on a substrate 1. In such a structure, the compound represented by the formula (1) may be included in the hole transport layer (4), the light emitting layer (5), or the electron transport layer (6).

도 4에는 기판(1) 위에 양극(2), 발광층(5), 전자 수송층(6) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1]로 표시되는 화합물은 상기 발광층(5) 또는 전자 수송층(6)에 포함될 수 있다.4 shows the structure of an organic electroluminescent device in which an anode 2, a light emitting layer 5, an electron transport layer 6 and a cathode 7 are sequentially laminated on a substrate 1. [ In such a structure, the compound represented by the formula (1) may be included in the light-emitting layer (5) or the electron-transporting layer (6).

도 5에는 기판(1) 위에 양극(2), 발광층(5) 및 음극(7)이 순차적으로 적층된 유기전계발광소자의 구조가 예시되어 있다. 이와 같은 구조에 있어서, 상기 [화학식 1]로 표시되는 화합물은 상기 발광층(5)에 포함될 수 있다.5 illustrates the structure of an organic electroluminescent device in which an anode 2, a light-emitting layer 5, and a cathode 7 are sequentially laminated on a substrate 1. As shown in FIG. In such a structure, the compound represented by the formula (1) may be included in the luminescent layer (5).

예컨대, 본 발명에 따른 유기전계발광소자는 스퍼터링(sputtering)이나 전자빔 증발(e-beam evaporation)과 같은 PVD(physical vapor deposition) 방법을 이용하여, 기판 상에 금속 또는 전도성을 가지는 금속 산화물 또는 이들의 합금을 증착시켜 양극을 형성하고, 그 위에 정공 주입층, 정공 수송층, 발광층, 전자 수송층을 포함하는 유기물층을 형성한 후, 그 위에 음극으로 사용할 수 있는 물질을 증착시킴으로써 제조될 수 있다.For example, the organic electroluminescent device according to the present invention can be manufactured by using a physical vapor deposition (PVD) method such as sputtering or e-beam evaporation to form a metal oxide or a conductive metal oxide on the substrate, An anode is formed by depositing an alloy on the anode, and an organic material layer including a hole injecting layer, a hole transporting layer, a light emitting layer, and an electron transporting layer is formed on the anode, and then a substance usable as a cathode is deposited thereon.

이와 같은 방법 외에도, 기판 상에 음극 물질부터 유기물층, 양극 물질을 차례로 증착시켜 유기전계발광소자를 만들 수도 있다. 상기 유기물층은 정공 주입층, 정공 수송층, 발광층 및 전자 수송층 등을 포함하는 다층 구조일 수도 있으나, 이에 한정되지 않고 단층 구조일 수 있다. 또한, 상기 유기물층은 다양한 고분자 소재를 사용하여 증착법이 아닌 솔벤트 프로세스(solvent process), 예컨대 스핀 코팅, 딥 코팅, 닥터 블레이딩, 스크린 프린팅, 잉크젯 프린팅 또는 열 전사법 등의 방법에 의하여 더 적은 수의 층으로 제조할 수 있다.In addition to such a method, an organic electroluminescent device may be formed by sequentially depositing a cathode material, an organic material layer, and a cathode material on a substrate. The organic material layer may have a multi-layer structure including a hole injection layer, a hole transport layer, a light emitting layer, and an electron transport layer, but is not limited thereto and may have a single layer structure. In addition, the organic material layer may be formed using a variety of polymer materials by a solvent process such as a spin coating process, a dip coating process, a doctor blading process, a screen printing process, an inkjet printing process or a thermal transfer process, Layer.

상기 양극 물질로는 통상 유기물층으로 정공주입이 원활할 수 있도록 일함수가 큰 물질이 바람직하다. 본 발명에서 사용될 수 있는 양극 물질의 구체적인 예로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금, 아연 산화물, 인듐 산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물, ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 및 폴리아닐린과 같은 전도성 고분자 등이 있으나, 이들에만 한정되는 것은 아니다.As the anode material, a material having a large work function is preferably used so that hole injection can be smoothly conducted into the organic material layer. Specific examples of the cathode material that can be used in the present invention include metals such as vanadium, chromium, copper, zinc and gold or alloys thereof, zinc oxide, indium oxide, indium tin oxide (ITO), indium zinc oxide (IZO) metal oxides, ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT) , Conductive polymers such as polypyrrole and polyaniline, but are not limited thereto.

상기 음극 물질로는 통상 유기물층으로 전자 주입이 용이하도록 일함수가 작은 물질인 것이 바람직하다. 음극 물질의 구체적인 예로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석 및 납과 같은 금속 또는 이들의 합금, LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있으나, 이들에만 한정되는 것은 아니다.The negative electrode material is preferably a material having a small work function to facilitate electron injection into the organic material layer. Specific examples of the negative electrode material include a metal such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin and lead or an alloy thereof, a multilayer such as LiF / Al or LiO 2 / Structural materials, and the like, but are not limited thereto.

정공 주입 물질로는 낮은 전압에서 양극으로부터 정공을 잘 주입받을 수 있는 물질로서, 정공 주입 물질의 HOMO(highest occupied molecular orbital)가 양극 물질의 일함수와 주변 유기물층의 HOMO 사이인 것이 바람직하다. 정공 주입 물질의 구체적인 예로는 금속 포피린(porphyrine), 올리고티오펜, 아릴아민 계열의 유기물, 헥사니트릴 헥사아자트리페닐렌, 퀴나크리돈(quinacridone) 계열의 유기물, 페릴렌(perylene) 계열의 유기물, 안트라퀴논 및 폴리아닐린과 폴리티오펜 계열의 전도성 고분자 등이 있으나, 이들에만 한정되는 것은 아니다.As the hole injecting material, it is preferable that the highest occupied molecular orbital (HOMO) of the hole injecting material be between the work function of the anode material and the HOMO of the surrounding organic layer. Specific examples of the hole injecting material include metal porphyrine, oligothiophene, arylamine-based organic materials, hexanitrile hexaazatriphenylene, quinacridone-based organic materials, perylene-based organic materials, Anthraquinone, polyaniline and a polythiophene-based conductive polymer, but are not limited thereto.

정공 수송 물질로는 양극이나 정공 주입층으로부터 정공을 수송 받아 발광층으로 옮겨줄 수 있는 물질로 정공에 대한 이동성이 큰 물질이 적합하다. 구체적인 예로는 아릴아민 계열의 유기물, 전도성 고분자, 및 공액 부분과 비공액 부분이 함께 있는 블록 공중합체 등이 있으나, 이들에만 한정되는 것은 아니다.As the hole transporting material, a material capable of transporting holes from the anode or the hole injection layer to the light emitting layer and having high mobility to holes is suitable. Specific examples include arylamine-based organic materials, conductive polymers, and block copolymers having a conjugated portion and a non-conjugated portion together, but are not limited thereto.

발광 물질로는 정공 수송층과 전자 수송층으로부터 정공과 전자를 각각 수송받아 결합시킴으로써 가시광선 영역의 빛을 낼 수 있는 물질로서, 형광이나 인광에 대한 양자효율이 좋은 물질이 바람직하다. 구체적인 예로는 8-히드록시-퀴놀린 알루미늄 착물(Alq3), 카르바졸 계열 화합물, 이량체화 스티릴(dimerized styryl) 화합물, BAlq, 10-히드록시벤조 퀴놀린-금속 화합물, 벤족사졸, 벤즈티아졸 및 벤즈이미다졸 계열의 화합물, 폴리(p-페닐렌비닐렌)(PPV) 계열의 고분자, 스피로(spiro) 화합물, 폴리플루오렌, 루브렌 등이 있으나, 이들에만 한정되는 것은 아니다.The light emitting material is preferably a material capable of emitting light in the visible light region by transporting and combining holes and electrons from the hole transporting layer and the electron transporting layer, respectively, and having a high quantum efficiency for fluorescence or phosphorescence. Specific examples include 8-hydroxy-quinoline aluminum complex (Alq 3 ), carbazol-based compounds, dimerized styryl compounds, BAlq, 10-hydroxybenzoquinoline-metal compounds, benzoxazole, benzthiazole and A benzimidazole-based compound, a poly (p-phenylene vinylene) (PPV) -based polymer, a spiro compound, polyfluorene, rubrene, and the like.

전자 수송 물질로는 음극으로부터 전자를 잘 주입 받아 발광층으로 옮겨줄 수 있는 물질로서, 전자에 대한 이동성이 큰 물질이 적합하다. 구체적인 예로는 8-히드록시퀴놀린의 Al 착물, Alq3를 포함한 착물, 유기 라디칼 화합물, 히드록시플라본-금속 착물 등이 있으나, 이들에만 한정되는 것은 아니다.
As the electron transporting material, a material capable of transferring electrons from the cathode well into the light emitting layer, which is highly mobile, is suitable. Specific examples thereof include, but are not limited to, an Al complex of 8-hydroxyquinoline, a complex containing Alq 3 , an organic radical compound, and a hydroxyflavone-metal complex.

본 발명에 따른 유기전계발광소자는 사용되는 재료에 따라 전면 발광형, 후면 발광형 또는 양면 발광형일 수 있다.The organic electroluminescent device according to the present invention may be a front emission type, a back emission type, or a both-sided emission type, depending on the material used.

또한, 본 발명에 따른 유기발광 화합물은 유기 태양 전지, 유기 감광체, 유기 트랜지스터 등을 비롯한 유기 전자 소자에서도 유기전계발광소자에 적용되는 것과 유사한 원리로 작용할 수 있다.
In addition, the organic electroluminescent compound according to the present invention can act on a principle similar to that applied to an organic electroluminescent device in an organic electronic device including an organic solar cell, an organophotoreceptor, an organic transistor and the like.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나, 하기의 실시예는 본 발명을 예시하기 위한 것이며, 이에 의하여 본 발명의 범위가 한정되는 것은 아니다.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are intended to illustrate the invention and are not intended to limit the scope of the invention.

실시예Example 1 : 화합물 366의 합성 1: Synthesis of Compound 366

(1) (One) 제조예Manufacturing example 1 : 중간체 1-1의 합성 1: Synthesis of intermediate 1-1

Figure pat00095
Figure pat00095

2-nitroaniline(3.0 g, 0.022 mol)에 phenylmethanamine(7.0 g, 0.066 mol), Ferric chloride(0.07 g, 0.0004 mol) 넣고, 120 ℃에서 48시간 교반하여 반응시켰다. 반응 종료 후 실온으로 냉각하여 M.C 50 mL 넣고 30분간 교반 후 여과하였다. 얻어진 고체를 컬럼정제(n-Hexane:EA)하여 중간체 1-1을 3.1 g (수율 80%) 수득하였다.(m/z=194)
Phenylmethanamine (7.0 g, 0.066 mol) and ferric chloride (0.07 g, 0.0004 mol) were added to 2-nitroaniline (3.0 g, 0.022 mol) and the mixture was reacted at 120 ° C for 48 hours with stirring. After completion of the reaction, the reaction mixture was cooled to room temperature, and 50 mL of MC was added thereto, followed by stirring for 30 minutes, followed by filtration. The obtained solid was subjected to column purification (n-hexane: EA) to obtain 3.1 g (yield 80%) of Intermediate 1-1. (M / z = 194)

(2) (2) 제조예Manufacturing example 2 : 중간체 1-2의 합성 2: Synthesis of intermediate 1-2

Figure pat00096
Figure pat00096

중간체 1-1(2.0 g, 0.010 mol)에 methyl 2,6-dibromobenzoate(3.0 g, 0.015 mol), Potassium carbonate(2.8 g, 0.020 mol), Copper(0.1 g, 0.0020 mol), iodine copper(1.1 g, 0.006 mol)에 n-butyl ether 70 mL에 녹인 후 질소 하에서 48시간 교반하여 반응시켰다. 반응 종료 후 실온으로 냉각하여 H20 : MC 층분리 후 컬럼정제(n-Hexane : EA)하여 중간체 1-2을 2.8 g(수율 68%)수득하였다.(m/z=407)
Potassium carbonate (2.8 g, 0.020 mol), Copper (0.1 g, 0.0020 mol), iodine copper (1.1 g, 0.020 mol) were added to intermediate 1-1 (2.0 g, 0.010 mol) , 0.006 mol) were dissolved in 70 mL of n-butyl ether and reacted under nitrogen for 48 hours with stirring. After completion of the reaction, the reaction mixture was cooled to room temperature, and subjected to column separation (n-hexane: EA) after separation of H 2 O: MC layer to obtain 2.8 g (m / z = 407)

(3) (3) 제조예Manufacturing example 3 : 중간체 1-3의 합성 3: Synthesis of intermediate 1-3

Figure pat00097
Figure pat00097

중간체 1-2(4.0 g, 0.010 mol)를 30 mL ehter에 녹이고, -78 ℃로 냉각시킨 후 2.5 M BuLi(0.01 mL, 0.0005 mol)을 dropping시킨 후, 1시간 동안 교반하였다. 이를 서서히 실온으로 올려 4 시간 동안 더 교반하였다. 반응 완료 후 물 100 mL로 추출하여 유기층을 감압 건조하였다. 이를 EtOH : Acetone으로 재결정하여 중간체 1-3 (2.7 g ,67%)수득하였다 .(m/z= 407)
Intermediate 1-2 (4.0 g, 0.010 mol) was dissolved in a 30 mL ehter, cooled to -78 ° C, and 2.5 M BuLi (0.01 mL, 0.0005 mol) was dropwise added thereto, followed by stirring for 1 hour. The mixture was slowly warmed to room temperature and stirred for 4 hours. After completion of the reaction, the reaction mixture was extracted with 100 mL of water, and the organic layer was dried under reduced pressure. This was recrystallized from EtOH: Acetone to give intermediate 1-3 (2.7 g, 67%). (M / z = 407)

(4) (4) 제조예Manufacturing example 4 : 중간체 1-4의 합성 4: Synthesis of intermediate 1-4

Figure pat00098
Figure pat00098

중간체 1-3(4.0 g, 0.010 mol)를 50 mL의 농축된 H3PO4에 녹인 후 5 시간 동안 교반시켰다. 이를 물 100 mL와 Ethyl Acetate 100 mL로 추출하고, 유기층을 감압 건조하였다. 이를 EtOH 100 mL로 재결정하여 중간체 1-4 (2.8 g ,72%)수득하였다. (m/z=389)
Intermediate 1-3 (4.0 g, 0.010 mol) was dissolved in 50 mL of concentrated H 3 PO 4 and stirred for 5 h. It was extracted with 100 mL of water and 100 mL of Ethyl Acetate, and the organic layer was dried under reduced pressure. This was recrystallized from 100 mL of EtOH to obtain intermediate 1-4 (2.8 g, 72%). (m / z = 389)

(5) (5) 제조예Manufacturing example 5 : 중간체 1-4'의 합성 5: Synthesis of intermediate 1-4 '

Figure pat00099
Figure pat00099

중간체 1-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol), PdCl2(dppf)(0.3 g, 0.0004 mol), potassium-acetate(2.2 g, 0.016 mol)에 1,4-dioxane 80 mL를 넣고 95 ℃에서 24시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 1-4' 2.5 g (수율 71%) 수득하였다. (m/z=436)
To a solution of bis (pinacolato) dibron (2.5 g, 0.010 mol), PdCl 2 (dppf) (0.3 g, 0.0004 mol) and potassium acetate (2.2 g, 0.016 mol) in Intermediate 1-4 (3.0 g, 0.008 mol) , 4-dioxane (80 mL), and the mixture was reacted at 95 ° C for 24 hours with stirring. After completion of the reaction, the reaction mixture was cooled, separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 2.5 g (yield 71%) of intermediate 1-4 '. (m / z = 436)

(6) (6) 제조예Manufacturing example 6 : 중간체 1-5의 합성 6: Synthesis of intermediate 1-5

Figure pat00100
Figure pat00100

중간체 1-4'(3.0 g, 0.007 mol)에 1,4-dibromobenzene(1.3 g, 0.006 mol) Pd(dba)2(0.5 g, 0.00006 mol), sodium-tert-butoxide(2.2 g, 0.022 mol)에 Tol 80 mL를 넣고 95 ℃에서 4 시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 1-5를 2.1 g(수율 77%)수득하였다.(m/z=465)
Pd (dba) 2 (0.5 g, 0.00006 mol) and sodium-tert-butoxide (2.2 g, 0.022 mol) in 1,4-dibromobenzene (1.3 g, 0.006 mol) Was added 80 mL of Tol, and the mixture was reacted at 95 DEG C for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and the product was separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 2.1 g (m / z = 465)

(7) (7) 제조예Manufacturing example 7 : 중간체 1-5'의 합성 7: Synthesis of intermediate 1-5 '

Figure pat00101
Figure pat00101

중간체 1-5(3.0 g, 0.006 mol)에 bis(pinacolato)dibron(2.0 g, 0.008 mol) 를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 1-5'> 2.2 g (수율 71%)을 얻었다. (m/z=512)
Intermediate 1-5 'was synthesized in the same manner as in Example 1 (5) except that bis (pinacolato) dibron (2.0 g, 0.008 mol) was added to Intermediate 1-5 (3.0 g, 0.006 mol) 2.2 g (71% yield) was obtained. (m / z = 512)

(8) (8) 제조예Manufacturing example 8 : 화합물 366의 합성 8: Synthesis of Compound 366

Figure pat00102
Figure pat00102

중간체 1-5'(5.0 g, 0.010 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(2.5 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 366> 4.4 g (수율 71%)을 얻었다.(2.5 g, 0.008 mol) was added to Intermediate 1-5 '(5.0 g, 0.010 mol) in the same manner as in Example 1 (6) except that 2-bromo-4,6-diphenyl- (Compound 366) (4.4 g, Yield: 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.71/d, 7.61/d, 7.41/d, 7.33/m, 7.22/d, 7.14/m) 2H(7.85/d, 7.25/d, 1.72/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.71 / d, 7.61 / d, 7.41 / d, 7.33 / m, 7.22 / d, 7.14 / m) 2H (7.85 / d, 7.25 / d, 1.72 / s) 3H (7.41 / m) 6H (8.28 / d, 7.51 / m)

LC/MS: m/z= 618[(M+1)+]
LC / MS: m / z = 618 [(M + 1) &lt; + &

실시예Example 2 : 화합물 371의 합성 2: Synthesis of Compound 371

(1) (One) 제조예Manufacturing example 1 : 화합물 371의 합성 1: Synthesis of Compound 371

Figure pat00103
Figure pat00103

중간체 1-5'(5.0 g, 0.010 mol)에 2-bromotriphenylene(2.5 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 371> 3.6 g (수율 73%)을 얻었다.(2.5 g, 0.008 mol) was added to Intermediate 1-5 '(5.0 g, 0.010 mol) in the same manner as in Example 1- (6) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.71/d, 7.61/d, 7.41/m, 7.41/d, 7.33/m, 7.22/d, 7.14/m) 2H(8.93/d, 8.28/d, 8.12/d, 7.88/m, 7.82/m, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.71 / d, 7.61 / d, 7.41 / m, 7.41 / d, 7.33 / m, 7.22 / d , 7.14 / m) 2H (8.93 d, 8.28 d, 8.12 d, 7.88 m, 7.82 m, 7.51 m, 1.72 s)

LC/MS: m/z=613 [(M+1)+]
LC / MS: m / z = 613 [(M + 1) &lt; + &

실시예Example 3 : 화합물 380의 합성 3: Synthesis of Compound 380

(1) (One) 제조예Manufacturing example 1 : 중간체 3-1의 합성 1: Synthesis of intermediate 3-1

Figure pat00104
Figure pat00104

중간체 1-5(3.0 g, 0.008 mol)에 9H-carbazol-3-ylboronic acid(2.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 3-1> 2.8 g (수율 73%)을 얻었다. (m/z=475)
3-ylboronic acid (2.1 g, 0.010 mol) was added to Intermediate 1-5 (3.0 g, 0.008 mol), and <Intermediate 3- 1> 2.8 g (yield: 73%). (m / z &lt; / RTI &gt; = 475)

(2) (2) 제조예Manufacturing example 2 : 화합물 380의 합성 2: Synthesis of Compound 380

Figure pat00105
Figure pat00105

중간체 3-1(3.0 g, 0.011 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(3.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 380> 5.8 g (수율 75%)을 얻었다.To the intermediate 3-1 (3.0 g, 0.011 mol) was added 2-bromo-4,6-diphenyl-1,3,5-triazine (3.5 g, 0.011 mol) Synthesis was conducted in the same manner to obtain 5.8 g (yield 75%) of Compound 380.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/d, 7.71/d, 7.69/d, 7.61/d, 7.41/d, 7.25/m, 7.22/d, 7.14/m) 2H(7.33/m, 1.72/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / d, 7.71 / d, 7.69 / d, 7.61 / d, 7.41 / d, 7.25 / m (7.28 / d, 7.14 / m) 2H (7.33 / m, 1.72 / s)

LC/MS: m/z= 707[(M+1)+]
LC / MS: m / z = 707 [(M + 1) &lt; + &

실시예 4 : 화합물 377의 합성Example 4: Synthesis of Compound 377

(1) (One) 제조예Manufacturing example 1 : 중간체 4-1의 합성 1: Synthesis of Intermediate 4-1

Figure pat00106
Figure pat00106

5-bromo-2-nitroaniline(3.0 g, 0.014 mol)에 phenylmethanamine(4.4 g, 0.041 mol)를 넣고 실시예 1-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 4-1> 3.0 g (수율 79%)을 얻었다.(m/z=273)
Intermediate 4-1 was synthesized in the same manner as in Example 1 (1) except that phenylmethanamine (4.4 g, 0.041 mol) was added to 5-bromo-2-nitroaniline (3.0 g, 0.014 mol) (Yield: 79%). (M / z = 273)

(2) (2) 제조예Manufacturing example 2 : 중간체 4-2의 합성 2: Synthesis of intermediate 4-2

Figure pat00107
Figure pat00107

중간체 4-1(3.0 g, 0.011 mol)에 methyl 2-iodobenzoate(2.9 g, 0.011 mol)을 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 4-2> 3.4 g (수율 77%)을 얻었다.(m/z=407)
Intermediate 4-2 was synthesized in the same manner as in Example 1 (2), except that methyl 2-iodobenzoate (2.9 g, 0.011 mol) was added to Intermediate 4-1 (3.0 g, 0.011 mol) (Yield: 77%). (M / z = 407)

(3) (3) 제조예Manufacturing example 3 : 중간체 4-3의 합성 3: Synthesis of intermediate 4-3

Figure pat00108
Figure pat00108

중간체 4-2(3.3 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 4-3> 2.3 g (수율 72%)을 얻었다.(m/z=407)
2.3 g (yield 72%) of Intermediate 4-3 (m / z) was obtained by the same method as in Example 1- (3) except that Intermediate 4-2 (3.3 g, 0.008 mol) = 407)

(4) (4) 제조예Manufacturing example 4 : 중간체 4-4의 합성 4: Synthesis of intermediate 4-4

중간체 4-3(3.3 g, 0.008 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 4-4> 2.2 g (수율 70%)을 얻었다.(m/z=389)
2.2 g (yield 70%) of Intermediate 4-4 was obtained by the same procedure as in Example 1 (4) except that Intermediate 4-3 (3.3 g, 0.008 mol) was added. M / z = 389)

(5) (5) 제조예Manufacturing example 5 : 중간체 4-5의 합성 5: Synthesis of intermediate 4-5

Figure pat00110
Figure pat00110

2-bromo-9H-carbazole(3.0 g, 0.012 mol)에 triisopropyl borate(2.6 g, 0.014 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 4-5> 1.9 g (수율 75%)을 얻었다.(m/z=211)
Synthesis was conducted in the same manner as in Example 1 (5), except that triisopropyl borate (2.6 g, 0.014 mol) was added to 2-bromo-9H-carbazole (3.0 g, 0.012 mol) g (yield: 75%). (m / z = 211)

(6) (6) 제조예Manufacturing example 6 : 중간체 4-6의 합성 6: Synthesis of intermediate 4-6

Figure pat00111
Figure pat00111

중간체 4-4(3.0 g, 0.008 mol)에 중간체 4-5(2.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 4-6> 2.7g (수율 70%)을 얻었다.(m/z=475)
Intermediate 4-6 (2.1 g, 0.010 mol) was added to Intermediate 4-4 (3.0 g, 0.008 mol) and 2.7 g of Intermediate 4-6 was synthesized in the same manner as in Example 1- (Yield: 70%). (M / z = 475)

(7) (7) 제조예Manufacturing example 7 : 화합물 377의 합성 7: Synthesis of Compound 377

Figure pat00112
Figure pat00112

중간체 4-6(5.0 g, 0.010 mol)에 2-bromo-4,6-diphenyl-1,3,5-triazine(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 377> 4.9 g (수율 70%)을 얻었다.To the intermediate 4-6 (5.0 g, 0.010 mol) was added 2-bromo-4,6-diphenyl-1,3,5-triazine (3.1 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 4.9 g (yield 70%) of <Compound 377>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.18/d, 7.99/d, 7.94/d, 7.79/d, 7.62/s, 7.47/d, 7.40/m, 7.37/m, 7.33/m, 7.30/d, 7.26/d, 7.25/m) 2H(1.72/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.18 / d, 7.99 / d, 7.94 / d, 7.79 / d, 7.62 / s, 7.47 / d, 7.40 / m, 7.37 / m M, 7,30 / d, 7.26 / d, 7.25 / m) 2H (1.72 / s) 3H (7.41 / m) 6H (8.28 / d, 7.51 /

LC/MS: m/z=707[(M+1)+]
LC / MS: m / z = 707 [(M + 1) &lt; + &

실시예Example 5 : 화합물 420의 합성 5: Synthesis of Compound 420

(1) (One) 제조예Manufacturing example 1 : 화합물 420의 합성 1: Synthesis of Compound 420

Figure pat00113
Figure pat00113

중간체 1-5'(4.1 g, 0.008 mol)에 4-bromodibenzo[b,d]thiophene(1.8 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 420> 2.9 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that 4-bromodibenzo [b, d] thiophene (1.8 g, 0.007 mol) was added to Intermediate 1-5 '(4.1 g, 0.008 mol) 420> 2.9 g (yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.71/d, 7.61/d, 7.58/m, 7.52/m, 7.50/m, 7.41/d, 7.41/m, 7.33/m, 7.22/d, 7.14/m) 2H(8.28/d, 7.51/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.71 / d, 7.61 / d, 7.58 / m, 7.52 / m, 7.50 / m , 7.41 / d, 7.41 / m, 7.33 / m, 7.22 / d, 7.14 / m) 2H (8.28 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=569 [(M+1)+]
LC / MS: m / z = 569 [(M + 1) &lt; + &

실시예Example 6 : 화합물 435의 합성 6: Synthesis of Compound 435

(1) (One) 제조예Manufacturing example 1 : 중간체 6-1의 합성 1: Synthesis of intermediate 6-1

Figure pat00114
Figure pat00114

중간체 1-4'(3.05 g, 0.008 mol)에 1,3,5-tribromobenzene(2.2 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 6-1> 2.7 g (수율 70%)을 얻었다. (m/z=544)
Synthesis was conducted in the same manner as in Example 1 (6), except that 1,3,5-tribromobenzene (2.2 g, 0.007 mol) was added to Intermediate 1-4 '(3.05 g, 0.008 mol) 1> 2.7 g (yield 70%). (m / z = 544)

(2) (2) 제조예Manufacturing example 2 : 화합물 435의 합성 2: Synthesis of Compound 435

Figure pat00115
Figure pat00115

중간체 6-1(5.0 g, 0.009 mol)에 9H-carbazole(4.4 g, 0.018 mol) 를 넣고 실시예1-제조예(2)에서 사용된 동일한 방법으로 합성하여 <화합물 435> 4.7 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (2), except that 9H-carbazole (4.4 g, 0.018 mol) was added to Intermediate 6-1 (5.0 g, 0.009 mol) to obtain 4.7 g (yield: 73% %).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.71/d, 7.61/d, 7.41/m, 7.41/d, 7.33/m, 7.22/d, 7.20/s, 7.14/m) 2H(8.55/d, 8.28/d, 8.12/d, 8.09/s, 7.94/d, 7.63/d, 7.51/m, 7.50/m, 7.33/m, 7.29/m, 7.25/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.71 / d, 7.61 / d, 7.41 / m, 7.41 / d, 7.33 / m, 7.22 / d, 7.20 / s, 7.14 / m) 2H (8.55 7.51 / m, 7.50 / m, 7.33 / m, 7.29 / m, 7.25 / m, 1.72 / s)

LC/MS: m/z=717 [(M+1)+]
LC / MS: m / z = 717 [(M + 1) &lt; + &

실시예Example 7 : 화합물 393의 합성 7: Synthesis of Compound 393

(1) (One) 제조예Manufacturing example 1 : 중간체 7-1의 합성 1: Synthesis of Intermediate 7-1

Figure pat00116
Figure pat00116

2-bromo-2'-nitrobiphenyl(5.0 g, 0.017 mol)에 triphenylphosphine(4.5 g, 0.017 mol)에 1,2-dichlorobenzene 100 mL를 넣고 180 ℃에서 24시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 7-1을 4.2 g (수율 83%)수득하였다.(m/z=246)
100 mL of 1,2-dichlorobenzene was added to triphenylphosphine (4.5 g, 0.017 mol) in 2-bromo-2'-nitrobiphenyl (5.0 g, 0.017 mol) and the mixture was reacted at 180 ° C for 24 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and the resultant product was separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 4.2 g (m / z = 246)

(2) (2) 제조예Manufacturing example 2 : 중간체 7-2의 합성 2: Synthesis of intermediate 7-2

Figure pat00117
Figure pat00117

중간체 7-1(3.0 g, 0.012 mol)에 무수 THF 30 mL에 녹인 후, -78 ℃에서 n-BuLi(2.5M) 5.9 mL를 천천히 적가하였다. 1시간 동안 유지시킨 후, triisopropyl borate(3.4 g, 0.018 mol)을 첨가한 후, 상온에서 24시간 교반하였다. 반응 종료 후 1 N HCl을 넣고 1시간 교반한 뒤, EA : H2O에 층분리 후 n-Hexane으로 재결정 하여 <중간체 7-2> 1.8 g (수율 70%)을 얻었다.(m/z=211)
After dissolving 30 mL of anhydrous THF in Intermediate 7-1 (3.0 g, 0.012 mol), 5.9 mL of n-BuLi (2.5 M) was slowly added dropwise at -78 ° C. After maintaining for 1 hour, triisopropyl borate (3.4 g, 0.018 mol) was added and stirred at room temperature for 24 hours. After completion of the reaction, 1 N HCl was added and the mixture was stirred for 1 hour. After separation into EA: H 2 O, the reaction product was recrystallized with n-hexane to obtain 1.8 g (yield 70% 211)

(3) (3) 제조예Manufacturing example 3 : 중간체 7-3의 합성 3: Synthesis of intermediate 7-3

Figure pat00118
Figure pat00118

중간체 1-4(3.0 g, 0.008 mol)에 중간체 7-2(2.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 7-3> 2.7 g (수율 70%)을 얻었다. (m/z=475)
Intermediate 7-3 (2.7 g, 0.010 mol) was added to intermediate 1-4 (3.0 g, 0.008 mol) and synthesized in the same manner as in Example 1- (6) (Yield: 70%). (m / z < / RTI > = 475)

(4) (4) 제조예Manufacturing example 4 : 화합물 393의 합성 4: Synthesis of compound 393

Figure pat00119
Figure pat00119

중간체 7-3(3.0 g, 0.011 mol)에 4-bromodibenzo[b,d]thiophene(2.9 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 393> 5.6 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (2) except that 4-bromodibenzo [b, d] thiophene (2.9 g, 0.011 mol) was added to Intermediate 7-3 (3.0 g, 0.011 mol) > 5.6 g (yield 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.98/d, 7.94/d, 7.79/d, 7.71/d, 7.61/d, 7.59/d, 7.50/m, 7.43/m, 7.41/d, 7.30/d, 7.25/m, 7.22/d, 7.14/m) 2H(8.45/d, 8.28/d, 7.52/m, 7.51/m, 7.33/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.71 / d, 7.61 / d, 7.59 / d, 7.50 / m, 7.43 / m M, 7.32 / d, 7.14 / m) 2H (8.45 / d, 8.28 / d, 7.52 / m, 7.51 / m, 7.33 / m, 1.72 / s)

LC/MS: m/z= 658[(M+1)+]
LC / MS: m / z = 658 [(M + 1) &lt; + &

실시예Example 8 : 화합물 395의 합성 8: Synthesis of Compound 395

(1) (One) 제조예Manufacturing example 1 : 중간체 8-1의 합성 1: Synthesis of Intermediate 8-1

Figure pat00120
Figure pat00120

3,6-dibromo-9H-carbazole(3.0 g, 0.009 mol)에 iodobenzene(1.8 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 8-1> 2.6 g (수율 71%)을 얻었다.(m/z=401)
Intermediate 8-1 was synthesized in the same manner as in Example 1 (2) except that iodobenzene (1.8 g, 0.009 mol) was added to 3,6-dibromo-9H-carbazole (3.0 g, 0.009 mol) 2.6 g (yield 71%) was obtained. (M / z = 401)

(2) (2) 제조예Manufacturing example 2 : 중간체 8-2의 합성 2: Synthesis of Intermediate 8-2

Figure pat00121
Figure pat00121

중간체 8-1(3.0 g, 0.007 mol)에 bis(pinacolato)dibron(2.0 g, 0.008 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 8-2> 2.7 g (수율 77%)을 얻었다.(m/z=495)
<Intermediate 8-2> 2.7 (2 g, 0.008 mol) was added to the intermediate 8-1 (3.0 g, 0.007 mol) and bis (pinacolato) dibron g (yield: 77%). (m / z = 495)

(3) (3) 제조예Manufacturing example 3 : 화합물 395의 합성 3: Synthesis of Compound 395

Figure pat00122
Figure pat00122

중간체 1-4(6.0 g, 0.016 mol)에 중간체 8-2(5.0 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 395> 4.8 g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 8 (5.0 g, 0.010 mol) was added to intermediate 1-4 (6.0 g, 0.016 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.18/d, 8.00/d, 7.87/d, 7.69/d, 7.45/m) 2H(7.77/s, 7.71/d, 7.61/d, 7.58/m, 7.50/d, 7.41/m, 7.41/d, 7.33/m, 7.22/d, 7.14/m) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.18 / d, 8.00 / d, 7.87 / d, 7.69 / d, 7.45 / m) 2H (7.77 / s, 7.71 / d, 7.61 / d, 7.58 7.41 / d, 7.33 / m, 7.22 / d, 7.14 / m) 4H (8.28 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=861[(M+1)+]
LC / MS: m / z = 861 [(M + 1) &lt; + &

실시예Example 9 : 화합물 405의 합성 9: Synthesis of Compound 405

(1) (One) 제조예Manufacturing example 1 : 화합물 405의 합성 1: Synthesis of compound 405

Figure pat00123
Figure pat00123

중간체 6-1(3.0 g, 0.009 mol)에 triphenylen-2-ylboronic acid(5.4 g, 0.020 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 405> 5.5 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that triphenylen-2-ylboronic acid (5.4 g, 0.020 mol) was added to Intermediate 6-1 (3.0 g, 0.009 mol) (Yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.71/d, 7.61/d, 7.41/d, 7.41/m, 7.33/m, 7.22/d, 7.14/m) 2H(9.15/s, 8.28/d, 8.18/d, 8.04/d, 7.51/m, 1.72/s) 3H(7.66/s) 4H(8.93/d, 8.12/d, 7.88/m, 7.82/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.71 / d, 7.61 / d, 7.41 / d, 7.41 / m, 7.33 / m, 7.22 / d, 7.14 / m) 2H (9.15 / s, 8.28 d, 8.08 / d, 7.51 / m, 1.72 / s) 3H (7.66 /

LC/MS: m/z=840[(M+1)+]
LC / MS: m / z = 840 [(M + 1) &lt; + &

실시예Example 10 : 화합물 407의 합성 10: Synthesis of Compound 407

(1) (One) 제조예Manufacturing example 1 : 화합물 407의 합성 1: Synthesis of compound 407

Figure pat00124
Figure pat00124

중간체 6-1(3.0 g, 0.009 mol), dibenzo[b,d]thiophen-4-ylboronic acid(4.6 g, 0.020 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 407> 4.5 g (수율 67%)을 얻었다.Was synthesized in the same manner as in Example 1 (6), except that Intermediate 6-1 (3.0 g, 0.009 mol) and dibenzo [b, d] thiophen-4-ylboronic acid (4.6 g, 0.020 mol) <Compound 407> 4.5 g (yield 67%) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.71/d, 7.61/d, 7.41/d, 7.41/m, 7.33/m, 7.22/d, 7.14/m) 2H(8.45/d, 8.41/d, 8.28/d, 8.20/d, 7.98/d, 7.58/m, 7.52/m, 7.51/m, 7.50/m, 1.72/s) 3H(7.66/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.71 / d, 7.61 / d, 7.41 / d, 7.41 / m, 7.33 / m, 7.22 / d, 7.14 / m) 2H (8.45 / d, 8.41 7.58 / m, 7.50 / m, 1.72 / s) 3H (7.66 / s)

LC/MS: m/z=751[(M+1)+]
LC / MS: m / z = 751 [(M + 1) &lt; + &

실시예Example 11 : 화합물 441의 합성 11: Synthesis of compound 441

(1) (One) 제조예Manufacturing example 1 : 중간체 11-1의 합성 1: Synthesis of intermediate 11-1

Figure pat00125
Figure pat00125

9H-carbazol-3-ylboronic acid(3.0 g, 0.014 mol), 2-bromo-9,9-dimethyl-9H-fluorene(3.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 11-1> 3.2 g (수율 67%)을 얻었다. (m/z=359)
The same procedure as in Example 1 (6) was repeated except that 9H-carbazol-3-ylboronic acid (3.0 g, 0.014 mol) and 2-bromo-9,9- Synthesis was conducted in the same manner to obtain 3.2 g (yield 67%) of Intermediate 11-1. (m / z = 359)

(2) (2) 제조예Manufacturing example 2 : 화합물 441의 합성 2: Synthesis of compound 441

Figure pat00126
Figure pat00126

중간체 1-4(3.0 g, 0.008 mol)에 중간체 11-1(3.2 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 441> 3.9 g (수율 73%)을 얻었다.(3.2 g, 0.008 mol) was added to Intermediate 1-4 (3.0 g, 0.008 mol) in the same manner as in Example 1- (2) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.93/d, 7.69/d, 7.63/d, 7.61/d, 7.55/d, 7.41/m, 7.41/d, 7.38/m, 7.33/m, 7.28/m, 7.27/m, 7.25/m, 7.14/m) 2H(8.28/d, 7.87/d, 7.77/s, 7.51/m, 7.26/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.93 / d, 7.69 / d, 7.63 / d, 7.61 / d, 7.55 / d, 7.41 / m, 7.41 / d 7.28 / m, 7.17 / m) 2H (8.28 / d, 7.87 / d, 7.77 / s, 7.51 / m, 7.26 / / s)

LC/MS: m/z=668[(M+1)+]
LC / MS: m / z = 668 [(M + 1) &lt; + &

실시예Example 12 : 화합물 450의 합성 12: Synthesis of Compound 450

(1) (One) 제조예Manufacturing example 1 : 중간체 12-1의 합성 1: Synthesis of Intermediate 12-1

Figure pat00127
Figure pat00127

1,4-dibromobenzene(3.5 g, 0.015 mol), dibenzo[b,d]thiophen-4-ylboronic acid(4.1 g, 0.018 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 12-1> 3.6 g (수율 71%)을 얻었다. (m/z=339)
Synthesis was carried out in the same manner as in Example 1 (6) except that 1,4-dibromobenzene (3.5 g, 0.015 mol) and dibenzo [b, d] thiophen-4-ylboronic acid (4.1 g, 0.018 mol) To obtain 3.6 g (yield 71%) of Intermediate 12-1. (m / z < / RTI > = 339)

(2) (2) 제조예Manufacturing example 2 : 중간체 12-2의 합성 2: Synthesis of intermediate 12-2

Figure pat00128
Figure pat00128

중간체 7-2(2.1 g, 0.010 mol), 중간체 12-1(2.7 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 12-2> 3.4 g (수율 67%)을 얻었다. (m/z=425)
Intermediate 12-2 was obtained from Intermediate 7-2 (2.1 g, 0.010 mol) and Intermediate 12-1 (2.7 g, 0.008 mol) in the same manner as in Example 1- (6) (Yield: 67%). (m / z = 425)

(3) (3) 제조예Manufacturing example 3 : 화합물 450의 합성 3: Synthesis of Compound 450

Figure pat00129
Figure pat00129

중간체 1-4(3.0 g, 0.008 mol)에 중간체 12-2(3.4 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 450> 4.3 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (2), except that Intermediate 12 (3.4 g, 0.008 mol) was added to Intermediate 1-4 (3.0 g, 0.008 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.94/d, 7.79/d, 7.61/d, 7.59/d, 7.58/m, 7.52/m, 7.50/m, 7.43/m, 7.41/d, 7.41/m, 7.33/m, 7.27/m, 7.25/m, 7.14/m) 2H(8.28/d, 7.51/m, 7.26/d, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.94 / d, 7.79 / d, 7.61 / d, 7.59 / d 7.58 m, 7.50 m, 7.50 m, 7.43 m, 7.41 / d, 7.41 m, 7.33 m, 7.27 m, 7.25 m, 7.14 m) , 7.26 / d, 1.72 / s) 4H (7.25 / d)

LC/MS: m/z=734[(M+1)+]
LC / MS: m / z = 734 [(M + 1) &lt; + &

실시예Example 13 : 화합물 471의 합성 13: Synthesis of compound 471

(1) (One) 제조예Manufacturing example 1 : 화합물 471의 합성 1: Synthesis of compound 471

Figure pat00130
Figure pat00130

중간체 3-1(3.0 g, 0.011 mol)에 2-bromotriphenylene(3.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 13> 5.8 g (수율 75%)을 얻었다.(2.5 g, 0.011 mol) was added to Intermediate 3-1 (3.0 g, 0.011 mol) and the compound obtained in Synthesis Example 2 (5.8 g, yield 75% %).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.93/d, 8.55/d, 8.12/d, 7.94/d, 7.90/m, 7.88/m, 7.87/d, 7.82/m, 7.77/s, 7.71/d, 7.69/d, 7.61/d, 7.41/d, 7.41/m, 7.25/m, 7.22/d, 7.14/m) 2H(8.90/s, 8.28/d, 8.10/d, 7.80/d, 7.51/m, 7.33/m, 7.20/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.93 / d, 8.55 / d, 8.12 / d, 7.94 / d, 7.90 / m, 7.88 / m, 7.87 / d, 7.82 / m, 7.77 / s , 7.71 / d, 7.69 / d, 7.61 / d, 7.41 / d, 7.41 / m, 7.25 / m, 7.22 / d, 7.14 / , 7.51 / m, 7.33 / m, 7.20 / s)

LC/MS: m/z=702[(M+1)+]
LC / MS: m / z = 702 [(M + 1) &lt; + &

실시예Example 14 : 화합물 476의 합성 14: Synthesis of compound 476

(1) (One) 제조예Manufacturing example 1 : 중간체 14-1의 합성 1: Synthesis of intermediate 14-1

Figure pat00131
Figure pat00131

2-bromo-5-chloro-1H-benzo[d]imidazole(3.0 g, 0.013 mol)에 phenyl boronic acid(1.8 g, 0.015 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 14-1> 2.1 g (수율 71%)을 얻었다.(m/z=228)
Phenylboronic acid (1.8 g, 0.015 mol) was added to 2-bromo-5-chloro-1H-benzo [d] imidazole (3.0 g, 0.013 mol) in the same manner as in Example 1- To obtain 2.1 g (yield: 71%) of Intermediate 14-1 (m / z = 228)

(2) (2) 제조예Manufacturing example 2 : 중간체 14-2의 합성 2: Synthesis of intermediate 14-2

Figure pat00132
Figure pat00132

중간체 1-4'(4.4 g, 0.010 mol)에 중간체 14-1(1.8 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 14-2> 2.9 g (수율 71%)을 얻었다.(m/z=502)
Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 14-1 (1.8 g, 0.008 mol) and Intermediate 14-2> 2.9 (4.4 g, 0.010 mol) g (yield: 71%). (m / z = 502)

(3) (3) 제조예Manufacturing example 3 : 중간체 14-3의 합성 3: Synthesis of intermediate 14-3

Figure pat00133
Figure pat00133

중간체 14-2(5.0 g, 0.010 mol)에 1,4-dibromobenzene(2.4 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 14-3> 4.8 g (수율 73%)을 얻었다.(m/z=657)
Intermediate 14-3> 4.8 g (0.010 mol) was obtained by synthesizing 1,4-dibromobenzene (2.4 g, 0.010 mol) in Intermediate 14-2 (5.0 g, 0.010 mol) g (yield: 73%). (m / z = 657)

(4) (4) 제조예Manufacturing example 4 : 중간체 14-4의 합성 4: Synthesis of intermediate 14-4

Figure pat00134
Figure pat00134

중간체 14-3(5.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 14-4> 4.1 g (수율 73%)을 얻었다.(m/z=704)
Synthesis was conducted in the same manner as in Example 1 (5), except that bis (pinacolato) dibron (2.5 g, 0.010 mol) was added to Intermediate 14-3 (5.0 g, 0.008 mol) g (yield: 73%). (m / z = 704)

(5) (5) 제조예Manufacturing example 5 : 화합물 476의 합성 5: Synthesis of compound 476

Figure pat00135
Figure pat00135

중간체 14-4(5.6 g, 0.008 mol)에 2-bromotriphenylene(2.1 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 476> 4.1 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (6), except that 2-bromotriphenylene (2.1 g, 0.007 mol) was added to Intermediate 14-4 (5.6 g, 0.008 mol) %).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.29/d, 8.18/d, 8.07/d, 8.04/d, 7.92/d, 7.71/d, 7.61/d, 7.41/d, 7.33/m, 7.22/d, 7.14/d) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.68/d, 7.41/m, 1.72/s) 4H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.29 / d, 8.18 / d, 8.07 / d, 8.04 / d, 7.92 / d, 7.71 / d, 7.61 / d, 7.41 / d 8.38 / d, 7.88 / d, 7.79 / d, 7.68 / d, 7.41 / m, 1.72 / s) / d, 7.51 / m)

LC/MS: m/z=805[(M+1)+]
LC / MS: m / z = 805 [(M + 1) &lt; + &

실시예Example 15 : 화합물 531의 합성 15: Synthesis of Compound 531

(1) (One) 제조예Manufacturing example 1 : 중간체 15-1의 합성 1: Synthesis of intermediate 15-1

Figure pat00136
Figure pat00136

3-iodo-1H-indole(3.0 g, 0.012 mol)에 phenyl boronic acid(1.7 g, 0.014 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 15-1> 1.6 g (수율 68%)을 얻었다.(m/z=193)
(Intermediate 15-1) was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.7 g, 0.014 mol) was added to 3-iodo-1H-indole (3.0 g, 0.012 mol) 1.6 g (yield 68%) of (m / z = 193)

(2) (2) 제조예Manufacturing example 2 : 중간체 15-2의 합성 2: Synthesis of intermediate 15-2

Figure pat00137
Figure pat00137

중간체 15-1(1.4 g, 0.007 mol)에 methyl 2,6-dibromobenzoate(2.9 g, 0.010 mol)을 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 15-2> 1.8 g (수율 62%)을 얻었다.(m/z=406)
Intermediate 15-2 was synthesized in the same manner as in Example 1 (2) except that methyl 2,6-dibromobenzoate (2.9 g, 0.010 mol) was added to Intermediate 15-1 (1.4 g, 0.007 mol) 1.8 g (yield 62%) of (m / z = 406)

(3) (3) 제조예Manufacturing example 3 : 중간체 15-3의 합성 3: Synthesis of intermediate 15-3

Figure pat00138
Figure pat00138

중간체 15-2(3.2 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 15-3> 2.3 g (수율 70%)을 얻었다.(m/z=406)
2.3 g (yield: 70%) of Intermediate 15-3 (3.2 g, 0.008 mol) was obtained in the same manner as in Example 1- (3) = 406)

(4) (4) 제조예Manufacturing example 4 : 중간체 15-4의 합성 4: Synthesis of intermediate 15-4

Figure pat00139
Figure pat00139

중간체 15-3(4.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 15-4> 3.1g (수율 73%)을 얻었다.(m/z=388)
3.1 g (yield: 73%) of Intermediate 15-4 was obtained by the same procedure as in Example 1 (4), except that Intermediate 15-3 (4.5 g, 0.011 mol) = 388)

(5) (5) 제조예Manufacturing example 5 : 중간체 15-4'의 합성 5: Synthesis of intermediate 15-4 '

Figure pat00140
Figure pat00140

중간체 15-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 15-4'> 2.5 g (수율 71%)을 얻었다.(m/z=435)
Intermediate 15-4 'was synthesized in the same manner as in Example 1 (5) except that bis (pinacolato) dibron (2.5 g, 0.010 mol) was added to Intermediate 15-4 (3.0 g, 0.008 mol) 2.5 g (yield 71%) of the title compound was obtained (m / z = 435)

(6) (6) 제조예Manufacturing example 6 : 중간체 15-5의 합성 6: Synthesis of intermediate 15-5

Figure pat00141
Figure pat00141

중간체 15-4'(4.0 g, 0.009 mol)에 1,4-dibromobenzene(1.8 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 15-5> 2.6 g (수율 71%)을 얻었다.(m/z=464)
Intermediate 15-5 was synthesized in the same manner as in Example 1 (6) except that 1,4-dibromobenzene (1.8 g, 0.008 mol) was added to Intermediate 15-4 '(4.0 g, 0.009 mol) 2.6 g (yield: 71%) was obtained. (M / z = 464)

(7) (7) 제조예Manufacturing example 7 : 중간체 15-5'의 합성 7: Synthesis of intermediate 15-5 '

Figure pat00142
Figure pat00142

중간체 15-5(3.7 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol) 를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 15-5'> 2.9 g (수율 71%)을 얻었다.(m/z=511)
Intermediate 15-5 'was synthesized in the same manner as in Example 1 (5) except that bis (pinacolato) dibron (2.5 g, 0.010 mol) was added to Intermediate 15-5 (3.7 g, 0.008 mol) 2.9 g (71% yield) of the title compound was obtained. (M / z = 511)

(8) (8) 제조예Manufacturing example 8 : 화합물 531의 합성 8: Synthesis of Compound 531

Figure pat00143
Figure pat00143

중간체 15-5'(5.0 g, 0.010 mol)에 3-bromo-9-phenyl-9H-carbazole(2.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 531> 3.6 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (4) except that 3-bromo-9-phenyl-9H-carbazole (2.6 g, 0.008 mol) was added to Intermediate 15-5 '(5.0 g, 0.010 mol) <Compound 531> 3.6 g (yield: 71%) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.99/d, 7.94/d, 7.87/d, 7.77/s, 7.71/d, 7.69/d, 7.45/m, 7.41/m, 7.36/s, 7.34/m, 7.25/m, 7.22/d, 7.04/d) 2H(7.58/m, 7.52/d, 7.51/m, 7.50/d, 7.33/m, 1.72/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.99 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.71 / d, 7.69 / d, 7.45 / m, 7.41 / m 7.51 / m, 7.50 / d, 7.33 / m, 1.72 / s) 4H (7.25 / m, 7.36 / s, 7.34 / m, 7.25 / / d)

LC/MS: m/z=627[(M+1)+]
LC / MS: m / z = 627 [(M + 1) &lt; + &

실시예Example 16 : 화합물 540의 합성 16: Synthesis of compound 540

(1) (One) 제조예Manufacturing example 1 : 중간체 16-1의 합성 1: Synthesis of intermediate 16-1

Figure pat00144
Figure pat00144

중간체 15-1(1.4 g, 0.007 mol)에 methyl 2-bromobenzoate(2.1 g, 0.010 mol)을 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 16-1> 1.4 g (수율 62%)을 얻었다.(m/z=327)
Intermediate 16-1 (1.4 g, 0.007 mol) was synthesized in the same manner as in Example 1 (2), except that methyl 2-bromobenzoate (2.1 g, 0.010 mol) (Yield: 62%). (M / z = 327)

(2) (2) 제조예Manufacturing example 2 : 중간체 16-2의 합성 2: Synthesis of intermediate 16-2

Figure pat00145
Figure pat00145

중간체 16-1(2.6 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 16-2> 1.8 g (수율 70%)을 얻었다.(m/z=327)
1.8 g (yield 70%) of <Intermediate 16-2> was obtained by the same method as employed in the preparation example (3) of Example 1, except that Intermediate 16-1 (2.6 g, 0.008 mol) = 327)

(3) (3) 제조예Manufacturing example 3 : 중간체 16-3의 합성 3: Synthesis of intermediate 16-3

Figure pat00146
Figure pat00146

중간체 16-2(3.6 g, 0.011 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 16-3> 2.5 g (수율 73%)을 얻었다.(m/z=309)
2.5 g (yield 73%) of <Intermediate 16-3> was obtained by the same method as in Example 1 (4), except that Intermediate 16-2 (3.6 g, 0.011 mol) = 309)

(4) (4) 제조예Manufacturing example 4 : 중간체 16-4의 합성 4: Synthesis of intermediate 16-4

Figure pat00147
Figure pat00147

중간체 16-3(3.0 g, 0.010 mol)에 N-bromosuccinimide(1.8 g, 0.010 mol)에 DMF 100 mL를 넣고 20 ℃에서 8시간 교반하여 반응시켰다. 반응 종료 후 H20 : 아세트산에틸로 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 16-4을 1.9 g(48%)수득하였다.(m/z=388)
100 mL of DMF was added to N-bromosuccinimide (1.8 g, 0.010 mol) in Intermediate 16-3 (3.0 g, 0.010 mol) and the mixture was reacted at 20 ° C for 8 hours with stirring. After completion of the reaction H 2 0: After phase separation with ethyl acetate and column purification (n-Hexane: MC) to give the intermediate 16-4 1.9 g (48%) ( m / z = 388).

(5) (5) 제조예Manufacturing example 5 : 중간체 16-5의 합성 5: Synthesis of intermediate 16-5

Figure pat00148
Figure pat00148

중간체 16-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron (2.5 g, 0.010 mol)을 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 16-5>을 2.5 g(73%)수득하였다.(m/z=435)
Intermediate 16-5 was synthesized by the same method as in Example 1 (5) except that bis (pinacolato) dibron (2.5 g, 0.010 mol) was added to Intermediate 16-4 (3.0 g, 0.008 mol) 2.5 g (73%) of (m / z = 435)

(6) (6) 제조예Manufacturing example 6 : 중간체 16-6의 합성 6: Synthesis of intermediate 16-6

Figure pat00149
Figure pat00149

중간체 16-5(3.0 g, 0.007 mol)에 1,4-dibromobenzene(1.4 g, 0.006 mol)을 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 16-6>을2.0 g(73%)수득하였다.(m/z=464)
Intermediate 16-6 was synthesized in the same manner as in Example 1- (6), except that 1,4-dibromobenzene (1.4 g, 0.006 mol) was added to Intermediate 16-5 (3.0 g, 0.007 mol) 2.0 g (73%) of (m / z = 464)

(7) (7) 제조예Manufacturing example 7 : 중간체 16-7의 합성 7: Synthesis of intermediate 16-7

Figure pat00150
Figure pat00150

1,3-dihydroindolo[2,3-b]carbazole(5.0 g, 0.020 mol) N-bromosuccinimide (3.5 g, 0.020 mol)을 넣은 후 실시예 16-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 16-7> 2.8 g (수율 43%)을 얻었다.(m/z=335)
(2.5 g, 0.020 mol) and N-bromosuccinimide (3.5 g, 0.020 mol) were added to the reaction mixture and the mixture was reacted in the same manner as in Example 16 (4) (M / z = 335) of <Intermediate 16-7> (yield: 43%).

(8) (8) 제조예Manufacturing example 8 : 중간체 16-8의 합성 8: Synthesis of intermediate 16-8

Figure pat00151
Figure pat00151

중간체 25-1(5.0 g, 0.020 mol)에 phenyl-boronic acid(2.4 g, 0.024 mol)에 THF 100 mL를 넣고 -78 ℃에서 5시간 교반하여 반응시켰다. 반응종료 후 H20 :MC에 층분리 후 컬럼정제(n-HEXANE : MC)하여 중간체 16-8를 4.9 g (72%)수득하였다 (m/z =339)
To the intermediate 25-1 (5.0 g, 0.020 mol) was added 100 mL of THF to phenyl-boronic acid (2.4 g, 0.024 mol) and the mixture was reacted at -78 ° C for 5 hours with stirring. After completion of the reaction H 2 0: column purification after separating layer on MC: the (n-HEXANE MC) to afford the intermediate 16-8 4.9 g (72%) ( m / z = 339)

(9) (9) 제조예Manufacturing example 9 : 중간체 16-9의 합성 9: Synthesis of intermediate 16-9

Figure pat00152
Figure pat00152

중간체 16-8(6.3 g, 0.020 mol), methyl magnesium iodide(4.0 g, 0.024 mol)에 THF 100 mL를 넣고 -78 ℃에서 5시간 교반하여 반응시켰다. 반응종료 후H20 : MC에 층분리 후 컬럼정제(n-HEXANE : MC)하여 중간체 16-9를 5.3 g (90%)수득하였다 (m/z =296)
100 mL of THF was added to intermediate 16-8 (6.3 g, 0.020 mol) and methyl magnesium iodide (4.0 g, 0.024 mol), and the mixture was reacted at -78 ° C for 5 hours with stirring. After completion of the reaction H 2 0: column purification after separating layer on MC: the (n-HEXANE MC) to afford the intermediate 16-9 5.3 g (90%) ( m / z = 296)

(10) (10) 제조예Manufacturing example 10 : 중간체 16-10의 합성 10: Synthesis of intermediate 16-10

Figure pat00153
Figure pat00153

중간체 16-9(3.0 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 16-10> 2.8 g (수율 75%)을 얻었다.(m/z=372)
(2.5 g, 0.010 mol) was added to intermediate 16-9 (3.0 g, 0.010 mol), and 2.8 g of Intermediate 16-10 (yield: 75%) was obtained in the same manner as in Example 1- %). (M / z = 372)

(11) (11) 제조예Manufacturing example 11 : 화합물 540의 합성 11: Synthesis of compound 540

Figure pat00154
Figure pat00154

중간체 16-6(5.0 g, 0.011 mol)에 중간체 16-10(4.1 g, 0.011 mol)을 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 16>을 6.1 g(73%)수득하였다.Compound 16 was synthesized in the same manner as in Example 1 (2) except that Intermediate 16-10 (4.1 g, 0.011 mol) was added to Intermediate 16-6 (5.0 g, 0.011 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.19/d, 8.12/d, 7.93/d, 7.76/d, 7.63/d, 7.50/m, 7.45/m, 7.41/m, 7.40/m, 7.37/d, 7.36/s, 7.30/d, 7.29/m, 7.26/d, 7.25/m, 7.22/s, 6.87/d) 2H(7.79/d, 7.68/d, 7.58/m, 7.52/d, 7.51/m, 7.50/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.19 / d, 8.12 / d, 7.93 / d, 7.76 / d, 7.63 / d, 7.50 / m, 7.45 / m, 7.41 / m, 7.40 / m 7.7 / d, 7.68 / d, 7.29 / d, 7.36 / d, 7.26 / d, 7.25 / , 7.51 / m, 7.50 / d) 4H (1.72 / s)

LC/MS: m/z=756[(M+1)+]
LC / MS: m / z = 756 [(M + 1) &lt; + &

실시예Example 17 : 화합물 572의 합성 17: Synthesis of compound 572

(1) (One) 제조예Manufacturing example 1 : 중간체 17-1의 합성 1: Synthesis of intermediate 17-1

Figure pat00155
Figure pat00155

중간체 15-4(3.0 g, 0.008 mol)에 3,6-dibromo-9H-carbazole(2.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체17-1> 3.6 g (수율 71%)을 얻었다.(m/z=632)
Intermediate 17 (3.0 g, 0.008 mol) was added to 3,6-dibromo-9H-carbazole (2.6 g, 0.008 mol) -1> 3.6 g (yield: 71%). (M / z = 632)

(2) (2) 제조예Manufacturing example 2 : 화합물 572의 합성 2: Synthesis of compound 572

Figure pat00156
Figure pat00156

중간체 17-1(5.0 g, 0.008 mol)에 2-phenyl-1H-benzo[d]imidazole(3.1 g, 0.016 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 572> 5.6g (수율 81%)을 얻었다.(m/z=632)Synthesis was conducted in the same manner as in Example 1 (2) except that 2-phenyl-1H-benzo [d] imidazole (3.1 g, 0.016 mol) was added to Intermediate 17-1 (5.0 g, 0.008 mol) To obtain 5.6 g (yield: 81%) of the compound 572. (m / z = 632)

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.94/d, 7.63/d, 7.62/d, 7.36/s, 7.34/m, 7.31/d, 7.27/m, 7.04/d) 2H(8.56/d, 7.59/d, 7.52/d, 7.50/s, 7.26/d, 1.72/s) 3H(7.41/m) 4H(8.28/d, 7.22/m) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.94 / d, 7.63 / d, 7.62 / d, 7.36 / s, 7.34 / m, 7.31 / d, 7.27 / m, 7.04 / d M) 2H (8.56 / d, 7.59 / d, 7.52 / d, 7.50 / s, 7.26 / d, 1.72 / s)

LC/MS: m/z=860[(M+1)+]
LC / MS: m / z = 860 [(M + 1) &lt; + &

실시예Example 18 : 화합물 573의 합성 18: Synthesis of compound 573

(1) (One) 제조예Manufacturing example 1 : 중간체 18-1의 합성 1: Synthesis of intermediate 18-1

Figure pat00157
Figure pat00157

중간체 15-5(3.7 g, 0.008 mol)에 1,3,5-tribromobenzene(2.2 g, 0.007 mol) 를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 15-5'> 3.1 g (수율 71%)을 얻었다.(m/z=619)
Intermediate 15-5 (3.7 g, 0.008 mol) was reacted with 1,3,5-tribromobenzene (2.2 g, 0.007 mol), and the reaction mixture was treated in the same manner as in Example 1- (M / z = 619) of 3.1 g (yield 71%).

(2) (2) 제조예Manufacturing example 2 : 화합물 573의 합성 2: Synthesis of compound 573

Figure pat00158
Figure pat00158

중간체 18-1(5.0 g, 0.008 mol)에 2-phenyl-1H-benzo[d]imidazole(3.1 g, 0.016 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 573> 4.8 g (수율 71%)을 얻었다.Synthesis was carried out in the same manner as in Example 1 (2) except that 2-phenyl-1H-benzo [d] imidazole (3.1 g, 0.016 mol) was added to Intermediate 18-1 (5.0 g, 0.008 mol) Compound 573> 4.8 g (71% yield) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.71/d, 7.36/s, 7.34/m, 7.33/m, 7.22/d, 7.20/s, 7.04/d) 2H(7.52/d, 1.72/s) 4H(8.56/d, 8.28/d, 8.09/d, 7.59/d, 7.25/d, 7.41/m, 7.22/m) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.71 / d, 7.36 / s, 7.34 / m, 7.33 / m, 7.22 / d, 7.20 / s, 7.04 / d) 2H (7.52 m), 6H (7.51 / m), &lt; / RTI &gt;

LC/MS: m/z=847[(M+1)+]
LC / MS: m / z = 847 [(M + 1) &lt; + &

실시예Example 19 : 화합물 596의 합성 19: Synthesis of compound 596

(1) (One) 제조예Manufacturing example 1 : 중간체 19-1의 합성 1: Synthesis of intermediate 19-1

Figure pat00159
Figure pat00159

perchloropyrimidine(3.0 g, 0.013 mol)에 phenyl boronic acid(3.6 g, 0.030 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 19-1> 2.8 g (수율 71%)을 얻었다.(m/z=301)
2.8 g (71%) of Intermediate 19-1 was synthesized in the same manner as in Example 1 (6) except that phenyl boronic acid (3.6 g, 0.030 mol) was added to perchloropyrimidine (3.0 g, 0.013 mol) ). (M / z = 301)

(2) (2) 제조예Manufacturing example 2 : 중간체 19-2의 합성 2: Synthesis of intermediate 19-2

Figure pat00160
Figure pat00160

중간체 19-1(3.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol) 를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 19-2> 3.6 g (수율 74%)을 얻었다.(m/z=484)
Intermediate 19-2> 3.6 (4-aminopyridine) was synthesized in the same manner as in Example 1 (5) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) g (yield: 74%). (m / z = 484)

(3) (3) 제조예Manufacturing example 3 : 중간체 19-3의 합성 3: Synthesis of intermediate 19-3

Figure pat00161
Figure pat00161

중간체 19-2(5.0 g, 0.010 mol)에 2-chloro-4,6-diphenyl-1,3,5-triazine (2.1 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 19-3> 3.5 g (수율 74%)을 얻었다.(m/z=589)
To the intermediate 19-2 (5.0 g, 0.010 mol) was added 2-chloro-4,6-diphenyl-1,3,5-triazine (2.1 g, 0.008 mol) Synthesis was conducted in the same manner to obtain 3.5 g (yield: 74%) of Intermediate 19-3 (m / z = 589)

(4) (4) 제조예Manufacturing example 4 : 화합물 596의 합성 4: Synthesis of compound 596

Figure pat00162
Figure pat00162

중간체 15-4(3.0 g, 0.009 mol)에 중간체 19-3(6.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 596> 5.1 g (수율 74%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 15-3 (3.0 g, 0.009 mol) and Intermediate 19-3 (6.5 g, 0.011 mol) 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.71/d, 7.36/s, 7.34/m, 7.33/m, 7.22/d, 7.04/d) 2H(7.52/d, 1.72/s) 4H(8.28/d, 7.79/d) 5H(7.41/m) 10H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.71 / d, 7.36 / s, 7.34 / m, 7.33 / m, 7.22 / d, 7.04 / d) 2H (7.52 / d, 1.72 / s) 4H (8.28 / d, 7.79 / d) 5H (7.41 / m) 10H (7.51 /

LC/MS: m/z=771[(M+1)+]
LC / MS: m / z = 771 [(M + 1) &lt; + &

실시예Example 20 : 화합물 609의 합성 20: Synthesis of Compound 609

(1) (One) 제조예Manufacturing example 1 : 중간체 20-1의 합성 1: Synthesis of intermediate 20-1

Figure pat00163
Figure pat00163

중간체 15-4'(4.0 g, 0.009 mol)에 1,3,5-tribromobenzene(2.5 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 20-1> 3.1 g (수율 71%)을 얻었다.(m/z=543)
Intermediate 20-4 was synthesized in the same manner as in Example 1- (6) except that 1,3,5-tribromobenzene (2.5 g, 0.008 mol) was added to Intermediate 15-4 '(4.0 g, 0.009 mol) 1> 3.1 g (yield: 71%). (M / z = 543)

(2) (2) 제조예Manufacturing example 2 : 중간체 20-2의 합성 2: Synthesis of intermediate 20-2

Figure pat00164
Figure pat00164

중간체 20-1(4.9 g, 0.009 mol)에 bis(pinacolato)dibron(2.7 g, 0.011 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 20-2> 4.1 g (수율 71%)을 얻었다.(m/z=637)
Intermediate 20-2 was synthesized according to the same procedure as in Preparation Example 5 (5), except that bis (pinacolato) dibron (2.7 g, 0.011 mol) was added to Intermediate 20-1 (4.9 g, 0.009 mol) g (yield: 71%). (m / z = 637)

(3) (3) 제조예Manufacturing example 3 : 화합물 609의 합성 3: Synthesis of Compound 609

Figure pat00165
Figure pat00165

중간체 20-2(5.0 g, 0.008 mol)에 2-bromo-1,8-naphthyridine(3.0 g, 0.014 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 609> 3.2 g (수율 71%)을 얻었다.Synthesis was carried out in the same manner as in Example 1 (4), except that 2-bromo-1,8-naphthyridine (3.0 g, 0.014 mol) was added to Intermediate 20-2 (5.0 g, 0.008 mol) > 3.2 g (yield 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.68/s, 7.99/d, 7.71/d, 7.41/m, 7.36/s, 7.34/m, 7.33/m, 7.22/d, 7.04/d) 2H(8.70/d, 8.39/d, 8.23/d, 8.11/d, 7.61/d, 7.52/d, 7.51/m, 7.41/m, 1.72/s)7.36 / s, 7.32 / d, 7.02 / d, 7.04 / d (1 H-NMR (200 MHz, CDCl 3 ) D, 7.61 / d, 7.52 / d, 7.51 / m, 7.41 / m, 1.72 / s)

LC/MS: m/z=642[(M+1)+]
LC / MS: m / z = 642 [(M + 1) &lt; + &

실시예Example 21 : 화합물 647의 합성 21: Synthesis of Compound 647

(1) (One) 제조예Manufacturing example 1 : 중간체 21-1의 합성 1: Synthesis of intermediate 21-1

Figure pat00166
Figure pat00166

2-iodo-1H-benzo[d]imidazole(3.0 g, 0.012 mol)에 phenyl boronic acid(1.7 g, 0.014 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 21-1> 1.5 g (수율 65%)을 얻었다.(m/z=194)
Was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.7 g, 0.014 mol) was added to 2-iodo-1H- benzo [d] imidazole (3.0 g, 0.012 mol) 21-1> 1.5 g (yield 65%). (M / z = 194)

(2) (2) 제조예Manufacturing example 2 : 중간체 21-2의 합성 2: Synthesis of intermediate 21-2

Figure pat00167
Figure pat00167

중간체 21-1(2.0 g, 0.010 mol), methyl 3-bromo-6-fluoropicolinate(2.3 g, 0.010 mol)을 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 21-2> 2.2 g (수율 64%)을 얻었다.(m/z=347)
Intermediate 21-1 (2.0 g, 0.010 mol) and methyl 3-bromo-6-fluoropicolinate (2.3 g, 0.010 mol) were placed in a manner similar to that used in Example 1- 2> 2.2 g (yield 64%). (M / z = 347)

(3) (3) 제조예Manufacturing example 3 : 중간체 21-3의 합성 3: Synthesis of intermediate 21-3

Figure pat00168
Figure pat00168

중간체 21-2(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 21-3> 1.7 g (수율 72%)을 얻었다.(m/z=347)
Intermediate 21-2 (3.0 g, 0.009 mol) was used to synthesize 1.7 g (yield 72%) of Intermediate 21-3 in the same manner as in Example 1- (3) = 347)

(4) (4) 제조예Manufacturing example 4 : 중간체 21-4의 합성 4: Synthesis of Intermediate 21-4

Figure pat00169
Figure pat00169

중간체 21-3(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 21-4> 2.1 g (수율 70%)을 얻었다.(m/z=329)
2.1 g (yield: 70%) of Intermediate 21-4 was obtained by the same procedure as in Example 1 (4), except that Intermediate 21-3 (3.0 g, 0.009 mol) = 329)

(5) (5) 제조예Manufacturing example 5 : 중간체 21-5의 합성 5: Synthesis of intermediate 21-5

Figure pat00170
Figure pat00170

2-(4-bromophenyl)-4,6-diphenyl-1,3,5-triazine(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 21-5> 2.6 g (수율 74%)을 얻었다.(m/z=435)
(Pinacolato) dibron (2.5 g, 0.010 mol) was added to 2- (4-bromophenyl) -4,6-diphenyl-1,3,5-triazine (3.0 g, 0.008 mol) 5) (2.6 g, yield 74%) as an intermediate 21-5 (m / z = 435).

(6) (6) 제조예Manufacturing example 6 : 화합물 647의 합성 6: Synthesis of Compound 647

Figure pat00171
Figure pat00171

중간체 21-4(3.0 g, 0.009 mol)에 중간체 21-5(3.9 g, 0.011 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 647> 4.1g (수율 74%)을 얻었다.Intermediate 21-5 (3.9 g, 0.011 mol) was added to Intermediate 21-4 (3.0 g, 0.009 mol) and the compound was synthesized by the same method as in Example 1 (4) 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.82/d, 7.77/d, 7.61/d, 7.41/d, 7.14/m) 2H(8.81/d, 7.88/d, 1.72/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.82 / d, 7.77 / d, 7.61 / d, 7.41 / d, 7.14 / m) 2H (8.81 / d, 7.88 / d, 1.72 / s) 3H (7.41 / m) 6H (8.28 / d, 7.51 / m)

LC/MS: m/z=619[(M+1)+]
LC / MS: m / z = 619 [(M + 1) &lt; + &

실시예Example 22 : 화합물 656의 합성 22: Synthesis of Compound 656

(1) (One) 제조예Manufacturing example 1 : 중간체 22-1의 합성 1: Synthesis of Intermediate 22-1

Figure pat00172
Figure pat00172

중간체 21-1(2.0 g, 0.010 mol)에 methyl 2-bromo-5-iodoisonicotinate(5.1 g, 0.015 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 22-1> 2.8 g (수율 68%)을 얻었다.(m/z=408)
Intermediate 22-1 (2.0 g, 0.010 mol) was synthesized in the same manner as in Example 1 (2) except that methyl 2-bromo-5-iodoisonicotinate (5.1 g, 0.015 mol) 1> 2.8 g (yield: 68%). (M / z = 408)

(2) (2) 제조예Manufacturing example 2 : 중간체 22-2의 합성 2: Synthesis of Intermediate 22-2

Figure pat00173
Figure pat00173

중간체 22-1(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 22-2> 1.9 g (수율 67%)을 얻었다.(m/z=408)
Intermediate 22-1 (3.0 g, 0.007 mol) was synthesized in the same manner as in Example 1 (3) to give 1.9 g (yield 67%) of Intermediate 22-2. M / z = 408)

(3) (3) 제조예Manufacturing example 3 : 중간체 22-3의 합성 3: Synthesis of intermediate 22-3

Figure pat00174
Figure pat00174

중간체 22-2(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 22-3> 2.1g (수율 74%)을 얻었다.(m/z=408)
2.1 g (yield 74%) of Intermediate 22-3 was obtained by the same method as in Example 1 (4), except that Intermediate 22-2 (3.0 g, 0.007 mol) was added. M / z = 408)

(4) (4) 제조예Manufacturing example 4 : 중간체 22-4의 합성 4: Synthesis of intermediate 22-4

Figure pat00175
Figure pat00175

triphenylen-2-ylboronic acid(3.0 g, 0.011 mol)에 1,4-dibromobenzene (2.1 g, 0.009 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 22-4> 2.6 g (수율 74%)을 얻었다.(m/z=383)
dibromobenzene (2.1 g, 0.009 mol) was added to triphenylen-2-ylboronic acid (3.0 g, 0.011 mol) in the same manner as in Example 1 (6) > 2.6 g (yield: 74%). (M / z = 383)

(5) (5) 제조예Manufacturing example 5 : 중간체 22-5의 합성 5: Synthesis of intermediate 22-5

Figure pat00176
Figure pat00176

중간체 22-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 22-5> 2.5 g (수율 74%)을 얻었다.(m/z=430)
(Intermediate 22-5) 2.5 (2.5 g, 0.010 mol) was added to Intermediate 22-4 (3.0 g, 0.008 mol) and bis (pinacolato) dibron g (yield: 74%). (m / z = 430)

(6) (6) 제조예Manufacturing example 6 : 화합물 656의 합성 6: Synthesis of compound 656

Figure pat00177
Figure pat00177

중간체 22-4(3.0 g, 0.008 mol)에 중간체 22-5(4.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 22> 3.5 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 22-5 (4.3 g, 0.010 mol) and Intermediate 22-4 (3.0 g, 0.008 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.60/s, 8.18/d, 8.04/d, 7.91/d, 7.61/d, 7.41/d, 7.41/m, 7.14/m) 2H(8.93/d, 8.81/d, 8.28/d, 8.12/d, 7.88/m, 7.88/d, 7.82/m, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.60 / s, 8.18 / d, 8.04 / d, 7.91 / d, 7.61 / d, 7.41 / d, 7.41 / m, 7.14 / m 7.81 / d, 7.88 / d, 7.82 / m, 7.51 / m, 1.72 / s)

LC/MS: m/z=614[(M+1)+]
LC / MS: m / z = 614 [(M + 1) &lt; + &

실시예Example 23 : 화합물 662의 합성 23: Synthesis of Compound 662

(1) (One) 제조예Manufacturing example 1 : 중간체 23-1의 합성 1: Synthesis of intermediate 23-1

Figure pat00178
Figure pat00178

중간체 21-1(2.0 g, 0.010 mol)에 methyl 6-bromo-3-iodopyrazine-2-carboxylate(5.1 g, 0.015 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 23-1> 2.8 g (수율 68%)을 얻었다.(m/z=409)
2-carboxylate (5.1 g, 0.015 mol) was added to Intermediate 21-1 (2.0 g, 0.010 mol) in the same manner as in Example 1 (2) (M / z = 409) of <Intermediate 23-1> (yield: 68%).

(2) (2) 제조예Manufacturing example 2 : 중간체 23-2의 합성 2: Synthesis of intermediate 23-2

Figure pat00179
Figure pat00179

중간체 23-1(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 23-2> 2.7 g (수율 72%)을 얻었다.(m/z=409)
2.7 g (yield 72%) of Intermediate 23-2 was obtained by the same method as in Example 1 (3), except that Intermediate 23-1 (3.0 g, 0.009 mol) was added. M / z = 409)

(3) (3) 제조예Manufacturing example 3 : 중간체 23-3의 합성 3: Synthesis of intermediate 23-3

Figure pat00180
Figure pat00180

중간체 23-2(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 23-3> 2.0 g (수율 74%)을 얻었다.(m/z=391)
2.0 g (yield 74%) of Intermediate 23-3 was obtained in the same manner as in Example 1- (4), except that Intermediate 23-2 (3.0 g, 0.007 mol) = 391)

(4) (4) 제조예Manufacturing example 4 : 중간체 23-4의 합성 4: Synthesis of intermediate 23-4

Figure pat00181
Figure pat00181

9-phenyl-9H-carbazol-3-ylboronic acid(3.0 g, 0.010 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 23-4> 2.3 g (수율 72%)을 얻었다.(m/z=398)
Synthesis was carried out in the same manner as in Example 1 (6), except that 1,4-dibromobenzene (1.9 g, 0.008 mol) was added to 9-phenyl-9H-carbazol-3-ylboronic acid (3.0 g, 0.010 mol) 2.3 g (yield: 72%) of Intermediate 23-4 was obtained (m / z = 398)

(5) (5) 제조예Manufacturing example 5 : 중간체 23-5의 합성 5: Synthesis of intermediate 23-5

Figure pat00182
Figure pat00182

중간체 23-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol) 를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 23-5> 2.6 g (수율 72%)을 얻었다.(m/z=445)
(Intermediate 23-5) 2.6 (0.2 g, 0.010 mol) was added to Intermediate 23-4 (3.0 g, 0.008 mol) and bis (pinacolato) dibron g (yield: 72%). (m / z = 445)

(6) (6) 제조예Manufacturing example 6 : 화합물 662의 합성 6: Synthesis of Compound 662

Figure pat00183
Figure pat00183

중간체 23-4(3.0 g, 0.008 mol)에 중간체 23-5(4.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 662> 3.6 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 23-5 (3.0 g, 0.008 mol) and Intermediate 23-5 (4.5 g, 0.010 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.54/s, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.61/d, 7.45/m, 7.41/m, 7.41/d, 7.33/m, 7.25/m, 7.14/m) 2H(8.30/d, 8.28/d, 7.85/d, 7.58/m, 7.51/m, 7.50/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.54 / s, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.61 / d, 7.45 / m, 7.41 / m 7.51 / m, 7.14 / m) 2H (8.30 d, 8.28 d, 7.85 d, 7.58 m, 7.51 m, 7.50 d, 1.72 s)

LC/MS: m/z=630[(M+1)+]
LC / MS: m / z = 630 [(M + 1) &lt; + &

실시예Example 24 : 화합물 651의 합성 24: Synthesis of Compound 651

(1) (One) 제조예Manufacturing example 1 : 중간체 24-1의 합성 1: Synthesis of intermediate 24-1

Figure pat00184
Figure pat00184

8-iodo-7H-purine (3.0g ,0.012mol)에 phenyl boronic acid(1.7g,0.014mol) 를 넣고 실시예1-제조예(6)에서 사용된 동일한 방법으로 합성하여 <중간체24-1>1.4g (수율 60%)을 얻었다.(m/z=196)
Synthesis was conducted in the same manner as in Example 1 (6), except that phenyl boronic acid (1.7 g, 0.014 mol) was added to 8-iodo-7H-purine (3.0 g, 0.012 mol) 1.4 g (yield: 60%) was obtained. (M / z = 196)

(2) (2) 제조예Manufacturing example 2 : 중간체 24-2의 합성 2: Synthesis of intermediate 24-2

Figure pat00185
Figure pat00185

중간체 24-1(2.0 g, 0.010 mol)에 methyl 2,6-dibromobenzoate(4.4 g, 0.015 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 24-2> 2.8 g (수율 68%)을 얻었다.(m/z=409)
Intermediate 24-2 was synthesized in the same manner as in Example 1 (2) except that methyl 2,6-dibromobenzoate (4.4 g, 0.015 mol) was added to Intermediate 24-1 (2.0 g, 0.010 mol) 2.8 g (yield 68%) of the title compound was obtained. (M / z = 409)

(3) (3) 제조예Manufacturing example 3 : 중간체 24-3의 합성 3: Synthesis of intermediate 24-3

Figure pat00186
Figure pat00186

중간체 24-2(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 24-3> 2.1 g (수율 72%)을 얻었다.(m/z=409)
2.1 g (yield 72%) of Intermediate 24-3 was obtained in the same manner as in Example 1- (3), except that Intermediate 24-2 (3.0 g, 0.007 mol) = 409)

(4) (4) 제조예Manufacturing example 4 : 중간체 24-4의 합성 4: Synthesis of intermediate 24-4

Figure pat00187
Figure pat00187

중간체 24-3(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 24-4> 2.0 g (수율 72%)을 얻었다.(m/z=391)
2.0 g (yield 72%) of <Intermediate 24-4> was obtained by the same method as in Example 1- (4), except that Intermediate 24-3 (3.0 g, 0.007 mol) = 391)

(5) (5) 제조예Manufacturing example 5 : 화합물 651의 합성 5: Synthesis of Compound 651

Figure pat00188
Figure pat00188

중간체 24-4(3.0 g, 0.008 mol)에 중간체 21-5(4.4 g, 0.010 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 651> 3.6 g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (4), except that Intermediate 21-5 (4.4 g, 0.010 mol) was added to Intermediate 24-4 (3.0 g, 0.008 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.86/s, 7.86/s, 7.61/d, 7.60/d) 2H(7.85/d, 7.25/d, 1.72/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.86 / s, 7.86 / s, 7.61 / d, 7.60 / d) 2H (7.85 / d, 7.25 / d, 1.72 / s) 3H (7.41 / m ) 6H (8.28 / d, 7.51 / m)

LC/MS: m/z=620[(M+1)+]
LC / MS: m / z = 620 [(M + 1) &lt; + &

실시예Example 25 : 화합물 664의 합성 25: Synthesis of compound 664

(1) (One) 제조예Manufacturing example 1 : 중간체 25-1의 합성 1: Synthesis of intermediate 25-1

Figure pat00189
Figure pat00189

2-amino-5-chlorophenol(3.0 g, 0.014 mol)에 1,2,3-tribromobenzene5(4.4 g, 0.014 mol)를 넣고 PPA(polyphosphoric acid) 100 mL를 넣고 180 ℃에서 4시간 교반하여 반응시켰다. 반응 종료 후 냉각하여 H20 : MC에 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 25-1을 2.1 g(51%)수득하였다.(m/z=296)
1,2,3-tribromobenzene 5 (4.4 g, 0.014 mol) was added to 2-amino-5-chlorophenol (3.0 g, 0.014 mol) and 100 mL of PPA (polyphosphoric acid) was added thereto and reacted at 180 ° C. for 4 hours with stirring. After completion of the reaction, the reaction mixture was cooled, and the product was separated into H 2 O: MC and subjected to column purification (n-hexane: MC) to obtain 2.1 g (51%) of Intermediate 25-1 (m / z = 296)

(2) (2) 제조예Manufacturing example 2 : 중간체 25-2의 합성 2: Synthesis of intermediate 25-2

Figure pat00190
Figure pat00190

중간체 25-1(3.0 g, 0.010 mol)에 carbonimidic dibromide(2.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 25-2> 1.8 g (수율 57%)을 얻었다.(m/z=321)
Intermediate 25-1 (3.0 g, 0.010 mol) was reacted with carbonimidic dibromide (2.2 g, 0.012 mol), and the reaction mixture was reacted in the same manner as in Example 1 (2) 25-2> 1.8 g (yield: 57%). (M / z = 321)

(3) (3) 제조예Manufacturing example 3 : 중간체 25-3의 합성 3: Synthesis of intermediate 25-3

Figure pat00191
Figure pat00191

중간체 25-2(3.0 g, 0.010 mol)에 phenyl boronic acid(1.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 25-3> 2.2 g (수율 70%)을 얻었다.(m/z=318)
Intermediate 25-3 was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.5 g, 0.012 mol) was added to Intermediate 25-2 (3.0 g, 0.010 mol) Yield: 70%). (M / z = 318)

(4) (4) 제조예Manufacturing example 4 : 화합물 664의 합성 4: Synthesis of Compound 664

Figure pat00192
Figure pat00192

중간체 25-3(3.0 g, 0.010 mol)에 중간체 22-5(5.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 664> 4.1 g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (4) to give Intermediate 22-5 (5.1 g, 0.012 mol) and Intermediate 25-3 (3.0 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.64/d, 7.41/m, 7.31/d, 7.18/m, 7.08/d) 2H(8.93/d, 8.28/d, 8.12/d, 7.88/m, 7.82/m, 7.51/m, 7.51/d) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.64 / d, 7.41 / m, 7.31 / d, 7.18 / m, 7.08 / d) 2H (8.93 d, 8.28 d, 8.12 d, 7.88 m, 7.82 m, 7.51 m, 7.51 d) 4H (7.25 d)

LC/MS: m/z=587[(M+1)+]
LC / MS: m / z = 587 [(M + 1) &lt; + &

실시예Example 26 : 화합물 671의 합성 26: Synthesis of Compound 671

(1) (One) 제조예Manufacturing example 1 : 중간체 26-1의 합성 1: Synthesis of intermediate 26-1

Figure pat00193
Figure pat00193

5-chlorobenzene-1,2-diamine(2.2 g, 0.010 mol)에 1,2,3-tribromobenzene(3.7 g, 0.012 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 26-1> 1.4 g (수율 48%)을 얻었다.(m/z=295)
1,2,3-tribromobenzene (3.7 g, 0.012 mol) was added to 5-chlorobenzene-1,2-diamine (2.2 g, 0.010 mol) in the same manner as in Example 25- 1.4 g (yield: 48%) of Intermediate 26-1 (m / z = 295) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 26-2의 합성 2: Synthesis of intermediate 26-2

Figure pat00194
Figure pat00194

중간체 26-1(3.0 g, 0.010 mol)에 1,1-dibromoethene(2.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 26-2> 1.8 g (수율 57%)을 얻었다.(m/z=320)
<Intermediate 26-2> 1.8 (dibromoethene) was synthesized in the same manner as in Example 1 (2) except that 1,1-dibromoethene (2.1 g, 0.012 mol) was added to Intermediate 26-1 g (yield: 57%). (m / z = 320)

(3) (3) 제조예Manufacturing example 3 : 중간체 26-3의 합성 3: Synthesis of intermediate 26-3

Figure pat00195
Figure pat00195

중간체 26-2(3.0 g, 0.010 mol)에 phenyl boronic acid(1.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 26-3> 2.0 g (수율 71%)을 얻었다.(m/z=283)
2.0 g of Intermediate 26-3 was synthesized in the same manner as in Example 1 (6) except that phenyl boronic acid (1.5 g, 0.012 mol) was added to Intermediate 26-2 (3.0 g, 0.010 mol) Yield: 71%). (M / z = 283)

(4) (4) 제조예Manufacturing example 4 : 중간체 26-4의 합성 4: Synthesis of intermediate 26-4

Figure pat00196
Figure pat00196

중간체 26-3(3.0 g, 0.010 mol)에 bromobenzene(1.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 26-4> 2.8 g (수율 71%)을 얻었다.(m/z=393)
(2.5 g, 0.010 mol) was added to intermediate 26-3 (3.0 g, 0.010 mol), and 2.8 g (yield: 71%) of Intermediate 26-4 was synthesized in the same manner as in Example 1- %). (M / z = 393)

(5) (5) 제조예Manufacturing example 5 : 화합물 671의 합성 5: Synthesis of Compound 671

Figure pat00197
Figure pat00197

중간체 26-4(3.0 g, 0.008 mol)에 중간체 21-5(4.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 671> 3.9 g (수율 73%)을 얻었다.Intermediate 21-5 (4.3 g, 0.010 mol) was added to Intermediate 26-4 (3.0 g, 0.008 mol) and the compound obtained in Synthesis Example 6 was reacted with 3.9 g (yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.43/d, 7.15/d, 6.97/m, 6.95/d, 6.89/s, 6.81/m, 6.46/d) 2H(7.85/d, 7.25/d, 7.20/m, 6.63/d) 3H(7.41/m) 6H(8.28/d, 7.51/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.43 / d, 7.15 / d, 6.97 / m, 6.95 / d, 6.89 / s, 6.81 / m, 6.46 / d) 2H (7.85 / d, 7.25 / d, 7.20 / m, 6.63 / d) 3H (7.41 / m) 6H (8.28 / d, 7.51 / d)

LC/MS: m/z=667[(M+1)+]
LC / MS: m / z = 667 [(M + 1) &lt; + &

실시예Example 27 : 화합물 678의 합성 27: Synthesis of compound 678

(1) (One) 제조예Manufacturing example 1 : 중간체 27-1의 합성 1: Synthesis of intermediate 27-1

Figure pat00198
Figure pat00198

benzene-1,2-diamine(1.9 g, 0.010 mol)에 1,2,3-tribromobenzene6(3.7 g, 0.012 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 27-1> 1.4 g (수율 52%)을 얻었다.(m/z=261)
1,2,3-tribromobenzene-6 (3.7 g, 0.012 mol) was added to benzene-1,2-diamine (1.9 g, 0.010 mol) (M / z = 261) was obtained in an amount of 1.4 g (yield: 52%).

(2) (2) 제조예Manufacturing example 2 : 중간체 27-2의 합성 2: Synthesis of intermediate 27-2

Figure pat00199
Figure pat00199

중간체 27-1(2.6 g, 0.010 mol)에 1,1-dibromoethene(2.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 26-2> 1.7 g (수율 59%)을 얻었다.(m/z=286)
<Intermediate 26-2> 1.7 (1) Synthesis was conducted in the same manner as in Example 1 (2) except that 1,1-dibromoethene (2.1 g, 0.012 mol) was added to Intermediate 27-1 g (yield: 59%). (m / z = 286)

(3) (3) 제조예Manufacturing example 3 : 중간체 27-3의 합성 3: Synthesis of intermediate 27-3

Figure pat00200
Figure pat00200

중간체 27-2(3.0 g, 0.0010 mol)에 phenyl boronic acid(1.5 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 27-3> 2.1 g (수율 73%)을 얻었다.(m/z=283)
2.1 g (intermediate 27-3) was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.5 g, 0.012 mol) was added to Intermediate 27-2 (3.0 g, 0.0010 mol) Yield: 73%). (M / z = 283)

(4) (4) 제조예Manufacturing example 4 : 화합물 678의 합성 4: Synthesis of Compound 678

Figure pat00201
Figure pat00201

중간체 27-3(3.0 g, 0.0010 mol)에 중간체 23-4(4.0 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 678> 4.6 g (수율 77%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (2) to give Intermediate 23-4 (4.0 g, 0.010 mol) and Intermediate 27-3 (3.0 g, 0.0010 mol) 77%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.45/m, 7.41/m, 7.37/d, 7.33/m, 7.25/m, 7.20/m, 6.97/m, 6.95/d, 6.94/m, 6.63/d, 6.46/d) 2H(8.28/d, 7.58/m, 7.54/d, 7.51/m, 7.50/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.45 / m, 7.41 / m, 7.37 / d, 7.33 / m 7.58 / m, 6.95 / d, 6.94 / m, 6.63 / d, 6.46 / d) 2H (8.28 / d, 7.58 / , 6.69 / d)

LC/MS: m/z=601[(M+1)+]
LC / MS: m / z = 601 [(M + 1) &lt; + &

실시예Example 28 : 화합물 668의 합성 28: Synthesis of compound 668

(1) (One) 제조예Manufacturing example 1 : 중간체 28-1의 합성 1: Synthesis of intermediate 28-1

Figure pat00202
Figure pat00202

2-amino-5-chlorobenzenethiol(2.4 g, 0.010 mol)에 1,2,3-tribromobenzene6(3.7 g, 0.012 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 28-1> 1.3 g (수율 41%)을 얻었다.(m/z=312)
1,2,3-tribromobenzene6 (3.7 g, 0.012 mol) was added to 2-amino-5-chlorobenzenethiol (2.4 g, 0.010 mol) (M / z = 312) (yield: 41%).

(2) (2) 제조예Manufacturing example 2 : 중간체 28-2의 합성 2: Synthesis of intermediate 28-2

Figure pat00203
Figure pat00203

중간체 28-1(3.1 g, 0.010 mol)에 1,1-dibromoethene(2.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 28-2> 1.9g (수율 55%)을 얻었다.(m/z=337)
Intermediate 28-2 1.9 g (0.012 mol) was obtained by synthesizing 1,1-dibromoethene (2.1 g, 0.012 mol) in Intermediate 28-1 (3.1 g, 0.010 mol) g (yield: 55%). (m / z = 337)

(3) (3) 제조예Manufacturing example 3 : 중간체 28-3의 합성 3: Synthesis of intermediate 28-3

Figure pat00204
Figure pat00204

중간체 28-2(3.0 g, 0.0009 mol)에 phenyl boronic acid(1.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 28-3> 2.1 g (수율 71%)을 얻었다.(m/z=334)
2.1 g (intermediate 28-3) was synthesized in the same manner as in Example 1 (6) except that phenyl boronic acid (1.5 g, 0.011 mol) was added to Intermediate 28-2 (3.0 g, 0.0009 mol) Yield: 71%). (M / z = 334)

(4) (4) 제조예Manufacturing example 4 : 화합물 668의 합성 4: Synthesis of compound 668

Figure pat00205
Figure pat00205

중간체 28-3(3.0 g, 0.0009 mol)에 중간체 22-5(4.7 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 668> 4.0 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 22-5 (4.7 g, 0.011 mol) and Intermediate 28-3 (3.0 g, 0.0009 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.53/d, 7.48/d, 7.41/m, 7.40/s, 7.33/d, 7.20/d, 7.02/m) 2H(8.93/d, 8.28/d, 8.12/d, 7.88/m, 7.82/m, 7.51/m) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.53 / d, 7.48 / d, 7.41 / m, 7.40 / s, 7.33 / d, 7.20 / d , 7.02 / m) 2H (8.93 d, 8.28 d, 8.12 d, 7.88 m, 7.82 m, 7.51 m)

LC/MS: m/z=603[(M+1)+]
LC / MS: m / z = 603 [(M + 1) &lt; + &

실시예Example 29 : 화합물 680의 합성 29: Synthesis of Compound 680

(1) (One) 제조예Manufacturing example 1 : 중간체 29-1의 합성 1: Synthesis of intermediate 29-1

Figure pat00206
Figure pat00206

6-bromo-3-chloro-2-(trimethylsilyl)aniline(2.8 g, 0.010 mol)에 1,2-dibromobenzene6(3.7 g, 0.012 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 29-1> 1.5 g (수율 45%)을 얻었다.(m/z=338)
1,2-dibromobenzene6 (3.7 g, 0.012 mol) was added to 6-bromo-3-chloro-2- (trimethylsilyl) aniline (2.8 g, 0.010 mol) To obtain 1.5 g (yield: 45%) of Intermediate 29-1 (m / z = 338)

(2) (2) 제조예Manufacturing example 2 : 중간체 29-2의 합성 2: Synthesis of intermediate 29-2

Figure pat00207
Figure pat00207

중간체 29-1(3.0 g, 0.009 mol)에 1,1-dibromoethene(2.0 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 29-2> 1.8g (수율 55%)을 얻었다.(m/z=362)
Intermediate 29-2> 1.8 (2.0 g, 0.011 mol) was synthesized in the same manner as in Example 1 (2) except that 1,1-dibromoethene (2.0 g, 0.011 mol) g (yield: 55%). (m / z = 362)

(3) (3) 제조예Manufacturing example 3 : 중간체 29-3의 합성 3: Synthesis of intermediate 29-3

Figure pat00208
Figure pat00208

중간체 29-2(3.0 g, 0.0008 mol)에 phenyl boronic acid(1.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 27-3> 1.8 g (수율 63%)을 얻었다.(m/z=361)
Intermediate 27-3 was synthesized in the same manner as in Example 1- (6), except that phenyl boronic acid (1.2 g, 0.010 mol) was added to Intermediate 29-2 (3.0 g, 0.0008 mol) Yield: 63%). (M / z = 361)

(4) (4) 제조예Manufacturing example 4 : 화합물 680의 합성 4: Synthesis of Compound 680

Figure pat00209
Figure pat00209

중간체 29-3(3.0 g, 0.008 mol)에 중간체 21-5(4.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 29> 3.6 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1- (6), except that Intermediate 21-5 (4.3 g, 0.010 mol) was added to Intermediate 29-3 (3.0 g, 0.008 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.17/d, 7.75/d, 7.72/d, 7.68/m, 7.46/d, 7.37/m) 2H(7.85/d, 7.25/d, 0.66/s) 3H(7.41/m) 6H(8.28/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.17 / d, 7.75 / d, 7.72 / d, 7.68 / m, 7.46 / d, 7.37 / m) 2H (7.85 / d, 7.25 / d, 0.66 / s) 3H (7.41 / m) 6H (8.28 / d, 7.51 / m)

LC/MS: m/z=634[(M+1)+]
LC / MS: m / z = 634 [(M + 1) &lt; + &

실시예Example 30 : 화합물 684의 합성 30: Synthesis of compound 684

(1) (One) 제조예Manufacturing example 1 : 중간체 30-1의 합성 1: Synthesis of intermediate 30-1

Figure pat00210
Figure pat00210

중간체 1-1(2.0 g, 0.010 mol)에 methyl 2-bromo-5-iodopyrimidine-4-carboxylate(5.1 g, 0.015 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 30-1> 2.5 g (수율 61%)을 얻었다.(m/z=409)
Synthesis was conducted in the same manner as in Example 1 (2) except that methyl 2-bromo-5-iodopyrimidine-4-carboxylate (5.1 g, 0.015 mol) was added to Intermediate 1-1 (2.0 g, 0.010 mol) 2.5 g (yield: 61%) of Intermediate 30-1 (m / z = 409)

(2) (2) 제조예Manufacturing example 2 : 중간체 30-2의 합성 2: Synthesis of intermediate 30-2

Figure pat00211
Figure pat00211

중간체 30-1(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 30-2> 1.7 g (수율 60%)을 얻었다.(m/z=409)
Intermediate 30-1 (1.7 g, yield 60%) was obtained by the same method as in Example 1- (3), except that 3.0 g (0.007 mol) of m / z = 409)

(3) (3) 제조예Manufacturing example 3 : 중간체 30-3의 합성 3: Synthesis of intermediate 30-3

Figure pat00212
Figure pat00212

중간체 30-2(3.0 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 30-3> 2.2 g (수율 70%)을 얻었다.(m/z=391)
2.2 g (yield 70%) of <Intermediate 30-3> was obtained by the same method as in Example 1- (3), except that Intermediate 30-2 (3.0 g, 0.008 mol) = 391)

(4) (4) 제조예Manufacturing example 4 : 화합물 684의 합성 4: Synthesis of Compound 684

Figure pat00213
Figure pat00213

중간체 30-3(3.0 g, 0.008 mol)에 중간체 23-5(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 684> 3.2 g (수율 63%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 23-5 (3.6 g, 0.010 mol) was added to Intermediate 30-3 (3.0 g, 0.008 mol) 63%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.60/s, 8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.75/d, 7.69/d, 7.45/m, 7.41/m, 7.33/m, 7.25/m, 7.17/m, 7.00/s, 6.60/s) 2H(7.85/d, 7.79/d, 7.58/m, 7.51/m, 7.50/d, 7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.60 / s, 8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.75 / d, 7.69 / d, 7.45 / m, 7.41 / m 7.51 / m, 7.17 / m, 7.00 / s, 6.60 / s) 2H (7.85 / d, 7.79 / d, 7.58 / )

LC/MS: m/z=628[(M+1)+]
LC / MS: m / z = 628 [(M + 1) &lt; + &

실시예Example 31 : 화합물 686의 합성 31: Synthesis of Compound 686

(1) (One) 제조예Manufacturing example 1 : 중간체 31-1의 합성 1: Synthesis of intermediate 31-1

Figure pat00214
Figure pat00214

2-amino-phenol(3.0 g, 0.016 mol)에 1,2,3-tribromo-4-chlorobenzene(5.6 g, 0.016 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 31-1> 2.1 g (수율 45%)을 얻었다.(m/z=296)
Was synthesized in the same manner as in Example 25 (1) except that 1,2,3-tribromo-4-chlorobenzene (5.6 g, 0.016 mol) was added to 2-amino-phenol (3.0 g, 0.016 mol) 2.1 g (yield: 45%) of Intermediate 31-1 (m / z = 296) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 31-2의 합성 2: Synthesis of intermediate 31-2

Figure pat00215
Figure pat00215

중간체 31-1(3.0 g, 0.010 mol)에 1,1-dibromoethene(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 31-2> 1.6 g (수율 51%)을 얻었다.(m/z=321)
<Intermediate 31-2> 1.6 (1 g, 0.010 mol) was synthesized in the same manner as in Example 1 (2) except that 1,1-dibromoethene (1.8 g, 0.010 mol) was added to Intermediate 31-1 g (yield: 51%). (m / z = 321)

(3) (3) 제조예Manufacturing example 3 : 중간체 31-3의 합성 3: Synthesis of intermediate 31-3

Figure pat00216
Figure pat00216

중간체 31-2(3.0 g, 0.0009 mol)에 phenyl boronic acid(1.3 g, 0.011 mol) 를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 31-3> 2.0 g (수율 71%)을 얻었다.(m/z=317)
Intermediate 31-3 was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.3 g, 0.011 mol) was added to Intermediate 31-2 (3.0 g, 0.0009 mol) Yield: 71%). (M / z = 317)

(4) (4) 제조예Manufacturing example 4 : 화합물 686의 합성 4: Synthesis of Compound 686

Figure pat00217
Figure pat00217

중간체 31-3(3.0 g, 0.0009 mol)에 중간체 22-5(4.7 g, 0.011 mol)를 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 31> 3.7 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (4), except that Intermediate 22-5 (4.7 g, 0.011 mol) was added to Intermediate 31-3 (3.0 g, 0.0009 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.21/d, 8.18/d, 8.06/d, 8.04/d, 7.58/d, 7.30/m, 7.14/d, 6.60/s) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.51/m, 7.41/m) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.21 / d, 8.18 / d, 8.06 / d, 8.04 / d, 7.58 / d, 7.30 / m, 7.14 / d, 6.60 / s ), 2H (8.93 / d, 8.12 / d, 7.88 / m, 7.82 / m, 7.79 / d, 7.51 / m, 7.41 /

LC/MS: m/z=586[(M+1)+]
LC / MS: m / z = 586 [(M + 1) &lt; + &

실시예Example 32 : 화합물 689의 합성 32: Synthesis of Compound 689

(1) (One) 제조예Manufacturing example 1 : 중간체 32-1의 합성 1: Synthesis of intermediate 32-1

Figure pat00218
Figure pat00218

6-phosphinoaniline(3.0 g, 0.015 mol)에 1,2,3-tribromo-4-chlorobenzene (5.5 g, 0.015 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 32-1> 1.5 g (수율 41%)을 얻었다.(m/z=312)
Was synthesized in the same manner as in Example 25 (1) except that 1,2,3-tribromo-4-chlorobenzene (5.5 g, 0.015 mol) was added to 6-phosphinoaniline (3.0 g, 0.015 mol) 32-1> 1.5 g (yield 41%). (M / z = 312)

(2) (2) 제조예Manufacturing example 2 : 중간체 32-2의 합성 2: Synthesis of intermediate 32-2

Figure pat00219
Figure pat00219

중간체 32-1(3.0 g, 0.010 mol)에 1,1-dibromoethene(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 32-2> 1.6 g (수율 47%)을 얻었다.(m/z=337)
<Intermediate 32-2> 1.6 (0.010 mol) was synthesized in the same manner as in Example 1 (2) except that 1,1-dibromoethene (1.8 g, 0.010 mol) was added to Intermediate 32-1 g (yield: 47%). (m / z = 337)

(3) (3) 제조예Manufacturing example 3 : 중간체 32-3의 합성 3: Synthesis of intermediate 32-3

Figure pat00220
Figure pat00220

중간체 32-2(3.0 g, 0.009 mol)에 bromobenzene(1.4 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 32-3> 2.9 g (수율 77%)을 얻었다.(m/z=413)
Intermediate 32-3 was obtained in a yield of 2.9 g (yield: 77%). Intermediate 32-2 (3.0 g, 0.009 mol) was added bromobenzene (1.4 g, 0.009 mol) %). (M / z = 413)

(4) (4) 제조예Manufacturing example 4 : 중간체 32-4의 합성 4: Synthesis of intermediate 32-4

Figure pat00221
Figure pat00221

중간체 32-3(3.0 g, 0.007mol)에 phenyl boronic acid(1.0 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 32-4> 2.0 g (수율 71%)을 얻었다.(m/z=410)
Intermediate 32-4 was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.0 g, 0.008 mol) was added to Intermediate 32-3 (3.0 g, 0.007 mol) Yield: 71%). (M / z = 410)

(5) (5) 제조예Manufacturing example 5 : 화합물 689의 합성 5: Synthesis of compound 689

Figure pat00222
Figure pat00222

중간체 32-4(3.0 g, 0.007 mol)에 중간체 21-5(2.8 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 689> 3.4 g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 21-5 (2.8 g, 0.008 mol) was added to Intermediate 32-4 (3.0 g, 0.007 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.82/d, 8.43/d, 7.91/m, 7.41/m, 6.60/s) 2H(7.85/d, 7.79/d, 7.51/m, 7.41/m, 7.25/d) 4H(8.28/d, 7.78/d, 7.51/m, 7.36/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.82 / d, 8.43 / d, 7.91 / m, 7.41 / m, 6.60 / s) 2H (7.85 / d, 7.79 / d, 7.51 / m, 7.41 / m, 7.25 / d) 4H (8.28 / d, 7.78 / d, 7.51 / m, 7.36 / m)

LC/MS: m/z=683[(M+1)+]
LC / MS: m / z = 683 [(M + 1) &lt; + &

실시예Example 33 : 화합물 690의 합성 33: Synthesis of Compound 690

(1) (One) 제조예Manufacturing example 1 : 중간체 33-1의 합성 1: Synthesis of intermediate 33-1

Figure pat00223
Figure pat00223

2-bromo-3-chloro-6-(trimethylsilyl)aniline(3.0 g, 0.011 mol)에 1,2, -dibromobenzene(3.4 g, 0.011 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 33-1> 1.2 g (수율 31%)을 얻었다.(m/z=338)
1,2-dibromobenzene (3.4 g, 0.011 mol) was added to 2-bromo-3-chloro-6- (trimethylsilyl) aniline (3.0 g, 0.011 mol) To obtain 1.2 g (yield: 31%) of intermediate < 33-1 > (m / z = 338)

(2) (2) 제조예Manufacturing example 2 : 중간체 33-2의 합성 2: Synthesis of intermediate 33-2

Figure pat00224
Figure pat00224

중간체 33-1(3.0 g, 0.009 mol)에 1,1-dibromoethene(1.6 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 33-2> 1.6 g (수율 50%)을 얻었다.(m/z=362)
Intermediate 33-2> 1.6 (0.009 mol) was synthesized in the same manner as in Example 1 (2) except that 1,1-dibromoethene (1.6 g, 0.009 mol) was added to Intermediate 33-1 g (yield: 50%). (m / z = 362)

(3) (3) 제조예Manufacturing example 3 : 중간체 33-3의 합성 3: Synthesis of intermediate 33-3

Figure pat00225
Figure pat00225

중간체 33-2(3.0 g, 0.008 mol)에 phenyl boronic acid(1.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 33-3> 2.0 g (수율 70%)을 얻었다.(m/z=359)
Intermediate 33-3 was synthesized in the same manner as in Example 1- (6), except that phenyl boronic acid (1.2 g, 0.010 mol) was added to Intermediate 33-2 (3.0 g, 0.008 mol) Yield: 70%). (M / z = 359)

(4) (4) 제조예Manufacturing example 4 : 화합물 690의 합성 4: Synthesis of Compound 690

Figure pat00226
Figure pat00226

중간체 33-3(3.0 g, 0.008 mol)에 중간체 22-5(3.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 690> 3.6 g (수율 71%)을 얻었다.Synthesis was carried out in the same manner as in Example 1 (6), except that Intermediate 22-5 (3.5 g, 0.010 mol) was added to Intermediate 33-3 (3.0 g, 0.008 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.27/d, 8.18/d, 8.04/d, 7.72/d, 7.68/m, 7.52/m, 7.50/d, 7.46/d, 7.37/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.79/d, 7.51/m, 0.66/s) 4H(7.25/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.27 / d, 8.18 / d, 8.04 / d, 7.72 / d, 7.68 / m, 7.52 / m, 7.50 / d, 7.46 / d (7.35 / d), 7.37 / m) 2H (8.93 d, 8.12 d, 7.88 m, 7.82 m, 7.79 d, 7.51 m, 0.66 s)

LC/MS: m/z=628[(M+1)+]
LC / MS: m / z = 628 [(M + 1) &lt; + &

실시예Example 34 : 화합물 691의 합성 34: Synthesis of Compound 691

(1) (One) 제조예Manufacturing example 1 : 중간체 34-1의 합성 1: Synthesis of Intermediate 34-1

Figure pat00227
Figure pat00227

2-iodo-1H-benzo[d]imidazole(3.0 g, 0.012 mol)에 triisopropyl borate(3.4 g, 0.018 mol)를 넣고 실시예 7-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 34-1> 1.4 g (수율 71%)을 얻었다.(m/z=161)
Was synthesized in the same manner as in Example 7-Preparation Example (2), except that triisopropyl borate (3.4 g, 0.018 mol) was added to 2-iodo-1H-benzo [d] imidazole (3.0 g, 0.012 mol) -1> 1.4 g (yield: 71%). (M / z = 161)

(2) (2) 제조예Manufacturing example 2 : 중간체 34-2의 합성 2: Synthesis of intermediate 34-2

Figure pat00228
Figure pat00228

중간체 34-1(2.0 g, 0.012 mol)에 2,5-dibromothiophene(2.4 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 34-2> 2.0 g (수율 73%)을 얻었다.(m/z=279)
Intermediate 34-2> 2.0 (2.0 g, 0.012 mol) was synthesized in the same manner as in Example 1- (6) except that 2,5-dibromothiophene (2.4 g, 0.010 mol) g (yield: 73%). (m / z = 279)

(3) (3) 제조예Manufacturing example 3 : 중간체 34-3의 합성 3: Synthesis of intermediate 34-3

Figure pat00229
Figure pat00229

중간체 34-2(3.0 g, 0.010 mol)에 triphenylen-2-ylboronic acid(3.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 34-3> 3.2 g (수율 75%)을 얻었다.(m/z=426)
Intermediate 34-3 was synthesized in the same manner as in Example 1 (6) except that triphenylen-2-ylboronic acid (3.4 g, 0.012 mol) was added to intermediate 34-2 (3.0 g, 0.010 mol) 3.2 g (yield 75%) was obtained. (M / z = 426)

(4) (4) 제조예Manufacturing example 4 : 중간체 34-4의 합성 4: Synthesis of intermediate 34-4

Figure pat00230
Figure pat00230

중간체 34-3(3.0 g, 0.007 mol)에 methyl 2-bromobenzoate(1.5 g, 0.007 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 34-4> 2.7 g (수율 68%)을 얻었다.(m/z=560)
Intermediate 34-4 was synthesized in the same manner as in Example 1 (2), except that methyl 2-bromobenzoate (1.5 g, 0.007 mol) was added to Intermediate 34-3 (3.0 g, 0.007 mol) (Yield: 68%). (M / z = 560)

(5) (5) 제조예Manufacturing example 5 : 중간체 34-5의 합성 5: Synthesis of intermediate 34-5

Figure pat00231
Figure pat00231

중간체 34-4(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 34-5> 3.6 g (수율 72%)을 얻었다.(m/z=560)
And 3.6 g (yield 72%) of Intermediate 34-5 (3.0 g, 0.009 mol) were synthesized in the same manner as in Example 1- (3) = 560)

(6) (6) 제조예Manufacturing example 6 : 화합물 691의 합성 6: Synthesis of Compound 691

Figure pat00232
Figure pat00232

중간체 34-5(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 691> 3.5 g (수율 72%)을 얻었다.3.5 g (yield 72%) of Compound 691 was obtained by the same method as in Example 1- (4), except that Intermediate 34-5 (3.0 g, 0.009 mol) was added.

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.61/d, 7.41/m, 7.40/m, 7.37/m, 7.30/d, 7.26/d, 7.14/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.73/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.61 / d, 7.41 / m, 7.40 / m, 7.37 / m, 7.30 / d, 7.26 / d , 7.14 / m) 2H (8.93 d, 8.12 d, 7.88 m, 7.82 m, 7.73 d, 1.72 s)

LC/MS: m/z=543[(M+1)+]
LC / MS: m / z = 543 [(M + 1) &lt; + &

실시예Example 35 : 화합물 692의 합성 35: Synthesis of Compound 692

(1) (One) 제조예Manufacturing example 1 : 중간체 35-1의 합성 1: Synthesis of intermediate 35-1

Figure pat00233
Figure pat00233

중간체 34-1(2.0 g, 0.012 mol)에 2,5-dibromofuran(2.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 35-1> 1.8 g (수율 70%)을 얻었다.(m/z=263)
Synthesis was conducted in the same manner as in Example 1 (6), except that 2,5-dibromofuran (2.3 g, 0.010 mol) was added to Intermediate 34-1 (2.0 g, 0.012 mol) g (yield: 70%). (m / z = 263)

(2) (2) 제조예Manufacturing example 2 : 중간체 35-2의 합성 2: Synthesis of intermediate 35-2

Figure pat00234
Figure pat00234

중간체 35-1(3.0 g, 0.010 mol)에 triphenylen-2-ylboronic acid(3.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 35-2> 3.0 g (수율 73%)을 얻었다.(m/z=410)
Intermediate 35-2 was synthesized in the same manner as in Example 1 (6) except that triphenylen-2-ylboronic acid (3.4 g, 0.012 mol) was added to Intermediate 35-1 (3.0 g, 0.010 mol) 3.0 g (yield: 73%). (M / z = 410)

(3) (3) 제조예Manufacturing example 3 : 중간체 35-3의 합성 3: Synthesis of intermediate 35-3

Figure pat00235
Figure pat00235

중간체 35-2(3.0 g, 0.007 mol)에 methyl 2-bromobenzoate(1.5 g, 0.007 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 35-3> 2.3 g (수율 65%)을 얻었다.(m/z=544)
2.3 g (0.007 mol) of intermediate <35-3> were synthesized in the same manner as in Example 1 (2) except that methyl 2-bromobenzoate (1.5 g, 0.007 mol) (Yield: 65%). (M / z = 544)

(4) (4) 제조예Manufacturing example 4 : 중간체 35-4의 합성 4: Synthesis of intermediate 35-4

Figure pat00236
Figure pat00236

중간체 35-3(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 35-4> 3.1g (수율 70%)을 얻었다.(m/z=544)
Intermediate 35-3 (3.0 g, 0.009 mol) was added thereto, and 3.1 g (yield 70%) of <Intermediate 35-4> was obtained in the same manner as in Example 1- = 544)

(5) (5) 제조예Manufacturing example 5 : 화합물 692의 합성 5: Synthesis of compound 692

Figure pat00237
Figure pat00237

중간체 35-4(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <화합물 692> 3.1 g (수율 71%)을 얻었다.3.1 g (yield 71%) of Compound 692 was obtained by the same method as in Example 1- (4), except that Intermediate 35-4 (3.0 g, 0.009 mol) was added.

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.61/d, 7.41/m, 7.40/m, 7.37/m, 7.30/d, 7.26/d, 7.14/m) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.07/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.61 / d, 7.41 / m, 7.40 / m, 7.37 / m, 7.30 / d, 7.26 / d , 7.14 / m) 2H (8.93 d, 8.12 d, 7.88 m, 7.82 m, 7.07 d, 1.72 s)

LC/MS: m/z=527[(M+1)+]
LC / MS: m / z = 527 [(M + 1) &lt; + &

실시예Example 36 : 화합물 693의 합성 36: Synthesis of Compound 693

(1) (One) 제조예Manufacturing example 1 : 중간체 36-1의 합성 1: Synthesis of Intermediate 36-1

Figure pat00238
Figure pat00238

3,6-dibromobenzene-1,2-diamine(3.0 g, 0.011 mol)에 dibromochloromethane (2.3 g, 0.011 mol)를 넣고 실시예 25-제조예 (1)에서 사용된 동일한 방법으로 합성하여 <중간체 36-1> 1.4 g (수율 41%)을 얻었다.(m/z=312)
Dibromochloromethane (2.3 g, 0.011 mol) was added to 3,6-dibromobenzene-1,2-diamine (3.0 g, 0.011 mol) and the reaction was conducted in the same manner as in Example 25- 1> 1.4 g (yield 41%). (M / z = 312)

(2) (2) 제조예Manufacturing example 2 : 중간체 36-2의 합성 2: Synthesis of intermediate 36-2

Figure pat00239
Figure pat00239

중간체 36-1(3.0 g, 0.010 mol)에 1-bromo-2-tert-butylbenzene(2.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 36-2> 1.9 g (수율 50%)을 얻었다.(m/z=386)
The intermediate 36-1 (3.0 g, 0.010 mol) was synthesized in the same manner as in Example 1 (2) except that 1-bromo-2-tert-butylbenzene (2.1 g, 0.010 mol) -2> 1.9 g (yield: 50%). (M / z = 386)

(3) (3) 제조예Manufacturing example 3 : 중간체 36-3의 합성 3: Synthesis of intermediate 36-3

Figure pat00240
Figure pat00240

중간체 36-2(3.0 g, 0.0008 mol)에 phenyl boronic acid(1.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 36-3> 2.1 g (수율 60%)을 얻었다.(m/z=428)
2.1 g (intermediate 36-3) was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.2 g, 0.010 mol) was added to Intermediate 36-2 (3.0 g, 0.0008 mol) Yield: 60%). (M / z = 428)

(4) (4) 제조예Manufacturing example 4 : 중간체 36-4의 합성 4: Synthesis of intermediate 36-4

Figure pat00241
Figure pat00241

중간체 36-3(3.0 g, 0.007 mol)에 N-bromosuccinimide(1.2 g, 0.007 mol)에 DMF 100 mL를 넣고 20 ℃에서 8시간 교반하여 반응시켰다. 반응 종료 후 H20 : 아세트산에틸로 층분리 후 컬럼정제(n-Hexane : MC)하여 중간체 36-4을 1.4 g(40%)수득하였다.(m/z=507)
100 mL of DMF was added to N-bromosuccinimide (1.2 g, 0.007 mol) in Intermediate 36-3 (3.0 g, 0.007 mol), and the mixture was reacted at 20 ° C for 8 hours with stirring. After completion of the reaction H 2 0: After phase separation with ethyl acetate and column purification: the (n-Hexane MC) to the intermediate 36-4 to give 1.4 g (40%) (m / z = 507).

(5) (5) 제조예Manufacturing example 5 : 중간체 36-4'의 합성 5: Synthesis of intermediate 36-4 '

Figure pat00242
Figure pat00242

중간체 36-4(5.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 36-4'> 3.9 g (수율 71%)을 얻었다.(m/z=554)
Intermediate 36-4 'was synthesized in the same manner as in Example 1 (5) except that bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to Intermediate 36-4 (5.0 g, 0.010 mol) 3.9 g (yield 71%) of the title compound was obtained (m / z = 554)

(6) (6) 제조예Manufacturing example 6 : 중간체 36-5의 합성 6: Synthesis of intermediate 36-5

Figure pat00243
Figure pat00243

2-bromo-4,6-diphenyl-1,3,5-triazine(2.5 g, 0.008 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 36-5> 2.1 g (수율 73%)을 얻었다.(m/z=359)
Bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to 2-bromo-4,6-diphenyl-1,3,5-triazine (2.5 g, 0.008 mol) (M / z = 359) (yield: 73%). &Lt; / RTI >

(7) (7) 제조예Manufacturing example 7 : 중간체 36-6의 합성 7: Synthesis of Intermediate 36-6

Figure pat00244
Figure pat00244

중간체 36-5(3.0 g, 0.008 mol)에 1,4-dibromobenzene(1.6 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 693> 2.0 g (수율 73%)을 얻었다.(m/z=388)
2.0 g (Compound 693) was synthesized in the same manner as in Example 1 (6), except that 1,4-dibromobenzene (1.6 g, 0.007 mol) was added to Intermediate 36-5 (3.0 g, 0.008 mol) Yield: 73%). (M / z = 388)

(8) (8) 제조예Manufacturing example 8 : 화합물 693의 합성 8: Synthesis of Compound 693

Figure pat00245
Figure pat00245

중간체 36-4'(5.0 g, 0.009 mol)에 중간체 36-6(3.1 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 693> 4.3 g (수율 73%)을 얻었다.4.3 g (Compound 693) was synthesized in the same manner as in Example 1- (6) except that Intermediate 36-6 (3.1 g, 0.008 mol) was added to Intermediate 36-4 '(5.0 g, 0.009 mol) Yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.26/m, 6.88/s, 5.04/s) 2H(7.85/d, 7.43/d, 7.41/m, 7.33/m, 7.25/d, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.26 / m, 6.88 / s, 5.04 / s) 2H (7.85 / d, 7.43 / d, 7.41 / m, 7.33 / m, 7.25 / d, 7.08 / d, 7.05 / m, 6.69 / m, 6.52 / d) 4H (8.28 / d, 7.51 /

LC/MS: m/z= 736[(M+1)+]
LC / MS: m / z = 736 [(M + 1) &lt; + &

실시예Example 37 : 화합물 694의 합성 37: Synthesis of Compound 694

(1) (One) 제조예Manufacturing example 1 : 화합물 694의 합성 1: Synthesis of compound 694

Figure pat00246
Figure pat00246

중간체 36-2(3.0 g, 0.008 mol), 중간체 21-5(4.3 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 694> 3.7g (수율 70%)을 얻었다.The compound obtained in the same manner as in Example 1 (6) was used in place of Intermediate 36-2 (3.0 g, 0.008 mol) and Intermediate 21-5 (4.3 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(5.04/d) 2H(8.52/d, 7.41/m, 7.29/d, 7.08/d, 7.05/m, 6.69/m, 6.52/d, 6.32/d) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (5.04 / d) 2H (8.52 / d, 7.41 / m, 7.29 / d, 7.08 / d, 7.05 / m, 6.69 / m, 6.52 / d, 6.32 / d) 4H (8.28 / d, 7.51 / m, 1.72 / s)

LC/MS: m/z=660 [(M+1)+]
LC / MS: m / z = 660 [(M + 1) &lt; + &

실시예Example 38 : 화합물 695의 합성 38: Synthesis of Compound 695

(1) (One) 제조예Manufacturing example 1 : 화합물 695의 합성 1: Synthesis of Compound 695

Figure pat00247
Figure pat00247

중간체 36-4(5.0 g, 0.010 mol), 중간체 22-5(5.1 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 695> 5.3 g (수율 73%)을 얻었다.(Compound 695) (synthesis amount: 5.3 g, yield: 5.0 g, 0.010 mol) and Intermediate 22-5 (5.1 g, 0.012 mol) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(9.15/s, 8.18/d, 8.04/d, 7.26/m, 6.88/s, 5.04/s) 2H(8.93/d, 8.12/d, 7.88/m, 7.82/m, 7.43/d, 7.33/m, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (9.15 / s, 8.18 / d, 8.04 / d, 7.26 / m, 6.88 / s, 5.04 / s) 2H (8.93 / d, 8.12 / d, 7.88 d, 7.02 / d, 7.05 / m, 6.69 / m, 6.52 / d) 4H (7.25 / d, 1.72 / s)

LC/MS: m/z=731[(M+1)+]
LC / MS: m / z = 731 [(M + 1) &lt; + &

실시예Example 39 : 화합물 696의 합성 39: Synthesis of Compound 696

(1) (One) 제조예Manufacturing example 1 : 중간체 39-1의 합성 1: Synthesis of intermediate 39-1

Figure pat00248
Figure pat00248

dibenzo[b,d]thiophen-4-ylboronic acid(2.3 g, 0.010 mol), 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 39-1> 1.9 g (수율 70%)을 얻었다.(m/z=339)
(6.9 g, 0.008 mol) and 1,4-dibromobenzene (1.9 g, 0.008 mol) were added in the same manner as in Example 1-Preparation Example (6), except that dibenzo [b, d] thiophen- 1.9 g (yield: 70%) of Intermediate 39-1 was obtained. (M / z = 339)

(2) (2) 제조예Manufacturing example 2 : 화합물 696의 합성 2: Synthesis of Compound 696

Figure pat00249
Figure pat00249

중간체36-4'(5.0 g, 0.009 mol), 중간체 39-1(2.7 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 696> 4.0 g (수율 73%)을 얻었다.4.0 g (Compound 696) was synthesized in the same manner as in Example 1- (6) except that Intermediate 36-4 '(5.0 g, 0.009 mol) and Intermediate 39-1 (2.7 g, 0.008 mol) Yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.45/d, 8.41/d, 8.20/d, 7.98/d, 7.58/m, 7.52/m, 7.50/m, 7.26/m, 6.88/s, 5.04/s) 2H(7.43/d, 7.33/m, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.45 / d, 8.41 / d, 8.20 / d, 7.98 / d, 7.58 / m, 7.52 / m, 7.50 / m, 7.26 / m, 6.88 / s , 7.04 / s, 7.04 / s) 2H (7.43 / d, 7.33 / m, 7.08 / d, 7.05 /

LC/MS: m/z=687[(M+1)+]
LC / MS: m / z = 687 [(M + 1) &lt; + &

실시예Example 40 : 화합물 697의 합성 40: Synthesis of Compound 697

(1) (One) 제조예Manufacturing example 1 : 중간체 40-1의 합성 1: Synthesis of intermediate 40-1

Figure pat00250
Figure pat00250

중간체 36-4'(5.0 g, 0.009 mol), 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 40-1> 3.4 g (수율 73%)을 얻었다.(m/z=583)
Intermediate 40-1 was synthesized in the same manner as in Example 1- (6) except that Intermediate 36-4 '(5.0 g, 0.009 mol) and 1,4-dibromobenzene (1.9 g, 0.008 mol) 3.4 g (yield: 73%) was obtained. (M / z = 583)

(2) (2) 제조예Manufacturing example 2 : 화합물 697의 합성 2: Synthesis of compound 697

Figure pat00251
Figure pat00251

중간체 40-1(5.0 g, 0.009 mol), 9H-carbazole(2.2 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 697> 4.8 g (수율 79%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (2), except that Intermediate 40-1 (5.0 g, 0.009 mol) and 9H-carbazole (2.2 g, 0.009 mol) %).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 8.12/d, 7.94/d, 7.63/d, 7.50/m, 7.33/m, 7.29/m, 7.26/m, 7.25/m, 6.88/s, 5.04/s) 2H(7.79/d, 7.68/d, 7.43/d, 7.33/m, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 8.12 / d, 7.94 / d, 7.63 / d, 7.50 / m, 7.33 / m, 7.29 / m, 7.26 / m, 7.25 / m , 6.88 / s, 5.04 / s) 2H (7.79 d, 7.68 d, 7.43 d, 7.33 m, 7.08 d, 7.05 m, 6.69 m, 6.52 d)

LC/MS: m/z=670[(M+1)+]
LC / MS: m / z = 670 [(M + 1) &lt; + &

실시예Example 41 : 화합물 698의 합성 41: Synthesis of compound 698

(1) (One) 제조예Manufacturing example 1 : 화합물 698의 합성 1: Synthesis of Compound 698

Figure pat00252
Figure pat00252

중간체 40-1(5.0 g, 0.009 mol), 9-phenyl-9H-carbazol-3-ylboronic acid(3.2 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 698> 4.9 g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 40-1 (5.0 g, 0.009 mol) and 9-phenyl-9H-carbazol-3-ylboronic acid (3.2 g, 0.011 mol) <Compound 698> 4.9 g (yield: 73%) was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.45/m, 7.33/m, 7.26/m, 7.25/m, 6.88/s, 5.04/s) 2H(7.58/m, 7.50/d, 7.43/d, 7.33/m, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(7.25/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.45 / m, 7.33 / m, 7.26 / m, 7.25 / m , 6.88 / s, 5.04 / s) 2H (7.58 / m, 7.50 / d, 7.43 / d, 7.33 / m, 7.08 / d, 7.05 / / s)

LC/MS: m/z=746[(M+1)+]
LC / MS: m / z = 746 [(M + 1) &lt; + &

실시예Example 42 : 화합물 699의 합성 42: Synthesis of Compound 699

(1) (One) 제조예Manufacturing example 1 : 중간체 42-1의 합성 1: Synthesis of intermediate 42-1

Figure pat00253
Figure pat00253

중간체 42-1(5.0 g, 0.009 mol)에 3-bromo-9H-carbazole(1.8 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 42-1> 2.9g (수율 71%)을 얻었다.(m/z=593)
Synthesis was conducted in the same manner as in Example 1 (6), except that 3-bromo-9H-carbazole (1.8 g, 0.007 mol) was added to Intermediate 42-1 (5.0 g, 0.009 mol) > 2.9 g (yield: 71%). (M / z = 593)

(2) (2) 제조예Manufacturing example 2 : 화합물 699의 합성 2: Synthesis of Compound 699

Figure pat00254
Figure pat00254

중간체 42-2(5.0 g, 0.008 mol)에 4-bromo-2,6-diphenylpyridine(2.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 699> 4.7g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that 4-bromo-2,6-diphenylpyridine (2.6 g, 0.008 mol) was added to Intermediate 42-2 (5.0 g, 0.008 mol) (Yield: 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.55/d, 7.94/d, 7.87/d, 7.77/s, 7.69/d, 7.33/m, 7.26/m, 7.25/m, 6.88/s, 5.04/s) 2H(7.47/m, 7.43/d, 7.33/m, 7.10/s, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(8.30/d, 7.54/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.55 / d, 7.94 / d, 7.87 / d, 7.77 / s, 7.69 / d, 7.33 / m, 7.26 / m, 7.25 / m, 6.88 / s D, 7.54 / m, 7.72 / d), 5.04 / s) 2H (7.47 / m, 7.43 / d, 7.33 / m, 7.10 / s, 7.08 / d, 7.05 / / s)

LC/MS: m/z=824[(M+1)+]
LC / MS: m / z = 824 [(M + 1) &lt; + &

실시예Example 43 : 화합물 700의 합성 43: Synthesis of Compound 700

(1) (One) 제조예Manufacturing example 1 : 화합물 700의 합성 1: Synthesis of Compound 700

Figure pat00255
Figure pat00255

중간체 42-1(5.0 g, 0.008 mol), 2-bromo-4,6-diphenyl-1,3,5-triazine (2.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 700> 4.7 g (수율 71%)을 얻었다.The same procedure as in Example 1 (6) was repeated except that Intermediate 42-1 (5.0 g, 0.008 mol) and 2-bromo-4,6-diphenyl-1,3,5-triazine (2.6 g, 0.008 mol) To obtain 4.7 g (yield 71%) of < Compound 700 >.

H-NMR (200MHz, CDCl3):δ ppm,1H(7.94/d, 7.87/d, 7.77/d, 7.69/d, 7.33/m, 7.26/m, 7.25/m, 6.88/s, 5.04/s) 2H(7.43/d, 7.41/m, 7.33/m, 7.08/d, 7.05/m, 6.69/m, 6.52/d) 4H(8.28/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.94 / d, 7.87 / d, 7.77 / d, 7.69 / d, 7.33 / m, 7.26 / m, 7.25 / m, 6.88 / s, 5.04 / s ), 2H (7.43 / d, 7.41 / m, 7.33 / m, 7.08 / d, 7.05 / m, 6.69 /

LC/MS: m/z=826[(M+1)+]
LC / MS: m / z = 826 [(M + 1) &lt; + &

실시예Example 44 : 화합물 2의 합성 44: Synthesis of Compound 2

(1) (One) 제조예Manufacturing example 1 : 중간체 44-1의 합성 1: Synthesis of intermediate 44-1

Figure pat00256
Figure pat00256

1H-indol-3-ylboronic acid(2.0 g, 0.012 mol), N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 44-1> 3.9g (수율 71%)을 얻었다.(m/z=552)
3-ylboronic acid (2.0 g, 0.012 mol), N- (biphenyl-4-yl) -N- (4-bromophenyl) -9,9-dimethyl-9H- (M / z = 552) was obtained in the same manner as in Example 1 (6), except that the compound (44)

(2) (2) 제조예Manufacturing example 2 : 중간체 44-2의 합성 2: Synthesis of intermediate 44-2

Figure pat00257
Figure pat00257

중간체 44-1(5.0 g, 0.008 mol), methyl 2-bromobenzoate(2.6 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 44-2> 4.3g (수율 79%)을 얻었다.(m/z=686)
Intermediate 44-2 was synthesized in the same manner as in Example 1 (2) except that Intermediate 44-1 (5.0 g, 0.008 mol) and methyl 2-bromobenzoate (2.6 g, 0.012 mol) (Yield: 79%). (M / z = 686)

(3) (3) 제조예Manufacturing example 3 : 중간체 44-3의 합성 3: Synthesis of intermediate 44-3

Figure pat00258
Figure pat00258

중간체 44-2(5.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 44-3> 3.6 g (수율 75%)을 얻었다.(m/z=686)
Synthesis was conducted in the same manner as in Example 1 (3), except that Intermediate 44-2 (5.0 g, 0.007 mol) was added to obtain 3.6 g (yield 75%) of Intermediate 44-3. M / z = 686)

(4) (4) 제조예Manufacturing example 4 : 화합물 2의 합성 4: Synthesis of compound 2

Figure pat00259
Figure pat00259

중간체 44-2(5.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 2> 3.5g (수율 75%)을 얻었다.3.5 g (yield 75%) of <Compound 2> was obtained by the same method as in Example 1- (6), except that Intermediate 44-2 (5.0 g, 0.007 mol) was added.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.28/m, 7.26/d, 7.04/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.40 / m, 7.38 / m, 7.37 / m, 7.36 / s , 7.54 / d, 6.69 / d, 6.72 / d, 7.58 / d) 2H (7.52 / d, 7.51 / / s)

LC/MS: m/z=669[(M+1)+]
LC / MS: m / z = 669 [(M + 1) &lt; + &

실시예Example 45 : 화합물 4의 합성 45: Synthesis of compound 4

(1) (One) 제조예Manufacturing example 1 : 화합물 4의 합성 1: Synthesis of Compound (4)

Figure pat00260
Figure pat00260

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol)대신에 N-(biphenyl-4-yl)-N-(4-bromophenyl)biphenyl-4-amine(4.8 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 4> 4.4g (수율 70%) 을 얻었다.4-yl) -N- (4-bromophenyl) -9,9-dimethyl-9H-fluoren-2-amine (5.2 g, 0.010 mol) instead of N- (biphenyl- 4.4 g (yield 70%) of Compound 4 was obtained in the same manner as in <Compound 2> using N- (4-bromophenyl) biphenyl-4-amine (4.8 g, 0.010 mol).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.40/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.26/d, 7.04/d) 2H(7.41/m, 1.72/s) 4H(7.52/d, 7.51/m) 6H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.40 / m, 7.37 / m, 7.36 / s, 7.34 / m, 7.30 / d, 7.26 / d, 7.04 / d) 2H (7.41 / m, 1.72 / s) 4H (7.52 / d, 7.51 / m) 6H (7.54 / d, 6.69 / d)

LC/MS: m/z=629[(M+1)+]
LC / MS: m / z = 629 [(M + 1) &lt; + &

실시예Example 46 : 화합물 11의 합성 46: Synthesis of Compound 11

(1) (One) 제조예Manufacturing example 1 : 화합물 11의 합성 1: Synthesis of Compound 11

Figure pat00261
Figure pat00261

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 46-1(5.1 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 11> 5.4g (수율 72%) 을 얻었다.Intermediate 46-1 (5.1 g, 0.010 mol) was used in the place of N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- ) Was used to obtain Compound (11) (5.4 g, Yield: 72%) in the same manner as in < Compound 2 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.42/s, 7.40/m, 7.37/m, 7.34/m, 7.30/d, 7.26/d, 7.04/d, 6.49/s) 2H(7.87/d, 7.62/d, 7.55/d, 7.38/m, 7.28/m, 6.75/s, 6.58/d, 2.59/s) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.42 / s, 7.40 / m, 7.37 / m, 7.34 / m, 7.30 / d, 7.26 / d, 7.04 / d, 6.49 / s ) 2H (7.87 d, 7.62 d, 7.55 d, 7.38 m, 7.28 m, 6.75 s, 6.58 d, 2.59 s)

LC/MS: m/z=737[(M+1)+]
LC / MS: m / z = 737 [(M + 1) &lt; + &

실시예Example 47 : 화합물 12의 합성 47: Synthesis of Compound 12

(1) (One) 제조예Manufacturing example 1 : 화합물 12의 합성 1: Synthesis of Compound 12

Figure pat00262
Figure pat00262

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 47-1(5.3 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 12> 5.2g (수율 72%) 을 얻었다.Intermediate 47-1 (5.3 g, 0.010 mol) was used in the place of N- (biphenyl-4-yl) -N- (4-bromophenyl) -9,9-dimethyl-9H- ), 5.2 g (yield 72%) of <Compound 12> was obtained in the same manner as in <Compound 2>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.87/d, 7.84/d, 7.74/d, 7.69/d, 7.64/d, 7.62/d, 7.55/d, 7.49/d, 7.46/s, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.28/m, 7.26/d, 7.04/d, 6.75/s, 6.58/d) 2H(7.54/d, 7.52/d, 7.51/m, 6.69/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.87 / d, 7.84 / d, 7.74 / d, 7.69 / d, 7.64 / d, 7.62 / d, 7.55 / d, 7.49 / d 7.36 / s, 7.34 / m, 7.30 / d, 7.28 / m, 7.26 / d, 7.04 / d, 6.75 / s, 6.58 / d) 2H (7.54 / d, 7.52 / d, 7.51 / m, 6.69 /

LC/MS: m/z=719[(M+1)+]
LC / MS: m / z = 719 [(M + 1) &lt; + &

실시예Example 48 : 화합물 19의 합성 48: Synthesis of Compound 19

(1) (One) 제조예Manufacturing example 1 : 화합물 19의 합성 1: Synthesis of Compound 19

Figure pat00263
Figure pat00263

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 48-1(5.5 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 19> 5.3g (수율 75%) 을 얻었다.Intermediate 48-1 (5.5 g, 0.010 mol) was used instead of N- (biphenyl-4-yl) -N- (4-bromophenyl) -9,9-dimethyl- ) Was used to obtain 5.3 g (yield 75%) of <Compound 19> by the same method as in <Compound 2>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.40/m, 7.37/m, 7.36/s, 7.34/m, 7.26/d, 7.04/d, 5.73/s) 2H(6.25/s, 1.72/s) 4H(2.34/s) 8H(6.98/d, 6.51/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.40 / m, 7.37 / m, 7.36 / s, 7.34 / m, 7.26 / d, 7.04 / d, 5.73 / s) 2H (6.25 / s, 1.72 / s) 4H (2.34 / s) 8H (6.98 / d, 6.51 / d)

LC/MS: m/z=700[(M+1)+]
LC / MS: m / z = 700 [(M + 1) &lt; + &

실시예Example 49 : 화합물 34의 합성 49: Synthesis of Compound 34

(1) (One) 제조예Manufacturing example 1 : 화합물 34의 합성 1: Synthesis of Compound 34

Figure pat00264
Figure pat00264

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 49-2(6.5 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 34> 6.0 g (수율 75%) 을 얻었다.Intermediate 49-2 (6.5 g, 0.010 mol) was used in the place of N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- ) Was used to obtain 6.0 g (yield 75%) of Compound 34 by the same method as in < Compound 2 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.87/d, 7.70/s, 7.62/d, 7.57/m, 7.55/d, 7.44/m, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.28/m, 7.26/d, 7.04/d, 6.89/s, 6.88/d, 6.75/s, 6.59/d, 6.58/d) 2H(7.54/d, 7.48/d, 7.38/d, 7.37/d, 6.69/d) 3H(1.35/s) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.87 / d, 7.70 / s, 7.62 / d, 7.57 / m, 7.55 / d, 7.44 / m, 7.40 / m, 7.38 / m D, 7.28 / d, 7.04 / d, 6.89 / s, 6.88 / d, 6.75 / s, 6.59 / d, 6.58 / d) (7.54 / d, 7.48 / d, 7.38 / d, 7.37 / d, 6.69 /

LC/MS: m/z=802[(M+1)+]
LC / MS: m / z = 802 [(M + 1) &lt; + &

실시예Example 50 : 화합물 39의 합성 50: Synthesis of Compound 39

(1) (One) 제조예Manufacturing example 1 : 중간체 50-1의 합성 1: Synthesis of intermediate 50-1

Figure pat00265
Figure pat00265

중간체 49-1(3.0 g, 0.007 mol)에 4-bromobiphenyl(1.6 g, 0.007 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 50-1> 2.7g (수율 65%)을 얻었다.(m/z=592)
Intermediate 49-1 (3.0 g, 0.007 mol) was mixed with 4-bromobiphenyl (1.6 g, 0.007 mol) and synthesized in the same manner as in Example 1- Yield: 65%). (M / z = 592)

(2) (2) 제조예Manufacturing example 2 : 중간체 50-2의 합성 2: Synthesis of intermediate 50-2

Figure pat00266
Figure pat00266

중간체 50-1(5.0 g, 0.008 mol)에 triisopropyl borate(1.9 g, 0.010 mol)을 넣고 실시예 7-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 50-2> 3.1g (수율 70%)을 얻었다.(m/z=557)
Synthesis was conducted in the same manner as in Example 7-Preparation Example (2), except that triisopropyl borate (1.9 g, 0.010 mol) was added to Intermediate 50-1 (5.0 g, 0.008 mol) 70%). (M / z = 557)

(3) (3) 제조예Manufacturing example 3 : 중간체 50-3의 합성 3: Synthesis of Intermediate 50-3

Figure pat00267
Figure pat00267

2-bromo-3-chloro-1H-indole(3.0 g, 0.013 mol)에 9,9-dimethyl-9H-fluoren-2-ylboronic acid(3.7 g, 0.016 mol)을 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 50-3> 3.3g (수율 75%)을 얻었다.(m/z=343)
2-ylboronic acid (3.7 g, 0.016 mol) was added to 2-bromo-3-chloro-1H-indole (3.0 g, 0.013 mol) ) To obtain 3.3 g (yield 75%) of Intermediate 50-3 (m / z = 343)

(4) (4) 제조예Manufacturing example 4 : 중간체 50-4의 합성 4: Synthesis of intermediate 50-4

Figure pat00268
Figure pat00268

중간체 50-3(3.0 g, 0.009 mol)에 중간체 50-2(5.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 50-4> 5.4 g (수율 73%)을 얻었다.(m/z=821)
Intermediate 50-4 (5.8 g, 0.011 mol) was added to Intermediate 50-3 (3.0 g, 0.009 mol) and the reaction mixture was treated in the same manner as in Example 1- (6) (Yield: 73%). (M / z = 821)

(5) (5) 제조예Manufacturing example 5 : 화합물 39의 합성 5: Synthesis of Compound 39

Figure pat00269
Figure pat00269

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 50-4(8.2 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 39> 5.7g (수율 61%) 을 얻었다.Intermediate 50-4 (8.2 g, 0.010 mol) was used in the place of N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- ) Was used to obtain 5.7 g (yield: 61%) of <Compound 39> by the same method as in <Compound 2>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.93/d, 7.77/s, 7.70/s, 7.63/d, 7.62/d, 7.57/m, 7.44/m, 7.40/m, 7.37/m, 7.34/m, 7.30/d, 7.26/d, 7.00/d, 6.89/s, 6.88/d, 6.75/s, 6.59/d, 6.58/d) 2H(7.87/d, 7.55/d, 7.54/d, 7.52/d, 7.51/m, 7.48/d, 7.38/m, 7.28/m, 6.69/d) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.93 / d, 7.77 / s, 7.70 / s, 7.63 / d, 7.62 / d, 7.57 / m, 7.44 / m, 7.40 / m D, 6.75 / d, 6.75 / s, 6.59 / d, 6.58 / d) 2H (7.87 / d, 7.55 / d 7.58 / d, 7.51 / m, 7.48 / d, 7.38 / m, 7.28 /

LC/MS: m/z=938[(M+1)+]
LC / MS: m / z = 938 [(M + 1) &lt; + &

실시예Example 51 : 화합물 46의 합성 51: Synthesis of Compound 46

(1) (One) 제조예Manufacturing example 1 : 중간체 51-1의 합성 1: Synthesis of Intermediate 51-1

Figure pat00270
Figure pat00270

2,7-dibromo-9,9-dimethyl-9H-fluorene(3.0 g, 0.008 mol)에 dibiphenyl-4-ylamine(2.6 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 51-1> 3.4g (수율 71%)을 얻었다.(m/z=592)
(2.6 g, 0.008 mol) was added to 2,7-dibromo-9,9-dimethyl-9H-fluorene (3.0 g, 0.008 mol) (M / z = 592) (Intermediate 51-1) (3.4 g, Yield: 71%).

(2) (2) 제조예Manufacturing example 2 : 화합물 46의 합성 2: Synthesis of Compound 46

Figure pat00271
Figure pat00271

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol) 대신에 중간체 51-1(5.9 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 46> 5.3g (수율 71%) 을 얻었다.Intermediate 51-1 (5.9 g, 0.010 mol) was used in the place of N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- fluoren- ), 5.3 g (yield: 71%) of Compound 46 was obtained in the same manner as in < Compound 2 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.93/d, 7.77/s, 7.63/d, 7.62/d, 7.40/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.26/d, 7.04/d, 6.75/s, 6.58/d) 2H(7.41/m) 4H(7.54/d, 7.52/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.93 / d, 7.77 / s, 7.63 / d, 7.62 / d, 7.40 / m, 7.37 / m, 7.36 / s, 7.34 / m (7.54 / d, 7.52 / d, 7.51 / m, 6.69 / d, 1.72 / s), 7.30 / d, 7.26 / d, 7.04 / d, 6.75 / s, 6.58 /

LC/MS: m/z=745[(M+1)+]
LC / MS: m / z = 745 [(M + 1) &lt; + &

실시예Example 52 : 화합물 50의 합성 52: Synthesis of Compound 50

(1) (One) 제조예Manufacturing example 1 : 중간체 52-1의 합성 1: Synthesis of Intermediate 52-1

Figure pat00272
Figure pat00272

2-bromo-1H-indol-3-ylboronic acid(2.2 g, 0.009 mol)에 naphthalen-2-ylboronic acid(1.9 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 52-1> 1.9 g (수율 73%)을 얻었다.(m/z=287)
2-ylboronic acid (1.9 g, 0.011 mol) was added to 2-bromo-1H-indol-3-ylboronic acid (2.2 g, 0.009 mol) in the same manner as in Example 1- To obtain 1.9 g (yield 73%) of Intermediate 52-1 (m / z = 287)

(2) (2) 제조예Manufacturing example 2 : 중간체 52-2의 합성 2: Synthesis of intermediate 52-2

Figure pat00273
Figure pat00273

중간체 52-1(3.4 g, 0.012 mol), N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 52-2> 4.8g (수율 71%)을 얻었다.(m/z=678)
N- (4-bromophenyl) -9,9-dimethyl-9H-fluoren-2-amine (5.2 g, 0.010 mol) (M / z = 678) (yield: 71%) was obtained by the same method as in the production example (6) of Example 1-

(3) (3) 제조예Manufacturing example 3 : 화합물 50의 합성 3: Synthesis of Compound 50

Figure pat00274
Figure pat00274

중간체 52-2(6.8 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 50> 5.7g (수율 71%) 을 얻었다.(Yield: 71%) was obtained in the same manner as in < Compound 2 >, using Intermediate 52-2 (6.8 g, 0.010 mol).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.34/d, 7.99/d, 7.92/d, 7.55/m, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.34/m, 7.30/d, 7.28/m, 7.26/d, 7.00/d, 6.75/s, 6.58/d) 2H(8.00/d, 7.87/d, 7.59/m, 7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.34 / d, 7.99 / d, 7.92 / d, 7.55 / m, 7.41 / m, 7.40 / m, 7.38 / m, 7.37 / m, 7.34 / m 7.50 / d, 7.30 / d, 7.28 / d, 7.26 / d, 7.00 / d, 6.75 / s, 6.58 / d) 2H (8.00 / d, 7.87 / d, 7.59 / / d, 6.69 / d, 1.72 / s)

LC/MS: m/z=796[(M+1)+]
LC / MS: m / z = 796 [(M + 1) &lt; + &

실시예Example 53 : 화합물 54의 합성 53: Synthesis of Compound 54

(1) (One) 제조예Manufacturing example 1 : 중간체 53-1의 합성 1: Synthesis of intermediate 53-1

Figure pat00275
Figure pat00275

3,3'-dibromobiphenyl(3.0 g, 0.010 mol)에 biphenyl-4-amine(1.7 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 53-1> 2.9g (수율 73%)을 얻었다.(m/z=400)
Was synthesized in the same manner as in Example 1 (2) except that biphenyl-4-amine (1.7 g, 0.010 mol) was added to 3,3'-dibromobiphenyl (3.0 g, 0.010 mol) > 2.9 g (yield: 73%). (M / z = 400)

(2) (2) 제조예Manufacturing example 2 : 중간체 53-2의 합성 2: Synthesis of intermediate 53-2

Figure pat00276
Figure pat00276

중간체 53-1(3.6 g, 0.009 mol)에 4-bromo-N,N-diphenylaniline(2.9 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 53-2> 4.2g (수율 73%)을 얻었다.(m/z=643)
The intermediate 53-1 (3.6 g, 0.009 mol) was synthesized in the same manner as in Example 1 (2) except that 4-bromo-N, N-diphenylaniline (2.9 g, 0.009 mol) -2> 4.2 g (yield: 73%). (M / z = 643)

(3) (3) 제조예Manufacturing example 3 : 중간체 53-3의 합성 3: Synthesis of intermediate 53-3

Figure pat00277
Figure pat00277

중간체 53-2(5.0 g, 0.008 mol)에 1H-indol-3-ylboronic acid(1.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 53-3> 4.0 g (수율 73%)을 얻었다.(m/z=679)
Intermediate 53-2 (5.0 g, 0.008 mol) was synthesized in the same manner as in Example 1 (6) except that 1H-indol-3-ylboronic acid (1.6 g, 0.010 mol) 3> 4.0 g (yield: 73%). (M / z = 679)

(4) (4) 제조예Manufacturing example 4 : 화합물 54의 합성 4: Synthesis of Compound 54

Figure pat00278
Figure pat00278

중간체 53-3(6.8 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 54> 5.6g (수율 70%) 을 얻었다.(6.8 g, 0.010 mol) was used in place of Intermediate 53-3 to obtain 5.6 g (Yield: 70%) of Compound 54 by the same procedure as in <Compound 2>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.70/s, 7.57/m, 7.44/m, 7.41/m, 7.40/m, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.26/d, 7.04/d, 6.89/d, 6.88/d, 6.59/d) 2H(7.54/d, 7.52/d, 7.51/m, 7.48/d, 6.81/m, 6.69/d, 1.72/s) 4H(7.20/m, 6.63/d, 6.38/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.70 / s, 7.57 / m, 7.44 / m, 7.41 / m, 7.40 / m, 7.37 / m, 7.36 / s, 7.34 / m 7.51 / d, 7.51 / m, 7.48 / d, 6.81 / m, 6.69 / d , 1.72 / s) 4H (7.20 / m, 6.63 / d, 6.38 / d)

LC/MS: m/z1=797[(M+1)+]
LC / MS: m / z 1 = 797 [(M + 1) &lt; + &

실시예Example 54 : 화합물 84의 합성 54: Synthesis of Compound 84

(1) (One) 제조예Manufacturing example 1 : 중간체 54-1의 합성 1: Synthesis of intermediate 54-1

Figure pat00279
Figure pat00279

1,3,5-tribromobenzene(3.1 g, 0.010 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 54-1> 4.3g (수율 73%)을 얻었다.(m/z=595)
(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (3.6 g, 0.010 mol) was added to 1,3,5-tribromobenzene (3.1 g, 0.010 mol) (M / z = 595) (Intermediate 54-1) (4.3 g, yield 73%) was synthesized in the same manner as in Preparation Example (2)

(2) (2) 제조예Manufacturing example 2 : 중간체 54-2의 합성 2: Synthesis of intermediate 54-2

Figure pat00280
Figure pat00280

중간체 54-1(5.0 g, 0.008 mol)에 1H-indol-3-ylboronic acid(1.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 54-2> 3.9 g (수율 73%)을 얻었다.(m/z=667)
Intermediate 54-1 (5.0 g, 0.008 mol) was synthesized in the same manner as in Example 1- (6) except that 1H-indol-3-ylboronic acid (1.6 g, 0.010 mol) 2> 3.9 g (yield: 73%). (M / z = 667)

(3) (3) 제조예Manufacturing example 3 : 중간체 54-3의 합성 3: Synthesis of intermediate 54-3

Figure pat00281
Figure pat00281

중간체 54-2(5.0 g, 0.007 mol)에 bromobenzene(1.1 g, 0.007 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 54-3> 4.0 g (수율 77%)을 얻었다.(m/z=743)
Intermediate 54-3 was synthesized in the same manner as in Example 1 (2), except that bromobenzene (1.1 g, 0.007 mol) was added to Intermediate 54-2 (5.0 g, 0.007 mol) %). (M / z = 743)

(4) (4) 제조예Manufacturing example 4 : 화합물 84의 합성 4: Synthesis of Compound 84

Figure pat00282
Figure pat00282

중간체 53-3(7.4 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 84> 6.3g (수율 73%) 을 얻었다.6.3 g (yield 73%) of Compound 84 was obtained using Intermediate 53-3 (7.4 g, 0.010 mol) using the same method as Compound 2.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.17/d, 7.99/d, 7.87/d, 7.71/d, 7.62/d, 7.55/d, 7.40/m, 7.38/m, 7.37/m, 7.34/m, 7.30/d, 7.28/m, 7.26/d, 7.06/s, 7.04/d, 6.75/s, 6.58/d) 2H(7.58/m, 7.54/d, 7.52/d, 7.51/m, 7.50/d, 7.42/m, 7.41/m, 7.36/s, 6.85/s, 6.69/d) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.17 / d, 7.99 / d, 7.87 / d, 7.71 / d, 7.62 / d, 7.55 / d, 7.40 / m, 7.38 / m, 7.37 / m 7.58 / d, 7.52 / d, 7.52 / d, 7.04 / d, 6.75 / , 7.50 / d, 7.42 / m, 7.41 / m, 7.36 / s, 6.85 / s, 6.69 /

LC/MS: m/z=861[(M+1)+]
LC / MS: m / z = 861 [(M + 1) &lt; + &

실시예Example 55 : 화합물 93의 합성 55: Synthesis of compound 93

(1) (One) 제조예Manufacturing example 1 : 중간체 55-1의 합성 1: Synthesis of intermediate 55-1

Figure pat00283
Figure pat00283

3-bromo-5-chloro-1H-indole(3.0 g, 0.013 mol)에 methyl 2-iodobenzoate(4.7 g, 0.018 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 55-1> 3.1g (수율 65%)을 얻었다.(m/z=364)
Was synthesized in the same manner as in Example 1 (2), except that methyl 2-iodobenzoate (4.7 g, 0.018 mol) was added to 3-bromo-5-chloro-1H- indole (3.0 g, 0.013 mol) 3.1 g (yield 65%) of intermediate 55-1 (m / z = 364) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 55-2의 합성 2: Synthesis of intermediate 55-2

Figure pat00284
Figure pat00284

중간체 55-1(3.0 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 55-2> 1.7g (수율 61%)을 얻었다.(m/z=340)
Intermediate 55-1 (3.0 g, 0.008 mol) was used to synthesize 1.7 g (yield: 61%) of Intermediate 55-2 in the same manner as in Example 1 (3) = 340)

(3) (3) 제조예Manufacturing example 3 : 중간체 55-3의 합성 3: Synthesis of intermediate 55-3

Figure pat00285
Figure pat00285

중간체 55-2(3.0 g, 0.009 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 55-3> 2.2g (수율 72%)을 얻었다.(m/z=346)
2.2 g (yield 72%) of Intermediate 55-3 was obtained in the same manner as in Example 1 (4), except that Intermediate 55-2 (3.0 g, 0.009 mol) was added. M / z = 346)

(4) (4) 제조예Manufacturing example 4 : 중간체 55-4의 합성 4: Synthesis of Intermediate 55-4

Figure pat00286
Figure pat00286

중간체 55-3(3.0 g, 0.009 mol)에 phenyl boronic acid(1.3 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 55-4> 1.9g (수율 60%)을 얻었다.(m/z=343)
Intermediate 55-4 was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.3 g, 0.011 mol) was added to Intermediate 55-3 (3.0 g, 0.009 mol) Yield: 60%). (M / z = 343)

(5) (5) 제조예Manufacturing example 5 : 중간체 55-5의 합성 5: Synthesis of intermediate 55-5

Figure pat00287
Figure pat00287

중간체 55-4(3.0 g, 0.009 mol)에 bis(pinacolato)dibron(2.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 55-5> 2.7g (수율 69%)을 얻었다.(m/z=435)
<Intermediate 55-5> 2.7 (4-aminopyrimidin-4-yl) pyridine was synthesized by the same method as in Example 1 (5), except that bis (pinacolato) dibron (2.8 g, 0.011 mol) was added to Intermediate 55-4 g (yield: 69%). (m / z = 435)

(6) (6) 제조예Manufacturing example 6 : 중간체 55-6의 합성 6: Synthesis of intermediate 55-6

Figure pat00288
Figure pat00288

중간체 55-5(3.0 g, 0.007 mol)에 1,4-dibromobenzene(1.4 g, 0.006 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 55-6> 1.9g (수율 69%)을 얻었다.(m/z=464)
Intermediate 55-6 was synthesized by the same method as in Example 1 (6), except that 1,4-dibromobenzene (1.4 g, 0.006 mol) was added to Intermediate 55-5 (3.0 g, 0.007 mol) g (yield: 69%). (m / z = 464)

(7) (7) 제조예Manufacturing example 7 : 화합물 93의 합성 7: Synthesis of compound 93

Figure pat00289
Figure pat00289

중간체 55-6(3.0 g, 0.006 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(2.2 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 93> 3.3g (수율 74%)을 얻었다.(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (2.2 g, 0.006 mol) was added to Intermediate 55-6 (3.0 g, 0.006 mol) (2), 3.3 g (yield: 74%) of Compound 93 was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.63/s, 7.87/d, 7.62/d, 7.55/d, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.30/d, 7.28/m, 7.26/d, 7.21/s, 6.75/s, 6.58/d) 2H(7.41/m) 4H(7.54/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.63 / s, 7.87 / d, 7.62 / d, 7.55 / d, 7.40 / m, 7.38 / m, 7.37 / m, 7.36 / s, 7.30 / d (7.24 / d, 7.51 / m, 6.69 / d, 1.72 / s)

LC/MS: m/z=745[(M+1)+]
LC / MS: m / z = 745 [(M + 1) &lt; + &

실시예Example 56 : 화합물 110의 합성 56: Synthesis of compound 110

(1) (One) 제조예Manufacturing example 1 : 중간체 56-1의 합성 1: Synthesis of intermediate 56-1

Figure pat00290
Figure pat00290

5-bromobenzene-1,3-diamine(2.0 g, 0.011 mol)에 bromobenzene(6.8 g, 0.044 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 56-1> 3.9g (수율 72%)을 얻었다.(m/z=491)
Intermediate 56-1 was synthesized by the same method as in Example 1 (2), except that bromobenzene (6.8 g, 0.044 mol) was added to 5-bromobenzene-1,3-diamine (2.0 g, 0.011 mol) 3.9 g (yield: 72%) was obtained. (M / z = 491)

(2) (2) 제조예Manufacturing example 2 : 화합물 110의 합성 2: Synthesis of compound 110

Figure pat00291
Figure pat00291

중간체 55-5(3.0 g, 0.007 mol)에 중간체 56-1(2.9 g, 0.006 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 110> 3.1g (수율 72%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 56-1 (2.9 g, 0.006 mol) and Intermediate 55-5 (3.0 g, 0.007 mol) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.63/d, 7.41/m, 7.40/m, 7.37/m, 7.36/s, 7.30/d, 7.26/d, 7.21/s, 5.73/s) 2H(7.52/d, 7.51/m, 6.25/s, 1.72/s) 4H(6.81/m) 8H(7.20/m, 6.63/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.63 / d, 7.41 / m, 7.40 / m, 7.37 / m, 7.36 / s, 7.30 / d, 7.26 / d, 7.21 / s, 5.73 / s ) 2H (7.52 / d, 7.51 / m, 6.25 / s, 1.72 / s)

LC/MS: m/z=720[(M+1)+]
LC / MS: m / z = 720 [(M + 1) &lt; + &

실시예Example 57 : 화합물 125의 합성 57: Synthesis of compound 125

(1) (One) 제조예Manufacturing example 1 : 중간체 57-1의 합성 1: Synthesis of intermediate 57-1

Figure pat00292
Figure pat00292

1,4-dibromonaphthalene(3.0 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 57-1> 2.0g (수율 72%)을 얻었다.(m/z=283)
2.0 g of Intermediate 57-1 was synthesized in the same manner as in Example 1 (6) except that phenyl boronic acid (1.4 g, 0.012 mol) was added to 1,4-dibromonaphthalene (3.0 g, 0.010 mol) (Yield: 72%). (M / z = 283)

(2) (2) 제조예Manufacturing example 2 : 중간체 57-2의 합성 2: Synthesis of intermediate 57-2

Figure pat00293
Figure pat00293

중간체 57-1(3.0 g, 0.010 mol)에 biphenyl-4-amine(1.7 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 57-1> 2.9 g (수율 77%)을 얻었다.(m/z=371)
Intermediate 57-1> 2.9 g (0.010 mol) of biphenyl-4-amine was added to Intermediate 57-1 (3.0 g, 0.010 mol) g (yield: 77%). (m / z = 371)

(3) (3) 제조예Manufacturing example 3 : 중간체 57-3의 합성 3: Synthesis of intermediate 57-3

Figure pat00294
Figure pat00294

중간체 55-5(3.0 g, 0.008 mol)에 3,3'-dibromobiphenyl(2.5 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 57-3> 3.6g (수율 75%)을 얻었다.(m/z=540)
Intermediate 57-3 was synthesized in the same manner as in Example 1 (6) except that 3,3'-dibromobiphenyl (2.5 g, 0.008 mol) was added to Intermediate 55-5 (3.0 g, 0.008 mol) 3.6 g (yield 75%) of the title compound (m / z = 540)

(4) (4) 제조예Manufacturing example 4 : 화합물 125의 합성 4: Synthesis of Compound 125

Figure pat00295
Figure pat00295

중간체 57-3(3.0 g, 0.007 mol)에 중간체 57-2(3.6 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 125> 4.1g (수율 75%)을 얻었다.Intermediate 57-2 (3.6 g, 0.006 mol) was added to Intermediate 57-3 (3.0 g, 0.007 mol), and the compound was synthesized by the same method as in Example 1- (2) 75%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.49/d, 8.19/d, 8.06/d, 7.93/d, 7.78/d, 7.70/s, 7.59/d, 7.57/m, 7.44/m, 7.40/m, 7.37/m, 7.30/d, 7.26/d, 7.04/d, 6.89/s, 6.88/d) 2H(7.79/d, 7.48/d, 7.41/m, 6.69/d, 1.72/s) 4H(7.54/d, 7.52/d) 6H(7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.49 / d, 8.19 / d, 8.06 / d, 7.93 / d, 7.78 / d, 7.70 / s, 7.59 / d, 7.57 / m, 7.44 / m M, 7.69 / d, 7.72 / d, 7.04 / d, 6.89 / s, 6.88 / d) ) 4H (7.54 / d, 7.52 / d) 6H (7.51 / m)

LC/MS: m/z=832[(M+1)+]
LC / MS: m / z = 832 [(M + 1) &lt; + &

실시예Example 58 : 화합물 132의 합성 58: Synthesis of Compound 132

(1) (One) 제조예Manufacturing example 1 : 화합물 132의 합성 1: Synthesis of Compound 132

Figure pat00296
Figure pat00296

중간체 57-3(5.0 g, 0.009 mol)에 N-(biphenyl-4-yl)naphthalen-1-amine(2.7 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 132> 5.1g (수율 75%)을 얻었다.4-yl) naphthalen-1-amine (2.7 g, 0.009 mol) was added to Intermediate 57-3 (5.0 g, 0.009 mol) in the same manner as in Example 1- To obtain 5.1 g (yield 75%) of < Compound 132 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.19/d, 8.02/d, 7.93/d, 7.70/s, 7.58/d, 7.57/m, 7.44/m, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.30/d, 7.26/d, 6.98/d, 6.89/d, 6.88/d, 6.59/d) 2H(7.48/d, 7.41/m, 6.69/d, 1.72/s) 4H(7.54/d, 7.52/d, 7.51/m) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.19 / d, 8.02 / d, 7.93 / d, 7.70 / s, 7.58 / d, 7.57 / m, 7.44 / m, 7.40 / m, 7.38 / m D, 7.41 / m, 6.69 / d, 1.72 / s, 7.37 / m, 7.36 / s, 7.30 / d, 7.26 / d, 6.98 / d, 6.89 / d, 6.88 / d, 6.59 / ) 4H (7.54 / d, 7.52 / d, 7.51 / m)

LC/MS: m/z=755[(M+1)+]
LC / MS: m / z = 755 [(M + 1) &lt; + &

실시예Example 59 : 화합물 172의 합성 59: Synthesis of Compound 172

(1) (One) 제조예Manufacturing example 1 : 중간체 59-1의 합성 1: Synthesis of intermediate 59-1

Figure pat00297
Figure pat00297

2-bromo-1H-indol-3-ylboronic acid(2.4 g, 0.010 mol)에 N-(biphenyl-4-yl)-N-(4-bromophenyl)biphenyl-4-amine(3.8 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 59-1> 3.4 g (수율 71%)을 얻었다.(m/z=591)
(Biphenyl-4-yl) -N- (4-bromophenyl) biphenyl-4-amine (3.8 g, 0.008 mol) was added to a solution of 2-bromo-1H-indol- (M / z = 591) was obtained in the same manner as in Example 1 (6), and 3.4 g (yield: 71%) of Intermediate 59-1 was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 59-2의 합성 2: Synthesis of intermediate 59-2

Figure pat00298
Figure pat00298

중간체 59-1(5.0 g, 0.011 mol)에 phenyl boronic acid(1.6 g, 0.013 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 59-2> 4.7g (수율 72%)을 얻었다.(m/z=588)
Intermediate 59-2 was synthesized in the same manner as in Example 1- (6), except that phenyl boronic acid (1.6 g, 0.013 mol) was added to Intermediate 59-1 (5.0 g, 0.011 mol) Yield: 72%). (M / z = 588)

(3) (3) 제조예Manufacturing example 3 : 화합물 172의 합성 3: Synthesis of Compound 172

Figure pat00299
Figure pat00299

중간체 59-2(5.9 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 172> 5.0g (수율 71%) 을 얻었다.5.0 g (Yield 71%) of <Compound 172> was obtained in the same manner as in <Compound 2> using Intermediate 59-2 (5.9 g, 0.010 mol).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.02/d, 7.40/m, 7.37/m, 7.30/d, 7.26/d, 7.00/d, 6.60/s) 2H(7.79/d, 1.72/s) 3H(7.51/m) 4H(7.52/d) 6H(7.54/d, 7.51/m, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.02 / d, 7.40 / m, 7.37 / m, 7.30 / d, 7.26 / d, 7.00 / d, 6.60 / s) 2H (7.79 / d, 1.72 / s) 3H (7.51 / m) 4H (7.52 / d) 6H (7.54 / d, 7.51 /

LC/MS: m/z=705[(M+1)+]
LC / MS: m / z = 705 [(M + 1) &lt; + &

실시예Example 60 : 화합물 183의 합성 60: Synthesis of Compound 183

(1) (One) 제조예Manufacturing example 1 : 중간체 60-1의 합성 1: Synthesis of intermediate 60-1

Figure pat00300
Figure pat00300

5-chloro-2-iodo-1H-benzo[d]imidazole(3.0 g, 0.011 mol)에 methyl 2-iodobenzoate(4.2 g, 0.016 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 60-1> 2.6g (수율 58%)을 얻었다.(m/z=412)
The same procedure as in Example 1-Preparation Example (2) was repeated except that methyl 2-iodobenzoate (4.2 g, 0.016 mol) was added to 5-chloro-2-iodo-1H- benzo [d] imidazole (3.0 g, To obtain 2.6 g (yield: 58%) of Intermediate 60-1 (m / z = 412)

(2) (2) 제조예Manufacturing example 2 : 중간체 60-2의 합성 2: Synthesis of intermediate 60-2

중간체 60-1(3.0 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 60-2> 1.8 g (수율 64%)을 얻었다.(m/z=412)
1.8 g (yield 64%) of Intermediate 60-2 (3.0 g, 0.007 mol) was obtained in the same manner as in Example 1- (3) = 412)

(3) (3) 제조예Manufacturing example 3 : 중간체 60-3의 합성 3: Synthesis of intermediate 60-3

Figure pat00302
Figure pat00302

중간체 60-2(3.0 g, 0.008 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 60-3> 1.6g (수율 51%)을 얻었다.(m/z=394)
1.6 g (51%) of Intermediate 60-3 was obtained in the same manner as in Example 1 (4), except that Intermediate 60-2 (3.0 g, 0.008 mol) was added. M / z = 394)

(4) (4) 제조예Manufacturing example 4 : 중간체 60-4의 합성 4: Synthesis of intermediate 60-4

Figure pat00303
Figure pat00303

중간체 60-3(3.0 g, 0.008 mol)에 phenyl boronic acid(1.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 60-4> 2.0g (수율 72%)을 얻었다.(m/z=344)
Intermediate 60-4 (2.0 g, 0.010 mol) was synthesized in the same manner as in Example 1- (6) except that phenyl boronic acid (1.2 g, 0.010 mol) was added to Intermediate 60-3 Yield: 72%). (M / z = 344)

(5) (5) 제조예Manufacturing example 5 : 중간체 60-4-1의 합성 5: Synthesis of intermediate 60-4-1

Figure pat00304
Figure pat00304

중간체 60-4(3.0 g, 0.009 mol)에 bis(pinacolato)dibron(2.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 60-4-1> 2.8g (수율 72%)을 얻었다.(m/z=436)
Synthesis was conducted in the same manner as in Example 1-Preparation Example (5), except that bis (pinacolato) dibron (2.8 g, 0.011 mol) was added to Intermediate 60-4 (3.0 g, 0.009 mol) > 2.8 g (yield: 72%) was obtained. (M / z = 436)

(6) (6) 제조예Manufacturing example 6 : 중간체 60-5의 합성 6: Synthesis of intermediate 60-5

Figure pat00305
Figure pat00305

중간체 60-4-1(3.9 g, 0.009 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 60-5> 2.7 g (수율 72%)을 얻었다.(m/z=465)
Synthesis was conducted in the same manner as in Example 1 (6), except that 1,4-dibromobenzene (1.9 g, 0.008 mol) was added to Intermediate 60-4-1 (3.9 g, 0.009 mol) > 2.7 g (yield 72%). (M / z = 465)

(7) (7) 제조예Manufacturing example 7 : 화합물 183의 합성 7: Synthesis of Compound 183

Figure pat00306
Figure pat00306

중간체 60-5(3.0 g, 0.006 mol)에 bis(9,9-dimethyl-9H-fluoren-2-yl)amine(2.6 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 183> 3.5g (수율 75%)을 얻었다.To the intermediate 60-5 (3.0 g, 0.006 mol) was added bis (9,9-dimethyl-9H-fluoren-2-yl) amine (2.6 g, 0.006 mol) Synthesis was conducted in the same manner to obtain 3.5 g (yield 75%) of <Compound 183>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.74/s, 7.41/m, 7.40/m, 7.37/m, 7.35/s, 7.30/d, 7.26/d) 2H(8.28/d, 7.87/d, 7.62/d, 7.55/d, 7.54/d, 7.51/m, 7.38/m, 7.28/m, 6.75/s, 6.69/d, 6.58/d) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.74 / s, 7.41 / m, 7.40 / m, 7.37 / m, 7.35 / s, 7.30 / d, 7.26 / d) 2H (8.28 / d, 7.87 7.58 / d, 7.54 / d, 7.51 / m, 7.38 / m, 7.28 / m, 6.75 / s, 6.69 / d, 6.58 / d)

LC/MS: m/z=787[(M+1)+]
LC / MS: m / z = 787 [(M + 1) &lt; + &

실시예Example 61 : 화합물 184의 합성 61: Synthesis of compound 184

(1) (One) 제조예Manufacturing example 1 : 화합물 184의 합성 1: Synthesis of Compound 184

Figure pat00307
Figure pat00307

중간체 60-5(3.0 g, 0.006 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(2.2 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 184> 3.4g (수율 77%)을 얻었다.(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (2.2 g, 0.006 mol) was added to Intermediate 60-5 (3.0 g, 0.006 mol) (2) to obtain 3.4 g (yield 77%) of < Compound 184 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.74/s, 7.62/d, 7.55/d, 7.40/m, 7.38/m, 7.37/m, 7.35/s, 7.30/d, 7.28/m, 6.75/s, 6.58/d) 2H(8.28/d, 7.52/d, 7.41/m) 4H(7.54/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.74 / s, 7.62 / d, 7.55 / d, 7.40 / m, 7.38 / m, 7.37 / m, 7.35 / s, 7.30 / d (7.58 / d, 7.51 / m, 6.69 / d, 1.72 / s), 7.28 /

LC/MS: m/z=746[(M+1)+]
LC / MS: m / z = 746 [(M + 1) &lt; + &

실시예Example 62 : 화합물 186의 합성 62: Synthesis of compound 186

(1) (One) 제조예Manufacturing example 1 : 중간체 62-1의 합성 1: Synthesis of intermediate 62-1

Figure pat00308
Figure pat00308

4-chloro-2-iodo-1H-benzo[d]imidazole(3.0 g, 0.011 mol)에 phenyl boronic acid(1.6 g, 0.013 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 62-1> 1.5g (수율 61%)을 얻었다.(m/z=228)
Phenyl boronic acid (1.6 g, 0.013 mol) was added to 4-chloro-2-iodo-1H-benzo [d] imidazole (3.0 g, 0.011 mol) in the same manner as in Example 1- 1.5 g (yield: 61%) of Intermediate 62-1 (m / z = 228) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 62-2의 합성 2: Synthesis of intermediate 62-2

Figure pat00309
Figure pat00309

중간체 62-1(2.5 g, 0.011 mol)에 methyl 2-iodobenzoate(2.9 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 62-2> 3.0g (수율 61%)을 얻었다.(m/z=362)
(2.9 g, 0.011 mol) was added to Intermediate 62-1 (2.5 g, 0.011 mol) and the same procedure as in Example 1 (2) was used to synthesize 3.0 g of Intermediate 62-2 (Yield: 61%). (M / z = 362)

(3) (3) 제조예Manufacturing example 3 : 중간체 62-3의 합성 3: Synthesis of intermediate 62-3

Figure pat00310
Figure pat00310

중간체 62-2(2.5 g, 0.007 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 62-3> 1.6g (수율 64%)을 얻었다.(m/z=362)
1.6 g (yield: 64%) of <Intermediate 62-3> was obtained by adding the intermediate 62-2 (2.5 g, 0.007 mol) in the same manner as in Example 1- (3) = 362)

(4) (4) 제조예Manufacturing example 4 : 중간체 62-4의 합성 4: Synthesis of intermediate 62-4

Figure pat00311
Figure pat00311

중간체 62-3(2.5 g, 0.007 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 62-4> 1.7g (수율 70%)을 얻었다.(m/z=344)
1.7 g (yield 70%) of Intermediate 62-4 was obtained in the same manner as in Example 1 (4) except that Intermediate 62-3 (2.5 g, 0.007 mol) was added. M / z = 344)

(5) (5) 제조예Manufacturing example 5 : 중간체 62-5의 합성 5: Synthesis of intermediate 62-5

Figure pat00312
Figure pat00312

중간체 62-4(3.0 g, 0.008 mol)에 bis(pinacolato)dibron(2.5 g, 0.010 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 62-5> 2.5g (수율 73%)을 얻었다.(m/z=436)
(Intermediate 62-5) 2.5 (2.5 g, 0.010 mol) was added to Intermediate 62-4 (3.0 g, 0.008 mol) in the same manner as in Example 1- g (yield: 73%). (m / z = 436)

(6) (6) 제조예Manufacturing example 6 : 중간체 62-6의 합성 6: Synthesis of intermediate 62-6

Figure pat00313
Figure pat00313

중간체 62-5(3.0 g, 0.007 mol)에 1,4-dibromobenzene(1.3 g, 0.006 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 62-6> 2.1g (수율 75%)을 얻었다.(m/z=465)
Intermediate 62-6> 2.1 (4-aminopyridine) was synthesized in the same manner as in Example 1 (6), except that 1,4-dibromobenzene (1.3 g, 0.006 mol) g (yield: 75%). (m / z = 465)

(7) (7) 제조예Manufacturing example 7 : 화합물 186의 합성 7: Synthesis of Compound 186

Figure pat00314
Figure pat00314

중간체 62-6(3.0 g, 0.006 mol)에 dibiphenyl-4-ylamine(2.1 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 186> 3.0 g (수율 71%)을 얻었다.3.0 g (186) of compound 186 was synthesized in the same manner as in Example 1 (2) except that dibiphenyl-4-ylamine (2.1 g, 0.006 mol) was added to Intermediate 62-6 (3.0 g, 0.006 mol) Yield: 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.67/d, 7.40/m, 7.37/m, 7.30/d, 7.26/d) 2H(8.28/d, 1.72/s) 3H(7.41/m) 4H(7.52/d) 6H(7.54/d, 7.51/m, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.67 / d, 7.40 / m, 7.37 / m, 7.30 / d, 7.26 / d) 2H (8.28 / d, 1.72 / s) 3H (7.41 / m) 4H (7.52 / d) 6H (7.54 / d, 7.51 / m, 6.69 / d)

LC/MS: m/z=706[(M+1)+]
LC / MS: m / z = 706 [(M + 1) &lt; + &

실시예Example 63 : 화합물 193의 합성 63: Synthesis of Compound 193

(1) (One) 제조예Manufacturing example 1 : 중간체 63-1의 합성 1: Synthesis of intermediate 63-1

Figure pat00315
Figure pat00315

중간체 60-4-1(3.0 g, 0.011 mol)에 1,4-dibromo-2,5-dimethylbenzene(2.2 g, 0.009 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 63-1> 3.2g (수율 71%)을 얻었다.(m/z=493)
Synthesis was conducted in the same manner as in Example 1 (6) except that 1,4-dibromo-2,5-dimethylbenzene (2.2 g, 0.009 mol) was added to Intermediate 60-4-1 (3.0 g, 0.011 mol) 3.2 g (yield: 71%) of Intermediate 63-1 (m / z = 493) was obtained.

(2) (2) 제조예Manufacturing example 2 : 화합물 193의 합성 2: Synthesis of Compound 193

Figure pat00316
Figure pat00316

중간체 63-1(5.0 g, 0.010 mol)에 bis(9,9-dimethyl-9H-fluoren-2-yl)amine(4.0 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 193> 6.3 g (수율 77%)을 얻었다.To the intermediate 63-1 (5.0 g, 0.010 mol) was added bis (9,9-dimethyl-9H-fluoren-2-yl) amine (4.0 g, 0.010 mol) Synthesis was conducted in the same manner to obtain 6.3 g (yield 77%) of <Compound 193>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.74/s, 7.42/s, 7.41/m, 7.40/m, 7.37/m, 7.35/s, 7.30/d, 7.26/d, 6.75/s, 6.49/s) 2H(8.28/d, 7.87/d, 7.62/d, 7.55/d, 7.51/m, 7.38/m, 7.28/m, 6.75/s, 6.58/d, 2.59/s) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.74 / s, 7.42 / s, 7.41 / m, 7.40 / m, 7.37 / m, 7.35 / s, 7.30 / d, 7.26 / d, 6.75 / s , 6.49 / s) 2H (8.28 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.51 / m, 7.38 / / s)

LC/MS: m/z=815[(M+1)+]
LC / MS: m / z = 815 [(M + 1) &lt; + &

실시예Example 64 : 화합물 194의 합성 64: Synthesis of compound 194

(1) (One) 제조예Manufacturing example 1 : 중간체 64-1의 합성 1: Synthesis of intermediate 64-1

Figure pat00317
Figure pat00317

중간체 60-4-1(3.0 g, 0.011 mol)에 2,6-dibromonaphthalene(2.6 g, 0.009 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 64-1> 3.4g (수율 73%)을 얻었다.(m/z=515)
2,6-dibromonaphthalene (2.6 g, 0.009 mol) was added to Intermediate 60-4-1 (3.0 g, 0.011 mol) and synthesized in the same manner as in Example 1-Preparation Example (6) (M / z = 515) was obtained in an amount of 3.4 g (yield: 73%).

(2) (2) 제조예Manufacturing example 2 : 화합물 194의 합성 2: Synthesis of Compound 194

Figure pat00318
Figure pat00318

중간체 64-1(3.0 g, 0.008 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(2.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 194> 3.1g (수율 80%)을 얻었다.(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (2.9 g, 0.008 mol) was added to Intermediate 64-1 (3.0 g, 0.008 mol) (2) to obtain 3.1 g (yield 80%) of < Compound 194 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.84/d, 7.74/s, 7.69/d, 7.64/d, 7.62/d, 7.55/d, 7.49/d, 7.46/s, 7.40/m, 7.38/m, 7.37/m, 7.35/s, 7.30/d, 7.28/m, 7.26/d, 6.75/s, 6.58/d) 2H(8.28/d, 7.54/d, 7.52/d, 7.41/m, 6.69/d) 4H(7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.84 / d, 7.74 / s, 7.69 / d, 7.64 / d, 7.62 / d, 7.55 / d, 7.49 / d, 7.46 / s D, 7.54 / d, 7.52 / d, 7.28 / d, 7.75 / d, 7.38 / , 7.41 / m, 6.69 / d) 4H (7.51 / m, 1.72 / s)

LC/MS: m/z=797[(M+1)+]
LC / MS: m / z = 797 [(M + 1) &lt; + &

실시예Example 65 : 화합물 212의 합성 65: Synthesis of Compound 212

(1)(One) 제조예Manufacturing example 1 : 중간체 65-1의 합성 1: Synthesis of intermediate 65-1

Figure pat00319
Figure pat00319

2-bromo-9,9-dimethyl-9H-fluorene(3.0 g, 0.0011 mol)에 4'-tert-butylbiphenyl-4-amine(2.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 65-1> 3.5g (수율 77%)을 얻었다.(m/z=417)
Tert-butylbiphenyl-4-amine (2.5 g, 0.011 mol) was added to 2-bromo-9,9-dimethyl-9H-fluorene (3.0 g, 0.0011 mol) (M / z = 417) of <Intermediate 65-1> (yield: 77%) was obtained by the same method as used

(2) (2) 제조예Manufacturing example 2 : 화합물 212의 합성 2: Synthesis of Compound 212

Figure pat00320
Figure pat00320

중간체 63-1(5.0 g, 0.0010 mol)에 중간체 65-1(4.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 212> 6.1g (수율 74%)을 얻었다.(m/z=417)Synthesis was conducted in the same manner as in Example 1 (2) to give Intermediate 65-1 (4.2 g, 0.010 mol) and Intermediate 63-1 (5.0 g, 0.0010 mol) 74%). (M / z = 417)

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.74/s, 7.62/d, 7.55/d, 7.42/s, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.35/s, 7.30/d, 7.28/m, 7.26/d, 6.75/s, 6.58/d, 6.49/s) 2H(8.28/d, 7.54/d, 7.51/m, 7.38/d, 7.37/d, 6.69/d, 2.59/s) 3H(1.35/s) 4H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.74 / s, 7.62 / d, 7.55 / d, 7.42 / s, 7.41 / m, 7.40 / m, 7.38 / m, 7.37 / m 7.58 / d, 7.58 / d, 7.38 / d, 7.38 / d, 7.28 / , 6.69 / d, 2.59 / s) 3H (1.35 / s) 4H (1.72 / s)

LC/MS: m/z=831[(M+1)+]
LC / MS: m / z = 831 [(M + 1) &lt; + &

실시예Example 66 : 화합물 215의 합성 66: Synthesis of compound 215

(1) (One) 제조예Manufacturing example 1 : 중간체 66-1의 합성 1: Synthesis of intermediate 66-1

Figure pat00321
Figure pat00321

3,3'-dibromobiphenyl(3.0 g, 0.0010 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(3.6 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 66-1> 4.4g (수율 75%)을 얻었다.(m/z=592)
(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (3.6 g, 0.010 mol) was added to 3,3'-dibromobiphenyl (3.0 g, 0.0010 mol) (M / z = 592) (4.4 g, yield 75%) was synthesized in the same manner as in Preparation Example (2)

(2) (2) 제조예Manufacturing example 2 : 화합물 215의 합성 2: Synthesis of Compound 215

Figure pat00322
Figure pat00322

중간체 60-4-1(3.0 g, 0.011 mol)에 중간체 66-1(5.3 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 215> 5.4g (수율 73%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (2), except that Intermediate 66-1 (5.3 g, 0.009 mol) was added to Intermediate 60-4-1 (3.0 g, 0.011 mol) (Yield: 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.99/d, 7.87/d, 7.70/s, 7.62/d, 7.57/m, 7.55/d, 7.47/d, 7.44/m, 7.40/m, 7.38/m, 7.37/m, 7.30/d, 7.28/m, 7.26/d, 6.89/s, 6.88/d, 6.75/d, 6.59/d, 6.58/d) 2H(8.28/d, 7.54/d, 7.52/d, 7.48/d, 7.41/m, 6.69/d) 4H(7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.99 / d, 7.87 / d, 7.70 / s, 7.62 / d, 7.57 / m, 7.55 / d, 7.47 / d, 7.44 / m, 7.40 / m , 7.38 / m, 7.30 / d, 7.28 / m, 7.26 / d, 6.89 / s, 6.88 / d, 6.75 / d, 6.59 / d, 6.58 / , 7.52 / d, 7.48 / d, 7.41 / m, 6.69 / d) 4H (7.51 / m, 1.72 / s)

LC/MS: m/z=823[(M+1)+]
LC / MS: m / z = 823 [(M + 1) &lt; + &

실시예Example 67 : 화합물 276의 합성 67: Synthesis of Compound 276

(1) (One) 제조예Manufacturing example 1 : 중간체 67-1의 합성 1: Synthesis of intermediate 67-1

Figure pat00323
Figure pat00323

중간체 55-3(3.0 g, 0.009 mol)에 4-aminophenylboronic acid(1.5 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 67-1> 2.0g (수율 63%)을 얻었다.(m/z=358)
4-aminophenylboronic acid (1.5 g, 0.011 mol) was added to Intermediate 55-3 (3.0 g, 0.009 mol), and the title compound was synthesized in the same manner as in Example 1- (M / z = 358) (yield: 63%).

(2) (2) 제조예Manufacturing example 2 : 중간체 67-2의 합성 2: Synthesis of intermediate 67-2

Figure pat00324
Figure pat00324

중간체 67-1(3.0 g, 0.008 mol)에 bromobenzene(2.6 g, 0.016 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 67-2> 3.1g (수율 77%)을 얻었다.(m/z=511)
Intermediate 67-2> 3.1 g (Yield 77%) was obtained according to the same method as that employed for the preparation of Example 1- (2) with the introduction of bromobenzene (2.6 g, 0.016 mol) into Intermediate 67-1 (3.0 g, 0.008 mol) %). (M / z = 511)

(3) (3) 제조예Manufacturing example 3 : 중간체 67-3의 합성 3: Synthesis of intermediate 67-3

Figure pat00325
Figure pat00325

N-(biphenyl-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine(5.0 g, 0.010 mol)에 bis(pinacolato)dibron(3.0 g, 0.012 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 67-3> 3.9g (수율 70%)을 얻었다.(m/z=563)
Bis (pinacolato) dibron (3.0 g, 0.012 mol) was added to N- (biphenyl-4-yl) -N- (4- bromophenyl) -9,9-dimethyl-9H- ) Was synthesized in the same manner as in Example 1 (5) to give 3.9 g (yield: 70%) of Intermediate 67-3 (m / z = 563)

(4) (4) 제조예Manufacturing example 4 : 화합물 276의 합성 4: Synthesis of Compound 276

Figure pat00326
Figure pat00326

중간체 67-2(5.0 g, 0.010 mol), 중간체 67-3(6.8 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 276> 6.2g (수율 68%)을 얻었다.Synthesis was conducted in the same manner as in Example 1- (6) to obtain Intermediate 67-2 (5.0 g, 0.010 mol) and Intermediate 67-3 (6.8 g, 0.012 mol) 68%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.63/s, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.36/s, 7.30/d, 7.28/m, 7.26/d, 7.21/s, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m, 6.81/m) 4H(7.20/m, 6.63/d, 1.72/s) 6H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.63 / s, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.40 / m, 7.38 / m, 7.37 / m, 7.36 / s (7.52 / d, 7.51 / m, 6.81 / m) 4H (7.20 / m, 6.63 / d, 1.72 / s) 6H (7.54 / d, 6.69 / d)

LC/MS: m/z=913[(M+1)+]
LC / MS: m / z = 913 [(M + 1) &lt; + &

실시예Example 68 : 화합물 281의 합성 68: Synthesis of Compound 281

(1) (One) 제조예Manufacturing example 1 : 화합물 281의 합성 1: Synthesis of Compound 281

Figure pat00327
Figure pat00327

중간체 54-2(6.7 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 281> 6.4g (수율 71%) 을 얻었다.6.4 g (Yield: 71%) of Compound 281 was obtained by using the same method as Compound 2 with the intermediate 54-2 (6.7 g, 0.010 mol).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 7.06/s, 6.75/s, 6.58/d) 2H(7.99/d, 7.54/d, 7.52/d, 7.51/m, 7.40/d, 7.37/m, 7.36/s, 7.34/m, 7.30/d, 7.26/d, 7.04/d, 6.85/s, 6.69/d) 6H(1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m, 7.06 / s, 6.75 / s, 6.58 / d 7.36 / s, 7.34 / m, 7.30 / d, 7.26 / d, 7.04 / d, 6.85 / s (7.99 / d, 7.54 / d, 7.52 / d, 7.51 / , 6.69 (d) 6H (1.72 / s)

LC/MS: m/z=901[(M+1)+]
LC / MS: m / z = 901 [(M + 1) &lt; + &

실시예Example 69 : 화합물 283의 합성 69: Synthesis of compound 283

(1) (One) 제조예Manufacturing example 1 : 화합물 283의 합성 1: Synthesis of compound 283

Figure pat00328
Figure pat00328

중간체 55-1(5.0 g, 0.011 mol)에 중간체 48-1(4.9 g, 0.009 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 283> 5.0g (수율 71%)을 얻었다.Synthesis was conducted in the same manner as in Example 1-Preparation Example (6), except that Intermediate 48-1 (4.9 g, 0.009 mol) was added to Intermediate 55-1 (5.0 g, 0.011 mol) 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.63/s, 7.41/m, 7.40/m, 7.37/m, 7.36/s, 7.30/d, 7.26/d, 7.21/s, 5.73/s) 2H(7.52/d, 7.51/m, 6.25/s, 1.72/s) 4H(2.34/s) 8H(6.98/d, 6.51/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.63 / s, 7.41 / m, 7.40 / m, 7.37 / m, 7.36 / s, 7.30 / d, 7.26 / d, 7.21 / s, 5.73 / s ) 2H (7.52 / d, 7.51 / m, 6.25 / s, 1.72 / s)

LC/MS: m/z=777[(M+1)+]
LC / MS: m / z = 777 [(M + 1) &lt; + &

실시예Example 70 : 화합물 288의 합성 70: Synthesis of compound 288

(1) (One) 제조예Manufacturing example 1 : 화합물 288의 합성 1: Synthesis of Compound 288

Figure pat00329
Figure pat00329

중간체 55-5(5.0 g, 0.011 mol)에 중간체 54-1(2.7 g, 0.005 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 288> 3.8g (수율 73%)을 얻었다.(2.7 g, 0.005 mol) was added to Intermediate 55-5 (5.0 g, 0.011 mol), and the compound was synthesized in the same manner as in Example 1- (6) 73%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.63/s, 7.87/d, 7.62/d, 7.55/d, 7.38/m, 7.28/m, 7.06/s, 6.75/s, 6.58/d) 2H(7.54/d, 7.40/m, 7.37/m, 7.36/s, 7.30/d, 7.26/d, 7.21/s, 6.85/s, 6.69/d) 3H(7.41/m) 6H(7.52/d, 7.51/m, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.63 / s, 7.87 / d, 7.62 / d, 7.55 / d, 7.38 / m, 7.28 / m, 7.06 / s, 6.75 / s, 6.58 / d ) 2H (7.54 / d, 7.40 / m, 7.37 / m, 7.36 / s, 7.30 / d, 7.26 / d, 7.21 / s, 6.85 / s, 6.69 / , 7.51 / m, 1.72 / s)

LC/MS: m/z=1053[(M+1)+]
LC / MS: m / z = 1053 [(M + 1) &lt; + &

실시예Example 71 : 화합물 295의 합성 71: Synthesis of compound 295

(1) (One) 제조예Manufacturing example 1 : 중간체 71-1의 합성 1: Synthesis of intermediate 71-1

Figure pat00330
Figure pat00330

중간체 55-6(3.0 g, 0.006 mol)에 9,9-dimethyl-9H-fluoren-2-amine(1.3 g, 0.006 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 71-1> 2.6g (수율 74%)을 얻었다.(m/z=592)
Synthesis was carried out in the same manner as in Example 1 (2) except that 9,9-dimethyl-9H-fluoren-2-amine (1.3 g, 0.006 mol) was added to Intermediate 55-6 (3.0 g, 0.006 mol) 2.6 g (yield: 74%) of Intermediate 71-1 (m / z = 592) was obtained.

(2) (2) 제조예Manufacturing example 2 : 중간체 71-2의 합성 2: Synthesis of intermediate 71-2

Figure pat00331
Figure pat00331

중간체 71-1(5.0 g, 0.008 mol)에 1,4-dibromobenzene(1.9 g, 0.008 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 71-2> 4.2g (수율 74%)을 얻었다.(m/z=712)
Synthesis was conducted in the same manner as in Example 1 (2) except that 1,4-dibromobenzene (1.9 g, 0.008 mol) was added to Intermediate 71-1 (5.0 g, 0.008 mol) g (yield: 74%). (m / z = 712)

(3) (3) 제조예Manufacturing example 3 : 화합물 295의 합성 3: Synthesis of compound 295

Figure pat00332
Figure pat00332

중간체 71-2(5.0 g, 0.007 mol), phenyl boronic acid(1.0 g, 0.008 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 295> 3.7g (수율 70%)을 얻었다.Compound 295 (3.7 g, Yield: 70%) was synthesized in the same manner as in Example 1- (6) except that Intermediate 71-2 (5.0 g, 0.007 mol) and phenyl boronic acid %).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.40/m, 7.38/m, 7.37/m, 7.30/d, 7.28/m, 7.26/d, 7.21/s, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.40 / m, 7.38 / m, 7.37 / m, 7.30 / d, 7.28 / m 7.56 / d, 7.21 / s, 6.75 / s, 6.58 / d) 2H (7.52 / d, 7.51 /

LC/MS: m/z=750[(M+1)+]
LC / MS: m / z = 750 [(M + 1) &lt; + &

실시예Example 72 : 화합물 298의 합성 72: Synthesis of compound 298

(1) (One) 제조예Manufacturing example 1 : 중간체 72-1의 합성 1: Synthesis of intermediate 72-1

Figure pat00333
Figure pat00333

1-phenyl-6,10b-dihydropyrrolo[2,3,4-kl]acridine(3.0 g, 0.011 mol), 1,4-dibromobenzene(2.6 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 72-1> 3.5g (수율 72%)을 얻었다.(m/z=437)
(6) was prepared by adding 1-phenyl-6,10b-dihydropyrrolo [2,3,4-kl] acridine (3.0 g, 0.011 mol) and 1,4- dibromobenzene (2.6 g, 0.011 mol) (M / z = 437) (intermediate 72-1) (yield: 72%).

(2) (2) 제조예Manufacturing example 2 : 화합물 298의 합성 2: Synthesis of compound 298

Figure pat00334
Figure pat00334

중간체 72-1(3.0 g, 0.007 mol), N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(2.5 g, 0.007 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 298> 3.6g (수율 72%)을 얻었다.To a solution of the intermediate 72-1 (3.0 g, 0.007 mol) and N- (biphenyl-4-yl) -9,9-dimethyl-9H- fluoren- (6), 3.6 g (yield 72%) of Compound 298 was obtained.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/s, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 4.10/s) 2H(7.51/m, 1.72/s) 4H(7.94/d, 7.01/m, 6.38/m) 5H(7.52/d) 6H(6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / s, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m, 4.10 / s) 2H (7.51 / m, 1.72 / s) 4H (7.94 / d, 7.01 / m, 6.38 / m) 5H (7.52 / d)

LC/MS: m/z=718[(M+1)+]
LC / MS: m / z = 718 [(M + 1) &lt; + &

실시예Example 73 : 화합물 302의 합성 73: Synthesis of compound 302

(1) (One) 제조예Manufacturing example 1 : 중간체 73-1의 합성 1: Synthesis of intermediate 73-1

Figure pat00335
Figure pat00335

2-iodo-3H-indole(3.0 g, 0.012 mol)에 methyl 2-iodobenzoate(4.7 g, 0.018 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 73-1> 3.1g (수율 68%)을 얻었다.(m/z=377)
Was synthesized in the same manner as in Example 1 (2) to give methyl 2-iodobenzoate (4.7 g, 0.018 mol) in the presence of 2-iodo-3H-indole (3.0 g, 0.012 mol) > 3.1 g (yield: 68%). (M / z = 377)

(2) (2) 제조예Manufacturing example 2 : 중간체 73-2의 합성 2: Synthesis of Intermediate 73-2

Figure pat00336
Figure pat00336

중간체 73-1(3.0 g, 0.008 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 73-2> 1.8 g (수율 61%)을 얻었다.(m/z=377)
1.8 g (yield: 61%) of Intermediate 73-2 (3.0 g, 0.008 mol) was synthesized in the same manner as in Example 1- (3) = 377)

(3) (3) 제조예Manufacturing example 3 : 중간체 73-3의 합성 3: Synthesis of Intermediate 73-3

Figure pat00337
Figure pat00337

중간체 73-2(3.0 g, 0.008 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 73-3> 2.0g (수율 70%)을 얻었다.(m/z=359)
2.0 g (yield 70%) of Intermediate 73-3 was obtained in the same manner as in Example 1- (4), except that Intermediate 73-2 (3.0 g, 0.008 mol) = 359)

(4) (4) 제조예Manufacturing example 4 : 화합물 302의 합성 4: Synthesis of Compound 302

Figure pat00338
Figure pat00338

중간체 73-3(3.0 g, 0.008 mol), 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 302> 4.0g (수율 75%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 73-3 (3.0 g, 0.008 mol) and Intermediate 67-3 (4.8 g, 0.010 mol) 75%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.62/s, 7.58/d, 7.55/d, 7.38/m, 7.28/m) 2H(7.54/d, 7.52/d, 7.51/m) 4H(7.30/d, 7.20/m, 6.69/d, 6.68/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.62 / s, 7.58 / d, 7.55 / d, 7.38 / m, 7.28 / m) 2H (7.54 / d, 7.52 / d, 7.51 / m) 4H (7.30 / d, 7.20 / m, 6.69 / d, 6.68 / d, 1.72 / s)

LC/MS: m/z=669[(M+1)+]
LC / MS: m / z = 669 [(M + 1) &lt; + &

실시예Example 74 : 화합물 306의 합성 74: Synthesis of Compound 306

(1) (One) 제조예Manufacturing example 1 : 중간체 74-1의 합성 1: Synthesis of intermediate 74-1

Figure pat00339
Figure pat00339

2-bromo-6-chloroaniline(2.0 g, 0.010 mol)에 4-bromo-3-vinylpyridine(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 74-1> 1.0g (수율 41%)을 얻었다.(m/z=244)
4-bromo-3-vinylpyridine (1.8 g, 0.010 mol) was added to 2-bromo-6-chloroaniline (2.0 g, 0.010 mol) 74-1> (yield: 41%). (M / z = 244)

(2) (2) 제조예Manufacturing example 2 : 중간체 74-2의 합성 2: Synthesis of intermediate 74-2

Figure pat00340
Figure pat00340

중간체 74-1(3.0 g, 0.012 mol)에 (E)-1,2-dibromoethene(2.2 g, 0.012 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 74-2> 1.6g (수율 50%)을 얻었다.(m/z=268)
(E) -1,2-dibromoethene (2.2 g, 0.012 mol) was added to Intermediate 74-1 (3.0 g, 0.012 mol) to obtain Intermediate 74 -2> 1.6 g (yield 50%). (M / z = 268)

(3) (3) 제조예Manufacturing example 3 : 화합물 306의 합성 3: Synthesis of Compound 306

Figure pat00341
Figure pat00341

중간체 74-2(3.0 g, 0.011 mol), 중간체 67-3(6.3 g, 0.013 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 306> 4.7g (수율 64%)을 얻었다.This compound was synthesized in the same manner as in Example 1- (6), except that Intermediate 74-2 (3.0 g, 0.011 mol) and Intermediate 67-3 (6.3 g, 0.013 mol) 64%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 8.41/s, 7.99/d, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.36/s, 7.34/m, 7.30/d, 7.28/m, 7.04/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 8.41 / s, 7.99 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.36 / s (7.54 / d, 6.69 / d, 1.72 / s), 7.34 / m, 7.30 / d, 7.28 / m, 7.04 / d, 6.75 / s, 6.58 /

LC/MS: m/z=670[(M+1)+]
LC / MS: m / z = 670 [(M + 1) &lt; + &

실시예Example 75 : 화합물 307의 합성 75: Synthesis of Compound 307

(1)(One) 제조예Manufacturing example 1 : 중간체 75-1의 합성 1: Synthesis of intermediate 75-1

Figure pat00342
Figure pat00342

3-bromobenzene-1,2-diamine(2.0 g, 0.011 mol)에 1,2-dibromobenzene(2.6 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 75-1> 2.0g (수율 71%)을 얻었다.(m/z=261)
1,2-dibromobenzene (2.6 g, 0.011 mol) was added to 3-bromobenzene-1,2-diamine (2.0 g, 0.011 mol) (Yield: 71%) of the title compound (m / z = 261)

(2) (2) 제조예Manufacturing example 2 : 중간체 75-2의 합성 2: Synthesis of intermediate 75-2

Figure pat00343
Figure pat00343

중간체 75-1(3.0 g, 0.011 mol)에 (E)-1,2-dibromoethene(2.0 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 75-2> 1.6g (수율 50%)을 얻었다.(m/z=285)
(E) -1,2-dibromoethene (2.0 g, 0.011 mol) was added to Intermediate 75-1 (3.0 g, 0.011 mol) to obtain Intermediate 75 -2> 1.6 g (yield: 50%). (M / z = 285)

(3) (3) 제조예Manufacturing example 3 : 중간체 75-3의 합성 3: Synthesis of Intermediate 75-3

Figure pat00344
Figure pat00344

중간체 75-2(3.0 g, 0.011 mol), bromobenzene(1.7 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 75-3> 2.9g (수율 74%)을 얻었다.(m/z=361)
Intermediate 75-3 (2.9 g, yield 74%) was obtained as a white solid from Intermediate 75-2 (3.0 g, 0.011 mol) and bromobenzene (1.7 g, 0.011 mol) %). (M / z = 361)

(4) (4) 제조예Manufacturing example 4 : 중간체 75-4의 합성 4: Synthesis of intermediate 75-4

Figure pat00345
Figure pat00345

1,4-dibromobenzene(2.4 g, 0.010 mol), bis(9,9-dimethyl-9H-fluoren-2-yl)amine(4.0 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 75-3-1> 4.1g (수율 74%)을 얻었다.(m/z=556)
Was used in the same manner as in Example 1 (2) except that 1,4-dibromobenzene (2.4 g, 0.010 mol) and bis (9,9-dimethyl-9H- fluoren- (M / z = 556) of <Intermediate 75-3-1> (yield: 74%).

(5) (5) 제조예Manufacturing example 5 : 중간체 75-4의 합성 5: Synthesis of intermediate 75-4

Figure pat00346
Figure pat00346

중간체 75-3-1(5.0 g, 0.009 mol), bis(pinacolato)dibron(2.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (5)에서 사용된 동일한 방법으로 합성하여 <중간체 75-4> 3.9g (수율 71%)을 얻었다.(m/z=603)
Intermediate 75-3-1 (5.0 g, 0.009 mol) and bis (pinacolato) dibron (2.8 g, 0.011 mol) were added to the reaction mixture to obtain Intermediate 75-4 > 3.9 g (yield: 71%). (M / z = 603)

(5) (5) 제조예Manufacturing example 5 : 화합물 307의 합성 5: Synthesis of Compound 307

Figure pat00347
Figure pat00347

중간체 75-3(3.0 g, 0.008 mol), 중간체 75-4(5.2 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 75-4> 4.3g (수율 71%)을 얻었다.<Intermediate 75-4> was synthesized in the same manner as in Example 1- (6), except that Intermediate 75-3 (3.0 g, 0.008 mol) and Intermediate 75-4 (5.2 g, 0.010 mol) (Yield: 71%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(6.81/m) 2H(7.87/d, 7.62/d, 7.55/d, 7.54/d, 7.38/m, 7.28/m, 6.75/s, 6.69/d, 6.58/d) 4H(7.20/m, 6.81/m, 6.63/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (6.81 / m) 2H (7.87 / d, 7.62 / d, 7.55 / d, 7.54 / d, 7.38 / m, 7.28 / m, 6.75 / s, 6.69 / d, 6.58 / d) 4H (7.20 / m, 6.81 / m, 6.63 / d, 1.72 / s)

LC/MS: m/z=758[(M+1)+]
LC / MS: m / z = 758 [(M + 1) &lt; + &

실시예Example 76 : 화합물 310의 합성 76: Synthesis of Compound 310

(1) (One) 제조예Manufacturing example 1 : 중간체 76-1의 합성 1: Synthesis of intermediate 76-1

Figure pat00348
Figure pat00348

2-bromopyrazine(2.0 g, 0.013mol)에 methyl 2-amino-3-bromobenzoate(2.9 g, 0.013 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 76-1> 2.4g (수율 59%)을 얻었다.(m/z=308)
(2.9 g, 0.013 mol) was added to 2-bromopyrazine (2.0 g, 0.013 mol) in the same manner as in Example 1-Preparation Example (2) > 2.4 g (yield: 59%). (M / z = 308)

(2) (2) 제조예Manufacturing example 2 : 중간체 76-2의 합성 2: Synthesis of intermediate 76-2

Figure pat00349
Figure pat00349

중간체 76-1(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 76-2> 2.0g (수율 64%)을 얻었다.(m/z=308)
2.0 g (yield: 64%) of <Intermediate 76-2> was obtained by the same method as employed in the preparation example (3) of Example 1, with the intermediate 76-1 (3.0 g, 0.010 mol) = 308)

(3) (3) 제조예Manufacturing example 3 : 중간체 76-3의 합성 3: Synthesis of intermediate 76-3

Figure pat00350
Figure pat00350

중간체 76-2(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 76-3> 2.0g (수율 70%)을 얻었다.(m/z=290)
2.0 g (yield 70%) of Intermediate 76-3 was obtained in the same manner as in Example 1 (4) except that Intermediate 76-2 (3.0 g, 0.010 mol) was added. M / z = 290)

(4) (4) 제조예Manufacturing example 4 : 중간체 76-4의 합성 4: Synthesis of intermediate 76-4

Figure pat00351
Figure pat00351

중간체 33-1(3.0 g, 0.010 mol)에 1,1-dibromoethene(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 76-4> 1.6g (수율 51%)을 얻었다.(m/z=314)
Synthesis was conducted in the same manner as in Example 1 (2), except that 1,1-dibromoethene (1.8 g, 0.010 mol) was added to Intermediate 33-1 (3.0 g, 0.010 mol) g (yield: 51%). (m / z = 314)

(5) (5) 제조예Manufacturing example 5 : 화합물 310의 합성 5: Synthesis of Compound 310

Figure pat00352
Figure pat00352

중간체 76-4(3.0 g, 0.010 mol)에 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 76> 4.8 g (수율72%)을 얻었다.(4.8 g, 0.010 mol) was added to Intermediate 76-4 (3.0 g, 0.010 mol) in the same manner as in Example 1- (6) 72%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.58/d, 8.51/d, 7.99/d, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.36/s, 7.34/m, 7.28/m, 7.04/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.58 / d, 8.51 / d, 7.99 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.36 / s (7.54 / d, 6.69 / d, 1.72 / s), 7.34 m, 7.28 m, 7.04 d, 6.75 s, 6.58 d)

LC/MS: m/z=671[(M+1)+]
LC / MS: m / z = 671 [(M + 1) &lt; + &

실시예Example 77 : 화합물 311의 합성 77: Synthesis of Compound 311

(1) (One) 제조예Manufacturing example 1 : 중간체 77-1의 합성 1: Synthesis of intermediate 77-1

Figure pat00353
Figure pat00353

2-amino-phenol(2.0 g, 0.010 mol)에 1,2,3-tribromobenzene(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 77-1> 1.1g (수율 41%)을 얻었다.(m/z=262)
Synthesis was conducted in the same manner as in Example 1 (2), except that 1,2,3-tribromobenzene (3.1 g, 0.010 mol) was added to 2-amino-phenol (2.0 g, 0.010 mol) 1> 1.1 g (yield: 41%). (M / z = 262)

(2) (2) 제조예Manufacturing example 2 : 중간체 77-2의 합성 2: Synthesis of Intermediate 77-2

Figure pat00354
Figure pat00354

중간체 77-1(3.0 g, 0.011 mol)에 1,2-dibromoethene(1.9 g, 0.0011 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 77-2> 1.6g (수율 51%)을 얻었다.(m/z=286)
Synthesis was conducted in the same manner as in Example 1 (2), except that 1,2-dibromoethene (1.9 g, 0.0011 mol) was added to Intermediate 77-1 (3.0 g, 0.011 mol) g (yield: 51%). (m / z = 286)

(3) (3) 제조예Manufacturing example 3 : 화합물 311의 합성 3: Synthesis of Compound 311

Figure pat00355
Figure pat00355

중간체 77-2(3.0 g, 0.010 mol)에 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 311> 4.5g (수율 70%)을 얻었다.Synthesis was conducted in the same manner as in Example 1- (6), except that Intermediate 67-3 (4.8 g, 0.010 mol) was added to Intermediate 77-2 (3.0 g, 0.010 mol) 70%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.89/d, 7.87/d, 7.62/d, 7.58/d, 7.55/d, 7.41/m, 7.36/s, 7.30/m, 7.28/m, 7.14/d, 6.88/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m, 7.38/m, 1.72/s) 4H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.89 / d, 7.87 / d, 7.62 / d, 7.58 / d, 7.55 / d, 7.41 / m, 7.36 / s, 7.30 / m, 7.28 / m (7.54 / d, 6.69 / d), 7.14 / d, 6.88 / d, 6.75 / s, 6.58 /

LC/MS: m/z=643[(M+1)+]
LC / MS: m / z = 643 [(M + 1) &lt; + &

실시예Example 78 : 화합물 312의 합성 78: Synthesis of Compound 312

(1) (One) 제조예Manufacturing example 1 : 중간체 78-1의 합성 1: Synthesis of intermediate 78-1

Figure pat00356
Figure pat00356

2-amino-benzenethiol(2.0 g, 0.010 mol)에 1,2,3-tribromobenzene(3.1 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 78-1> 1.2g (수율 43%)을 얻었다.(m/z=278)
Synthesis was conducted in the same manner as in Example 1 (2), except that 1,2,3-tribromobenzene (3.1 g, 0.010 mol) was added to 2-amino-benzenethiol (2.0 g, 0.010 mol) 1> 1.2 g (yield: 43%). (M / z = 278)

(2) (2) 제조예Manufacturing example 2 : 중간체 78-2의 합성 2: Synthesis of intermediate 78-2

Figure pat00357
Figure pat00357

중간체 78-1(3.0 g, 0.010 mol)에 1,2-dibromoethene(1.7 g, 0.0010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 77-2> 1.5g (수율 51%)을 얻었다.(m/z=302)
Synthesis was conducted in the same manner as in Example 1 (2), except that 1,2-dibromoethene (1.7 g, 0.0010 mol) was added to Intermediate 78-1 (3.0 g, 0.010 mol) g (yield: 51%). (m / z = 302)

(3) (3) 제조예Manufacturing example 3 : 화합물 312의 합성 3: Synthesis of Compound 312

Figure pat00358
Figure pat00358

중간체 78-2(3.0 g, 0.010 mol)에 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 312> 4.9 g (수율74%)을 얻었다.Synthesis was conducted in the same manner as in Example 1- (6) to obtain Intermediate 67-3 (4.8 g, 0.010 mol) and Intermediate 78-2 (3.0 g, 0.010 mol) 74%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.91/d, 7.87/d, 7.62/d, 7.55/d, 7.42/d, 7.41/d, 7.41/m, 7.38/m, 7.36/s, 7.32/m, 7.28/m, 7.25/m, 7.22/m, 7.11/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m, 1.72/s) 4H(7.54/d, 6.69/d) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.91 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.42 / d, 7.41 / d, 7.41 / m, 7.38 / m, 7.36 / s (7.52 / d, 7.51 / m, 1.72 / s) 4H (7.54 / d, 6.69 / d), 7.32 / m, 7.28 / m, 7.25 / / d)

LC/MS: m/z=659[(M+1)+]
LC / MS: m / z = 659 [(M + 1) &lt; + &

실시예Example 79 : 화합물 313의 합성 79: Synthesis of Compound 313

(1) (One) 제조예Manufacturing example 1 : 중간체 79-1의 합성 1: Synthesis of intermediate 79-1

Figure pat00359
Figure pat00359

3-bromopyridine(2.0 g, 0.013 mol)에 methyl 2-amino-3-bromobenzoate(2.9 g, 0.013 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 79-1> 1.8g (수율 45%)을 얻었다.(m/z=307)
(2.9 g, 0.013 mol) of methyl 2-amino-3-bromobenzoate was added to 3-bromopyridine (2.0 g, 0.013 mol) > 1.8 g (yield: 45%). (M / z = 307)

(2) (2) 제조예Manufacturing example 2 : 중간체 79-2의 합성 2: Synthesis of intermediate 79-2

Figure pat00360
Figure pat00360

중간체 79-1(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 79-2> 1.8g (수율 60%)을 얻었다.(m/z=307)
1.8 g (yield: 60%) of <Intermediate 79-2> was obtained in the same manner as in Example 1- (3) except that Intermediate 79-1 (3.0 g, 0.010 mol) = 307)

(3) (3) 제조예Manufacturing example 3 : 중간체 79-3의 합성 3: Synthesis of intermediate 79-3

Figure pat00361
Figure pat00361

중간체 79-2(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예(3)에서 사용된 동일한 방법으로 합성하여 <중간체 79-3> 2.0g (수율 70%)을 얻었다.(m/z=289)
2.0 g (yield 70%) of <Intermediate 79-3> was obtained by the same method as in Example 1- (3) except that Intermediate 79-2 (3.0 g, 0.010 mol) = 289)

(4) (4) 제조예Manufacturing example 4 : 중간체 79-4의 합성 4: Synthesis of intermediate 79-4

Figure pat00362
Figure pat00362

중간체 79-3(3.0 g, 0.010 mol)에 1,1-dibromoethene(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 79-4> 1.7g (수율 54%)을 얻었다.(m/z=313)
Intermediate 79-4 was synthesized by the same method as in the preparation example (2) of Example 1, except that 1,1-dibromoethene (1.8 g, 0.010 mol) was added to Intermediate 79-3 (3.0 g, 0.010 mol) g (yield: 54%). (m / z = 313)

(5) (5) 제조예Manufacturing example 5 : 화합물 313의 합성 5: Synthesis of Compound 313

Figure pat00363
Figure pat00363

중간체 79-4(3.0 g, 0.010 mol)에 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 313> 4.4g (수율66%)을 얻었다.Synthesis was conducted in the same manner as in Example 1- (6), except that Intermediate 67-3 (4.8 g, 0.010 mol) was added to Intermediate 79-4 (3.0 g, 0.010 mol) 66%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.60/s, 8.10/d, 7.99/d, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.36/s, 7.34/m, 7.28/m, 7.04/d, 6.97/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.60 / s, 8.10 / d, 7.99 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.36 / s (7.54 / d, 6.69 / d, 1.72 / s), 7.34 / m, 7.28 / m, 7.04 / d, 6.97 / d, 6.75 / s, 6.58 /

LC/MS: m/z=670[(M+1)+]
LC / MS: m / z = 670 [(M + 1) &lt; + &

실시예Example 80 : 화합물 314의 합성 80: Synthesis of Compound 314

(1) (One) 제조예Manufacturing example 1 : 중간체 80-1의 합성 1: Synthesis of intermediate 80-1

Figure pat00364
Figure pat00364

3-bromopyridine(2.0 g, 0.013 mol)에 methyl 2-amino-3-bromobenzoate(2.9 g, 0.013 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 80-1> 1.7g (수율 41%)을 얻었다.(m/z=307)
(2.9 g, 0.013 mol) was added to 3-bromopyridine (2.0 g, 0.013 mol) in the same manner as in Example 1 (2) to obtain Intermediate 80-1 > 1.7 g (yield: 41%). (M / z = 307)

(2) (2) 제조예Manufacturing example 2 : 중간체 80-2의 합성 2: Synthesis of intermediate 80-2

Figure pat00365
Figure pat00365

중간체 80-1(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예 (3)에서 사용된 동일한 방법으로 합성하여 <중간체 80-2> 1.6g (수율 53%)을 얻었다.(m/z=307)
1.6 g (yield 53%) of Intermediate 80-2 (3.0 g, 0.010 mol) was obtained by the same method as in Example 1- (3) = 307)

(3) (3) 제조예Manufacturing example 3 : 중간체 80-3의 합성 3: Synthesis of Intermediate 80-3

Figure pat00366
Figure pat00366

중간체 80-2(3.0 g, 0.010 mol)을 넣고 실시예 1-제조예 (4)에서 사용된 동일한 방법으로 합성하여 <중간체 80-3> 1.8g (수율 61%)을 얻었다.(m/z=289)
1.8 g (yield: 61%) of Intermediate 80-3 was obtained in the same manner as in Example 1 (4), except that Intermediate 80-2 (3.0 g, 0.010 mol) = 289)

(4) (4) 제조예Manufacturing example 4 : 중간체 80-4의 합성 4: Synthesis of Intermediate 80-4

Figure pat00367
Figure pat00367

중간체 80-3(3.0 g, 0.010 mol)에 1,1-dibromoethene(1.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <중간체 80-4> 1.4g (수율 44%)을 얻었다.(m/z=313)
Intermediate 80-4> 1.4 (1) Synthesis was conducted in the same manner as in Example 1 (2) except that 1,1-dibromoethene (1.8 g, 0.010 mol) was added to Intermediate 80-3 (3.0 g, 0.010 mol) g (yield: 44%). (m / z = 313)

(5) (5) 제조예Manufacturing example 5 : 화합물 314의 합성 5: Synthesis of Compound 314

Figure pat00368
Figure pat00368

중간체 80-4(3.0 g, 0.010 mol)에 중간체 67-3(4.8 g, 0.010 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <화합물 314> 4.0g (수율60%)을 얻었다.Synthesis was conducted in the same manner as in Example 1 (6) to give Intermediate 67-3 (4.8 g, 0.010 mol) and Intermediate 80-4 (3.0 g, 0.010 mol) 60%).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.43/d, 8.10/d, 7.99/d, 7.87/d, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.36/s, 7.34/m, 7.28/m, 7.20/m, 7.04/d, 6.75/s, 6.58/d) 2H(7.52/d, 7.51/m) 4H(7.54/d, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.43 / d, 8.10 / d, 7.99 / d, 7.87 / d, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.36 / s (7.54 / d, 6.69 / d, 1.72 / s), 7.34 m, 7.28 m, 7.20 m, 7.04 d, 6.75 s, 6.58 d)

LC/MS: m/z=670[(M+1)+]
LC / MS: m / z = 670 [(M + 1) &lt; + &

실시예Example 81 : 화합물 315의 합성 81: Synthesis of Compound 315

(1) (One) 제조예Manufacturing example 1 : 중간체 81-1의 합성 1: Synthesis of intermediate 81-1

Figure pat00369
Figure pat00369

2-bromo-1H-indol-3-ylboronic acid(2.4 g, 0.010 mol)에 phenyl boronic acid(1.4 g, 0.012 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 81-1> 1.7g (수율 72%)을 얻었다.(m/z=237)
The title compound was synthesized in the same manner as in Example 1 (6), except that phenyl boronic acid (1.4 g, 0.012 mol) was added to 2-bromo-1H-indol-3-ylboronic acid (2.4 g, 0.010 mol) 1.7 g (yield: 72%) of Intermediate 81-1 was obtained. (M / z = 237)

(2) (2) 제조예Manufacturing example 2 : 중간체 81-2의 합성 2: Synthesis of Intermediate 81-2

Figure pat00370
Figure pat00370

2,5-dibromothiophene(3.0 g, 0.012 mol)에 중간체 67-3(7.9 g, 0.014 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 81-2> 5.0g (수율 70%)을 얻었다.(m/z=598)
Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 67-3 (7.9 g, 0.014 mol) was added to 2,5-dibromothiophene (3.0 g, 0.012 mol) g (yield 70%). (m / z = 598)

(3) (3) 제조예Manufacturing example 3 : 중간체 81-3의 합성 3: Synthesis of intermediate 81-3

Figure pat00371
Figure pat00371

중간체 81-1(3.0 g, 0.013 mol)에 중간체 81-2(7.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 81-3> 5.0g (수율 64%)을 얻었다.(m/z=710)
Intermediate 81-3 (5.0 g, 0.011 mol) was added to Intermediate 81-1 (3.0 g, 0.013 mol) to obtain Intermediate 81-2 (7.8 g, 0.011 mol) (Yield: 64%). (M / z = 710)

(4) (4) 제조예Manufacturing example 4 : 화합물 315의 합성 4: Synthesis of Compound 315

Figure pat00372
Figure pat00372

중간체 81-3(7.1 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 315> 6.2g (수율 75%) 을 얻었다.6.2 g (yield 75%) of <compound 315> was obtained in the same manner as in <compound 2> using Intermediate 81-3 (7.1 g, 0.010 mol).

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.37/d, 7.87/d, 7.55/d, 7.62/d, 7.40/m, 7.38/m, 7.37/m, 7.30/d, 7.28/m, 7.27/d, 7.17/m, 7.00/d, 6.75/s, 6.58/d) 2H(7.73/d, 7.41/m) 4H(7.54/d, 7.52/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.37 / d, 7.87 / d, 7.55 / d, 7.62 / d, 7.40 / m, 7.38 / m, 7.37 / m, 7.30 / d, 7.28 / m D, 7.57 / d, 7.17 / m, 7.00 / d, 6.75 / s, 6.58 / d) 2H (7.73 / d, 7.41 / / s)

LC/MS: m/z=828[(M+1)+]
LC / MS: m / z = 828 [(M + 1) &lt; + &

실시예Example 82 : 화합물 316의 합성 82: Synthesis of Compound 316

(1) (One) 제조예Manufacturing example 1 : 중간체 82-1의 합성 1: Synthesis of intermediate 82-1

Figure pat00373
Figure pat00373

2,5-dibromofuran(3.0 g, 0.012 mol)에 중간체 67-3(7.9 g, 0.014 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 82-1> 4.5g (수율 65%)을 얻었다.(m/z=582)
Synthesis was conducted in the same manner as in Example 1 (6), except that Intermediate 67-3 (7.9 g, 0.014 mol) was added to 2,5-dibromofuran (3.0 g, 0.012 mol) g (yield: 65%). (m / z = 582)

(2) (2) 제조예Manufacturing example 2 : 중간체 82-2의 합성 2: Synthesis of intermediate 82-2

Figure pat00374
Figure pat00374

중간체 81-1(3.0 g, 0.013 mol)에 중간체 82-1(6.8 g, 0.011 mol)를 넣고 실시예 1-제조예 (6)에서 사용된 동일한 방법으로 합성하여 <중간체 82-2> 4.6g (수율 60%)을 얻었다.(m/z=694)
Intermediate 82-1 (6.8 g, 0.011 mol) was added to Intermediate 81-1 (3.0 g, 0.013 mol), and the reaction was conducted in the same manner as in Example 1- (6) (Yield: 60%). (M / z = 694)

(3) (3) 제조예Manufacturing example 3 : 화합물 316의 합성 3: Synthesis of Compound 316

Figure pat00375
Figure pat00375

중간체 82-2(6.9 g, 0.010 mol)을 사용하여 <화합물 2>와 동일한 방법을 사용하여 <화합물 316> 5.8g (수율 71%) 을 얻었다.Using the intermediate 82-2 (6.9 g, 0.010 mol), 5.8 g (Yield 71%) of <Compound 316> was obtained in the same manner as in <Compound 2>.

H-NMR (200MHz, CDCl3):δ ppm, 1H(8.37/d, 7.87/d, 7.55/d, 7.62/d, 7.40/m, 7.38/m, 7.37/m, 7.30/d, 7.28/m, 7.27/d, 7.17/m, 7.00/d, 6.75/s, 6.58/d) 2H(7.41/m, 7.07/d) 4H(7.54/d, 7.52/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (8.37 / d, 7.87 / d, 7.55 / d, 7.62 / d, 7.40 / m, 7.38 / m, 7.37 / m, 7.30 / d, 7.28 / m M, 7.07 / d) 4H (7.54 / d, 7.52 / d, 7.51 / m, 6.69 / d, 1.72 / s)

LC/MS: m/z=812[(M+1)+]
LC / MS: m / z = 812 [(M + 1) &lt; + &

실시예Example 83 : 화합물 317의 합성 83: Synthesis of Compound 317

(1) (One) 제조예Manufacturing example 1 : 화합물 317의 합성 1: Synthesis of Compound 317

Figure pat00376
Figure pat00376

중간체 40-1(3.0 g, 0.009 mol)에 N-(biphenyl-4-yl)-9,9-dimethyl-9H-fluoren-2-amine(3.2 g, 0.009 mol)를 넣고 실시예 1-제조예 (2)에서 사용된 동일한 방법으로 합성하여 <화합물 317> 6.0g (수율 77%)을 얻었다.(Biphenyl-4-yl) -9,9-dimethyl-9H-fluoren-2-amine (3.2 g, 0.009 mol) was added to Intermediate 40-1 (3.0 g, 0.009 mol) (2) to obtain 6.0 g (yield: 77%) of < Compound 317 >.

H-NMR (200MHz, CDCl3):δ ppm, 1H(7.87/d, 7.83/m, 7.62/d, 7.55/d, 7.41/m, 7.38/m, 7.28/m, 7.08/d, 7.05/m, 6.75/s, 6.58/d, 6.52/d, 5.04/s) 2H(7.33/m, 7.26/m) 6H(7.54/d, 7.51/m, 6.69/d, 1.72/s) H-NMR (200MHz, CDCl 3 ): δ ppm, 1H (7.87 / d, 7.83 / m, 7.62 / d, 7.55 / d, 7.41 / m, 7.38 / m, 7.28 / m, 7.08 / d, 7.05 / m (7.54 / d, 7.51 / m, 6.69 / d, 1.72 / s), 6.75 / s, 6.58 / d, 6.52 /

LC/MS: m/z=865[(M+1)+]
LC / MS: m / z = 865 [(M + 1) &lt; + &

소자 device 실시예Example 1 : 화합물 1을  1: Compound 1 발광층의The light- 호스트 재료로 하여  As a host material 유기전계발광소자Organic electroluminescent device 제조 Produce

ITO로 코팅된 유리기판 위에 NPB를 증착하여 120 nm의 정공수송층을 형성하였으며, 이어서 Ir(ppy)3을 도펀트로 하여 화합물 1의 증착속도를 0.1 nm/sec, Ir(ppy)3 증착속도를 0.009 nm/sec로 증착하고, 증착속도 비율이 9%가 되도록 Ir(ppy)3을 도핑하여 정공수송층 상에 발광층을 30 nm 두께로 형성하였다.Depositing NPB on a glass substrates, coated with ITO, and was to form a hole transport layer of 120 nm, followed by Ir (ppy) the deposition rate of the compounds 1 to 3 as the dopant 0.1 nm / sec, Ir (ppy) 0.009 3 deposition rate nm / sec, and Ir (ppy) 3 was doped so that the deposition rate ratio was 9% to form a light emitting layer with a thickness of 30 nm on the hole transport layer.

그 위에 Balq를 10 nm 두께로 증착하여 정공이 발광층을 지나 전자수송층으로 이동하는 것을 방지하는 정공차단층을 형성하고, 그 위에 Alq3를 증착하여 40 nm의 전자수송층을 형성하였으며, 그 위에 불화리튬을 증착하여 1 nm의 전자주입층을 형성하였다. 전자주입층 상에 알루미늄을 증착하여 120 nm의 음극을 형성하여 유기전계발광소자를 제조하였다.Balq was deposited thereon to a thickness of 10 nm to form a hole blocking layer for preventing holes from moving to the electron transporting layer through the light emitting layer, and Alq 3 was deposited thereon to form an electron transporting layer of 40 nm. Lithium fluoride To form a 1 nm electron injection layer. Aluminum was deposited on the electron injection layer to form a 120 nm negative electrode, thereby fabricating an organic electroluminescent device.

이때, 각 물질의 증착속도는 유기물질인, 화합물 1, NPB, Alq3, Balq는 0.1 nm/sec, 불화리튬은 0.01 nm/sec, 알루미늄은 0.5 nm/sec로 하였다.
At this time, the deposition rate of each material was set to 0.1 nm / sec for compound 1, NPB, Alq 3 , Balq, 0.01 nm / sec for lithium fluoride, and 0.5 nm / sec for aluminum.

소자 device 실시예Example 2 내지 43 2 to 43

상기 화합물 1 대신 하기 [표 1]에 기재된 화합물을 사용한 것을 제외하고는 소자실시예 1와 동일한 방법으로 소자 실시예 2 내지 43의 유기전계발광소자를 제조하였다.
An organic electroluminescent device of each of the device embodiments 2 to 43 was fabricated in the same manner as in the device example 1, except that the compound described in [Table 1] was used in place of the compound 1 described above.

소자 device 비교예Comparative Example 1 One

비교예 1을 위한 유기발광다이오드 소자는 상기 실시예의 소자구조에서 발명에 의해 제조된 화합물 1 대신 일반적으로 인광호스트 물질로 많이 사용되고 있는 CBP를 사용한 점을 제외하고 동일하게 제작하였다.
The organic light emitting diode device for Comparative Example 1 was fabricated in the same manner except that CBP, which is generally used as a phosphorescent host material, was used instead of the compound 1 produced by the invention in the device structure of the embodiment.

소자실시예Device Example 44: 화합물 44를  44: Compound 44 정공수송재료로With hole transport material 하여  So 유기전계발광소자Organic electroluminescent device 제조 Produce

ITO로 코팅된 유리기판 위에 화합물 44를 증착하여 120 nm의 정공수송층을 형성하였으며, 이어서 Ir(ppy)3을 도펀트로 하여 CBP를 호스트로 하여 증착속도를 0.1 nm/sec, Ir(ppy)3 증착속도를 0.009 nm/sec로 증착하고, 증착속도 비율이 9%가 되도록 Ir(ppy)3을 도핑하여 정공수송층 상에 발광층을 30 nm 두께로 형성하였다.Compound 44 was deposited on ITO-coated glass substrate to form a 120 nm hole transport layer. Subsequently, Ir (ppy) 3 was used as a dopant to deposit CBP at 0.1 nm / sec and Ir (ppy) 3 And the Ir (ppy) 3 was doped so that the deposition rate ratio was 9% to form a light emitting layer with a thickness of 30 nm on the hole transport layer.

그 위에 Balq를 10 nm 두께로 증착하여 정공이 발광층을 지나 전자수송층으로 이동하는 것을 방지하는 정공차단층을 형성하고, 그 위에 Alq3를 증착하여 40 nm의 전자수송층을 형성하였으며, 그 위에 불화리튬을 증착하여 1 nm의 전자주입층을 형성하였다. 전자주입층 상에 알루미늄을 증착하여 120 nm의 음극을 형성하여 유기전계발광소자를 제조하였다.Balq was deposited thereon to a thickness of 10 nm to form a hole blocking layer for preventing holes from moving to the electron transporting layer through the light emitting layer, and Alq 3 was deposited thereon to form an electron transporting layer of 40 nm. Lithium fluoride To form a 1 nm electron injection layer. Aluminum was deposited on the electron injection layer to form a 120 nm negative electrode, thereby fabricating an organic electroluminescent device.

이때, 각 물질의 증착속도는 유기물질인, 화합물 1, CBP, Alq3, Balq는 0.1 nm/sec, 불화리튬은 0.01 nm/sec, 알루미늄은 0.5 nm/sec로 하였다.
At this time, the deposition rate of each material was set to 0.1 nm / sec for compound 1, CBP, Alq 3 , Balq, 0.01 nm / sec for lithium fluoride, and 0.5 nm / sec for aluminum.

소자 device 실시예Example 45 내지 83 45 to 83

화합물 44 대신에 하기 [표 2]에 기재된 화합물을 사용한 것을 제외하고는 소자실시예 44과 동일한 방법으로 소자 실시예 45 내지 83의 유기전계발광소자를 제조하였다.
Organic electroluminescent devices of Device Examples 45 to 83 were fabricated in the same manner as in Example 44 except that the compound described in [Table 2] was used instead of Compound 44.

소자 device 비교예Comparative Example 2 2

비교예2를 위한 유기발광다이오드 소자는 상기 실시예의 소자구조에서 발명에 의해 제조된 화합물1 대신 일반적으로 정공수송물질로 많이 사용되고 있는 NPB를 사용한 점을 제외하고 동일하게 제작하였다.The organic light emitting diode device for Comparative Example 2 was fabricated in the same manner except that NPB, which is generally used as a hole transport material, was used instead of the compound 1 produced by the invention in the device structure of the embodiment.

상기에서 사용된 Ir(ppy)3, CBP, NPB의 구조는 다음과 같다.The structures of Ir (ppy) 3 , CBP and NPB used in the above are as follows.

Figure pat00377
Figure pat00377

[표 1][Table 1]

Figure pat00378
Figure pat00378

Figure pat00379
Figure pat00379

[표 2][Table 2]

Figure pat00380
Figure pat00380

Figure pat00381

Figure pat00381

구동전압 및 발광효율 측정Measurement of driving voltage and luminous efficiency

상기 유기발광소자(기판크기 : 25 × 25 ㎟ / 증착면적 : 2 × 2 ㎟)를 IVL 측정셋트(CS-2000+지그+IVL프로그램)에 고정한 후 전류를 1 mA/㎡씩 상승시키며 증착면의 발광 휘도(cd/㎡), 구동전압(V), 전류밀도(A/㎡), 발광효율(cd/A)을 측정하여 휘도가 1000 cd/㎡ 일 때 구동전압과 발광효율을 상기 [표 1] 및 [표 2]에 나타내었다.After fixing the organic light emitting device (substrate size: 25 × 25 mm 2 / deposition area: 2 × 2 mm 2) to the IVL measurement set (CS-2000 + jig + IVL program), the current was increased by 1 mA / The driving voltage and the luminous efficiency were measured at a luminance of 1000 cd / m 2 by measuring the luminance (cd / m 2), the driving voltage (V), the current density (A / ] And [Table 2].

[표 1]과 [표 2]에 따르면, 본 발명에 따른 유기전계발광소자용 화합물이 유기전계발광소자의 발광층의 호스트 물이나, 정공수송물질로 사용될 때 종래의 CBP(호스트재료), NPB(정공수송재료)를 사용할 때보다 구동전압은 낮아지고, 발광효율은 증가됨을 볼 수 있다.According to [Table 1] and [Table 2], when the compound for an organic electroluminescent device according to the present invention is used as a host material or a hole transport material of the light emitting layer of an organic electroluminescent device, conventional CBP (host material), NPB Hole transporting material), the driving voltage is lowered and the luminous efficiency is increased.

Claims (12)

하기 [화학식 1]로 표시되는 유기발광 화합물:
[화학식 1]
Figure pat00382

상기 [화학식 1]에서,
X1 내지 X10은 각각 독립적으로 N 또는 CR1이고, X11은 단일결합이거나, CR2R3, CR4, NR5, PR6, SiR7R8, O 및 S 중에서 선택되고,
상기 R1 내지 R8은 각각 독립적으로 수소, 중수소, 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐기, 치환 또는 비치환된 탄소수 3 내지30의 시클로알킬기, 치환 또는 비치환된 탄소수 2 내지 30의 헤테로시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 30의 시클로알케닐기, 치환 또는 비치환된 탄소수 1 내지 30의 알콕시기, 치환 또는 비치환된 탄소수 6 내지 30의 아릴옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬티옥시기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴티옥시기, 치환 또는 비치환된 탄소수 1 내지 30의 알킬아민기, 치환 또는 비치환된 탄소수 5 내지 30의 아릴아민기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 실릴기, 아미노기, 싸이올기, 시아노기, 히드록시기, 니트로기 및 할로겐기로 이루어진 군에서 선택되고,
상기 R1 내지 R8 중 인접한 치환기는 서로 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있고,
상기 R1 내지 R8은 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
An organic light-emitting compound represented by the following Formula 1:
[Chemical Formula 1]
Figure pat00382

In the above formula (1)
X 1 to X 10 are each independently N or CR 1 and X 11 is a single bond or is selected from CR 2 R 3 , CR 4 , NR 5 , PR 6 , SiR 7 R 8 , O and S,
Each of R 1 to R 8 is independently selected from the group consisting of hydrogen, deuterium, a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 30 carbon atoms, a substituted or unsubstituted alkoxy group having 2 to 30 carbon atoms A substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted heterocycloalkyl group having 2 to 30 carbon atoms, a substituted or unsubstituted cycloalkenyl group having 5 to 30 carbon atoms, a substituted or unsubstituted C1- A substituted or unsubstituted C1 to C30 alkoxy group, a substituted or unsubstituted C6 to C30 aryloxy group, a substituted or unsubstituted C1 to C30 alkylthio group, a substituted or unsubstituted C1 to C30 arylthio group, An unsubstituted alkylamine group having 1 to 30 carbon atoms, a substituted or unsubstituted arylamine group having 5 to 30 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted aryl group having 5 to 50 carbon atoms, a substituted or unsubstituted C3 to C30 cycloalkyl having 3 to 30 carbon atoms, a substituted or unsubstituted C3 to C30 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl, A substituted or unsubstituted aryl group having 2 to 50 carbon atoms, a substituted or unsubstituted silyl group, an amino group, a thiol group, a cyano group, a hydroxyl group, a nitro group and a halogen group,
The adjacent substituents of R 1 to R 8 may be connected to form a single alicyclic or aromatic ring or polycyclic ring. The carbon atom of the alicyclic or aromatic monocyclic or polycyclic ring may be substituted with N, S and O Which may be substituted with any one or more hetero atoms selected,
Each of R 1 to R 8 may be further substituted with at least one substituent, and the at least one substituent may be one selected from the group consisting of deuterium, cyano, halogen, hydroxy, nitro, alkyl having 1 to 24 carbon atoms, A halogenated alkyl group, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, An aryl group or a heteroarylalkyl group having 2 to 24 carbon atoms, an alkoxy group having 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, An alkylsilyl group of 1 to 24 carbon atoms, an arylsilyl group of 1 to 24 carbon atoms, and an aryloxy group of 1 to 24 carbon atoms.
제1항에 있어서,
상기 [화학식 1]은 하기 [화학식 2] 내지 [화학식 17] 중에서 선택되는 어느 하나인 것을 특징으로 하는 유기발광 화합물:
Figure pat00383

상기 [화학식 2] 내지 [화학식 17]에서,
X1 내지 X11의 정의는 상기 [화학식 1]에서의 정의와 동일하고, 상기 X1 내지 X11의 각 치환기는 인접한 치환기와 서로 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있다.
The method according to claim 1,
The organic electroluminescent compound according to claim 1, wherein the compound represented by Formula 1 is any one selected from the following Formulas (2) to (17):
Figure pat00383

In the above Chemical Formulas 2 to 17,
X 1 to X 11 are the same as defined in the above formula (1), and each of the substituents of X 1 to X 11 is linked to adjacent substituents to form a monocyclic or polycyclic ring of alicyclic or aromatic And the carbon atom of the formed alicyclic or aromatic monocyclic or polycyclic ring may be substituted with any one or more heteroatoms selected from N, S and O.
제1항에 있어서,
상기 X2 내지 X6 중 하나 이상은 CR3이고, 상기 *-R3는 하기 [구조식 1]인 것을 특징으로 하는 유기발광 화합물:
[구조식 1]
Figure pat00384

[구조식 1]에서,
L1은 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택되며,
n은 0 내지 4의 정수이고, n이 2 이상인 경우, 복수 개의 L1은 서로 동일하거나 상이하며,
Ar1 및 Ar2는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택되며,
상기 Ar1 및 Ar2는 서로 결합하거나 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있으며,
p는 0 내지 3이 정수이고, 상기 p가 2 이상인 경우 복수의 *-( )는 서로 동일하거나 상이할 수 있고,
상기 L1, Ar1 및 Ar2는 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
The method according to claim 1,
At least one of X 2 to X 6 is CR 3 , and * -R 3 is represented by the following formula 1:
[Structural formula 1]
Figure pat00384

In the structural formula 1,
L 1 is a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted aliphatic hydrocarbon group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted C2 to C50 heteroarylene group in which one or more substituted or unsubstituted C 3 -C 30 cycloalkyl is fused,
n is an integer of 0 to 4, and when n is 2 or more, a plurality of L &lt; 1 &gt; s are the same as or different from each other,
Ar 1 and Ar 2 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted group having 5 to 50 carbon atoms A substituted or unsubstituted aryl group, a substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C2 to C50 heteroaryl group in which one or more ring-opened cycloalkyls having 3 to 30 carbon atoms is fused,
Ar 1 and Ar 2 may be bonded to each other or may be connected to adjacent substituents to form a single alicyclic or aromatic ring or polycyclic ring, and the carbon atom of the alicyclic or aromatic monocyclic or polycyclic ring may be N, S, O, &lt; / RTI &gt;&lt; RTI ID = 0.0 &gt;
p is an integer of 0 to 3, and when p is 2 or more, a plurality of * - () may be the same or different from each other,
Wherein L 1, Ar 1 and Ar 2 each may be further substituted with one or more substituents, the one or more substituents are deuterium, a cyano group, a halogen group, a hydroxyl group, a nitro group, an alkyl group having 1 to 24 carbon atoms, having a carbon number of 1 A halogenated alkyl group having 1 to 24 carbon atoms, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, A heteroaryl group having 2 to 24 carbon atoms, a heteroarylalkyl group having 2 to 24 carbon atoms, an alkoxy group having 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, An alkylsilyl group having 1 to 24 carbon atoms, an arylsilyl group having 1 to 24 carbon atoms, and an aryloxy group having 1 to 24 carbon atoms.
제1항에 있어서,
상기 X2 내지 X10 중 하나 이상은 CR3이고, 상기 *-R3는 하기 [구조식 2]인 것을 특징으로 하는 유기발광 화합물:
[구조식 2]
Figure pat00385

상기 [구조식 2]에서,
L2는 치환 또는 비치환된 탄소수 1 내지 30의 알킬렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알케닐렌기, 치환 또는 비치환된 탄소수 2 내지 30의 알키닐렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬렌기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴렌기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴렌기 중에서 선택되며,
m은 0 내지 4의 정수이고, m이 2 이상인 경우, 복수 개의 L2는 서로 동일하거나 상이하며,
Ar3는 서로 동일하거나 상이하고, 각각 독립적으로 치환 또는 비치환된 탄소수 1 내지 30의 알킬기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬기, 치환 또는 비치환된 탄소수 5 내지 50의 아릴기, 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기, 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 5 내지 50의 아릴기 및 치환 또는 비치환된 탄소수 3 내지 30의 시클로알킬이 하나 이상 융합된 치환 또는 비치환된 탄소수 2 내지 50의 헤테로아릴기 중에서 선택되며,
q는 0 내지 3이 정수이고, 상기 q가 2 이상인 경우 복수의 Ar3는 서로 동일하거나 상이할 수 있고,
상기 복수의 Ar3 및 이의 치환기는 인접한 치환기와 연결되어 지환족, 방향족의 단일환 또는 다환 고리를 형성할 수 있으며, 상기 형성된 지환족, 방향족의 단일환 또는 다환 고리의 탄소원자는 N, S 및 O 중에서 선택되는 어느 하나 이상의 헤테로원자로 치환될 수 있고,
상기 L2 및 Ar3는 각각 1종 이상의 치환기로 더 치환될 수 있고, 상기 1종 이상의 치환기는 중수소, 시아노기, 할로겐기, 히드록시기, 니트로기, 탄소수 1 내지 24의 알킬기, 탄소수 1 내지 24의 할로겐화된 알킬기, 탄소수 1 내지 24의 알케닐기, 탄소수 1 내지 24의 알키닐기, 탄소수 1 내지 24의 헤테로알킬기, 탄소수 6 내지 24의 아릴기, 탄소수 6 내지 24의 아릴알킬기, 탄소수 2 내지 24의 헤테로아릴기, 또는 탄소수 2 내지 24의 헤테로아릴알킬기, 탄소수 1 내기 24의 알콕시기, 탄소수 1 내지 24의 알킬아미노기, 탄소수 1 내지 24의 아릴아미노기, 탄소수 1 내지 24의 헤테로아릴아미노기, 탄소수 1 내지 24의 알킬실릴기, 탄소수 1 내지 24의 아릴실릴기 및 탄소수 1 내지 24의 아릴옥시기로 이루어진 군에서 선택된다.
The method according to claim 1,
Wherein at least one of X 2 to X 10 is CR 3 , and * -R 3 is represented by the following formula 2:
[Structural formula 2]
Figure pat00385

In the above formula 2,
L 2 is a substituted or unsubstituted alkylene group having 1 to 30 carbon atoms, a substituted or unsubstituted alkylene group having 2 to 30 carbon atoms A substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C3-C30 A substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkyl, a substituted or unsubstituted C1 to C50 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, A substituted or unsubstituted C2 to C50 heteroarylene group in which one or more substituted or unsubstituted C 3 -C 30 cycloalkyl is fused,
m is an integer of 0 to 4, and when m is 2 or more, a plurality of L 2 are the same or different from each other,
And Ar 3 are the same or different and each independently represents a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 30 carbon atoms, a substituted or unsubstituted aryl group having 5 to 50 carbon atoms, A substituted or unsubstituted C2 to C50 heteroaryl group, a substituted or unsubstituted C3 to C30 heteroaryl group, a substituted or unsubstituted C6 to C30 heteroaryl group, a substituted or unsubstituted C3 to C30 cycloalkyl, Substituted or unsubstituted heteroaryl group having 2 to 50 carbon atoms in which at least one of 3 to 30 cycloalkyls is fused,
q is an integer of 0 to 3, and when q is 2 or more, a plurality of Ar 3 may be the same or different,
The plurality of Ar 3 and substituents thereof may be connected to adjacent substituents to form a single alicyclic or aromatic ring or polycyclic ring, and the carbon atoms of the formed alicyclic or aromatic monocyclic or polycyclic ring may be N, S, and O &Lt; / RTI &gt; and &lt; RTI ID = 0.0 &gt;
Each of L 2 and Ar 3 may be further substituted with one or more substituents each of which may be substituted with one or more substituents selected from the group consisting of deuterium, cyano, halogen, hydroxy, nitro, alkyl having 1 to 24 carbon atoms, A halogenated alkyl group, an alkenyl group having 1 to 24 carbon atoms, an alkynyl group having 1 to 24 carbon atoms, a heteroalkyl group having 1 to 24 carbon atoms, an aryl group having 6 to 24 carbon atoms, an arylalkyl group having 6 to 24 carbon atoms, An aryl group or a heteroarylalkyl group having 2 to 24 carbon atoms, an alkoxy group having 24 carbon atoms, an alkylamino group having 1 to 24 carbon atoms, an arylamino group having 1 to 24 carbon atoms, a heteroarylamino group having 1 to 24 carbon atoms, An alkylsilyl group of 1 to 24 carbon atoms, an arylsilyl group of 1 to 24 carbon atoms, and an aryloxy group of 1 to 24 carbon atoms.
제1항에 있어서,
상기 [화학식 1]은 하기 [화합물 1] 내지 [화합물 324] 중에서 선택되는 것을 특징으로 하는 유기발광 화합물:
Figure pat00386

Figure pat00387

Figure pat00388

Figure pat00389

Figure pat00390

Figure pat00391

Figure pat00392

Figure pat00393

Figure pat00394

Figure pat00395

Figure pat00396

Figure pat00397

Figure pat00398

Figure pat00399

Figure pat00400

Figure pat00401

Figure pat00402

Figure pat00403

Figure pat00404

Figure pat00405

Figure pat00406

Figure pat00407

Figure pat00408

Figure pat00409

Figure pat00410

Figure pat00411

Figure pat00412

Figure pat00413

Figure pat00414

Figure pat00415

Figure pat00416

Figure pat00417

Figure pat00418

Figure pat00419

Figure pat00420

Figure pat00421

Figure pat00422

Figure pat00423

Figure pat00424

Figure pat00425

Figure pat00426

Figure pat00427
The method according to claim 1,
The organic electroluminescent compound according to claim 1, wherein the organic electroluminescent compound is selected from the following compounds [1] to [324]:
Figure pat00386

Figure pat00387

Figure pat00388

Figure pat00389

Figure pat00390

Figure pat00391

Figure pat00392

Figure pat00393

Figure pat00394

Figure pat00395

Figure pat00396

Figure pat00397

Figure pat00398

Figure pat00399

Figure pat00400

Figure pat00401

Figure pat00402

Figure pat00403

Figure pat00404

Figure pat00405

Figure pat00406

Figure pat00407

Figure pat00408

Figure pat00409

Figure pat00410

Figure pat00411

Figure pat00412

Figure pat00413

Figure pat00414

Figure pat00415

Figure pat00416

Figure pat00417

Figure pat00418

Figure pat00419

Figure pat00420

Figure pat00421

Figure pat00422

Figure pat00423

Figure pat00424

Figure pat00425

Figure pat00426

Figure pat00427
제1항에 있어서,
상기 [화학식 1]은 하기 [화합물 325] 내지 [화합물 700] 중에서 선택되는 것을 특징으로 하는 유기발광 화합물:
Figure pat00428

Figure pat00429

Figure pat00430

Figure pat00431

Figure pat00432

Figure pat00433

Figure pat00434

Figure pat00435

Figure pat00436

Figure pat00437

Figure pat00438

Figure pat00439

Figure pat00440

Figure pat00441

Figure pat00442

Figure pat00443

Figure pat00444

Figure pat00445

Figure pat00446

Figure pat00447

Figure pat00448

Figure pat00449

Figure pat00450

Figure pat00451

Figure pat00452

Figure pat00453

Figure pat00454

Figure pat00455

Figure pat00456

Figure pat00457

Figure pat00458

Figure pat00459

Figure pat00460

Figure pat00461
The method according to claim 1,
Wherein the compound represented by Formula 1 is selected from the following compounds 325 to 700:
Figure pat00428

Figure pat00429

Figure pat00430

Figure pat00431

Figure pat00432

Figure pat00433

Figure pat00434

Figure pat00435

Figure pat00436

Figure pat00437

Figure pat00438

Figure pat00439

Figure pat00440

Figure pat00441

Figure pat00442

Figure pat00443

Figure pat00444

Figure pat00445

Figure pat00446

Figure pat00447

Figure pat00448

Figure pat00449

Figure pat00450

Figure pat00451

Figure pat00452

Figure pat00453

Figure pat00454

Figure pat00455

Figure pat00456

Figure pat00457

Figure pat00458

Figure pat00459

Figure pat00460

Figure pat00461
제1 전극, 제2 전극, 및 상기 제1 전극과 제2 전극 사이에 배치된 1층 이상의 유기물층을 포함하는 유기전계발광소자로서,
상기 유기물층 중 1 층 이상은 청구항 1 내지 6 중 어느 한 항에 따른 [화학식 1]의 유기발광 화합물을 포함하는 것인 유기전계발광소자.
1. An organic electroluminescent device comprising a first electrode, a second electrode, and at least one organic material layer disposed between the first electrode and the second electrode,
Wherein at least one of the organic material layers contains an organic light emitting compound of Formula 1 according to any one of claims 1 to 6.
제7항에 있어서,
상기 유기물층은 정공 주입층, 정공 수송층, 정공 주입 및 정공 수송을 동시에 하는 층, 전자 수송층, 전자 주입층, 전자 수송 및 전자 주입을 동시에 하는 층 및 발광층 중 1층 이상을 포함하고, 상기 층들 중 1층 이상이 상기 [화학식 1]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
8. The method of claim 7,
Wherein the organic material layer includes at least one of a hole injecting layer, a hole transporting layer, a hole injecting and transporting layer, an electron transporting layer, an electron injecting layer, a layer simultaneously performing electron transport and electron injection, and a light emitting layer, Wherein at least one layer comprises an organic light-emitting compound represented by the above formula (1).
제8항에 있어서,
상기 발광층이 상기 [화학식 1]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
9. The method of claim 8,
Wherein the light emitting layer comprises an organic light emitting compound represented by the following formula (1).
제9항에 있어서,
상기 [화학식 1]로 표시되는 유기발광 화합물은 상기 발광층 내의 호스트 화합물로 사용되고, 상기 발광층은 도판트 화합물을 1종 이상 더 포함하는 것을 특징으로 하는 유기전계발광소자.
10. The method of claim 9,
The organic electroluminescent compound represented by Formula 1 is used as a host compound in the light emitting layer, and the light emitting layer further includes at least one dopant compound.
제8항에 있어서,
상기 정공수송층 또는 정공 주입 및 정공 수송을 동시에 하는 층이 상기 [화학식 1]로 표시되는 유기발광 화합물을 포함하는 것을 특징으로 하는 유기전계발광소자.
9. The method of claim 8,
Wherein the hole transport layer or the layer simultaneously injecting holes and transporting holes comprises an organic light emitting compound represented by the following formula (1).
제7항에 있어서,
상기 유기물층에 적색, 녹색 또는 청색 발광을 하는 유기 발광층을 하나 이상을 더 포함하여 백색 발광을 하는 것을 특징으로 하는 유기전계발광소자.
8. The method of claim 7,
Wherein at least one of the organic light emitting layers emitting red, green or blue light is further included in the organic material layer to emit white light.
KR1020140059983A 2014-05-19 2014-05-19 An electroluminescent compound and an electroluminescent device comprising the same KR20150133097A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140059983A KR20150133097A (en) 2014-05-19 2014-05-19 An electroluminescent compound and an electroluminescent device comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140059983A KR20150133097A (en) 2014-05-19 2014-05-19 An electroluminescent compound and an electroluminescent device comprising the same

Publications (1)

Publication Number Publication Date
KR20150133097A true KR20150133097A (en) 2015-11-27

Family

ID=54847659

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140059983A KR20150133097A (en) 2014-05-19 2014-05-19 An electroluminescent compound and an electroluminescent device comprising the same

Country Status (1)

Country Link
KR (1) KR20150133097A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016101865A1 (en) * 2014-12-26 2016-06-30 Dow Global Technologies Llc Organic compounds and electronic device comprising organic layer comprising organic compounds
CN106189363A (en) * 2016-07-01 2016-12-07 湘潭大学 One class closes polymer-metal complex dye sensitizing agent of Cd (II) and its production and use containing 2 (2 ' hydroxy phenyl) benzimidizole derivatives
WO2017105106A1 (en) * 2015-12-18 2017-06-22 주식회사 두산 Organic compound, and organic electroluminescent element including same
CN107325103A (en) * 2017-07-07 2017-11-07 中节能万润股份有限公司 A kind of electroluminescent organic material, its preparation method and application
WO2018058497A1 (en) * 2016-09-30 2018-04-05 Dow Global Technologies Llc Organic compound and electronic device comprising organic layer comprising organic compound
CN107915748A (en) * 2017-11-14 2018-04-17 华东师范大学 A kind of preparation method of 4 (tert-butyl group) 1 phenylimidazoles simultaneously [4,5,1 kl] phenoxazine
CN111170956A (en) * 2020-01-10 2020-05-19 黄锦海 Hole transport material composition containing benzoxazole and thiazole group and application thereof
CN111170957A (en) * 2020-01-10 2020-05-19 上海百豪新材料有限公司 Preparation method of hole transport material composition containing benzoxazole and thiazole group
CN113121493A (en) * 2021-04-13 2021-07-16 吉林奥来德光电材料股份有限公司 Arylamine compound, preparation method thereof, organic electroluminescent device and display device
WO2023011581A1 (en) * 2021-08-04 2023-02-09 江苏恒瑞医药股份有限公司 Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
CN115947698A (en) * 2022-12-26 2023-04-11 郑州海阔光电材料有限公司 Synthesis method of phenoxazine
CN116554154A (en) * 2023-05-25 2023-08-08 中国科学院长春应用化学研究所 Thermal-induction delayed fluorescence compound, preparation method thereof and organic electroluminescent device
CN118084927A (en) * 2024-04-19 2024-05-28 季华恒烨(佛山)电子材料有限公司 Indolocarbazole compound and application thereof

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016101865A1 (en) * 2014-12-26 2016-06-30 Dow Global Technologies Llc Organic compounds and electronic device comprising organic layer comprising organic compounds
US10005729B2 (en) 2014-12-26 2018-06-26 Rohm And Haas Electronic Materials Korea Ltd Organic compounds and electronic device comprising an organic layer comprising the organic compounds
WO2017105106A1 (en) * 2015-12-18 2017-06-22 주식회사 두산 Organic compound, and organic electroluminescent element including same
KR20170073122A (en) * 2015-12-18 2017-06-28 주식회사 두산 Organic compounds and organic electro luminescence device comprising the same
CN106189363A (en) * 2016-07-01 2016-12-07 湘潭大学 One class closes polymer-metal complex dye sensitizing agent of Cd (II) and its production and use containing 2 (2 ' hydroxy phenyl) benzimidizole derivatives
WO2018058497A1 (en) * 2016-09-30 2018-04-05 Dow Global Technologies Llc Organic compound and electronic device comprising organic layer comprising organic compound
CN107325103A (en) * 2017-07-07 2017-11-07 中节能万润股份有限公司 A kind of electroluminescent organic material, its preparation method and application
CN107915748A (en) * 2017-11-14 2018-04-17 华东师范大学 A kind of preparation method of 4 (tert-butyl group) 1 phenylimidazoles simultaneously [4,5,1 kl] phenoxazine
CN111170956A (en) * 2020-01-10 2020-05-19 黄锦海 Hole transport material composition containing benzoxazole and thiazole group and application thereof
CN111170957A (en) * 2020-01-10 2020-05-19 上海百豪新材料有限公司 Preparation method of hole transport material composition containing benzoxazole and thiazole group
CN111170957B (en) * 2020-01-10 2023-03-21 上海百豪新材料有限公司 Preparation method of hole transport material composition containing benzoxazole and thiazole groups
CN113121493A (en) * 2021-04-13 2021-07-16 吉林奥来德光电材料股份有限公司 Arylamine compound, preparation method thereof, organic electroluminescent device and display device
WO2023011581A1 (en) * 2021-08-04 2023-02-09 江苏恒瑞医药股份有限公司 Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
CN115947698A (en) * 2022-12-26 2023-04-11 郑州海阔光电材料有限公司 Synthesis method of phenoxazine
CN115947698B (en) * 2022-12-26 2024-05-03 郑州海阔光电材料有限公司 Synthesis method of phenoxazine
CN116554154A (en) * 2023-05-25 2023-08-08 中国科学院长春应用化学研究所 Thermal-induction delayed fluorescence compound, preparation method thereof and organic electroluminescent device
CN118084927A (en) * 2024-04-19 2024-05-28 季华恒烨(佛山)电子材料有限公司 Indolocarbazole compound and application thereof
CN118084927B (en) * 2024-04-19 2024-08-23 季华恒烨(佛山)电子材料有限公司 Indolocarbazole compound and application thereof

Similar Documents

Publication Publication Date Title
KR101825405B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101627691B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101852926B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101530266B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20150133097A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160066308A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101842013B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101790550B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20170082459A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160127429A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101626524B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20150037623A (en) Heterocyclic compound and organic light emitting device using the same
KR101837048B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101913628B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20150110101A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101713530B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160054870A (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101666826B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101627695B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20160040826A (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
JP6766303B2 (en) Nitrogen-containing polycyclic compound and organic light emitting device using it
KR101816810B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101638073B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR101640478B1 (en) Novel compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR20170003470A (en) An electroluminescent compound and an electroluminescent device comprising the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application